{"directed": true, "multigraph": true, "graph": {"pybel_version": "0.13.1-dev", "document_metadata": {"name": "GSK3 subgraph", "version": "5.1.2", "copyright": "Copyright © 2019 Fraunhofer SCAI, All rights reserved.", "licenses": "CC BY 4.0", "contact": "daniel.domingo.fernandez@scai.fraunhofer.de"}, "namespace_url": {"CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns", "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns", "GFAM": "https://raw.githubusercontent.com/pharmacome/terminology/3f89d31906739fce9678d868b6a599a851aa7c00/external/hgnc.genefamily-names.belns", "GO": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go.belns", "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/570376e4c233483b667eab12a1f964950368282a/export/hbp-names.belns", "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/hgnc-symbols.belns", "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh.belns", "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns", "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns", "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns", "GOBP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20170725.belns", "GOCC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20170725.belns", "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns", "MESHC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20170725.belns", "MESHCS": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-cell-structures/mesh-cell-structures-20170511.belns", "MESHD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20170725.belns", "MESHPP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20170725.belns", "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns", "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns", "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns", "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns", "INTERPRO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns", "ADO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns", "BRCO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns", "NIFT": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/imaging-ontology/imaging-ontology-1.0.6.belns", "PTS": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/neurodegeneration-pathways/neurodegeneration-pathways-1.0.0.belns"}, "namespace_pattern": {"DBSNP": "^rs\\d+$", "TAXONOMY": "^\\d+$"}, "namespaces_uncached": [], "annotation_url": {"Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno", "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno", "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno", "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno", "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno", "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno", "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno", "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno", "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno", "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno", "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"}, "annotation_pattern": {"Species": "\\d+"}, "annotation_list": {"Duration_of_Chemical_Exposure": ["Chronic", "Subchronic"], "NIFT": ["Positron Emission Tomography", "Volumetric MRI"], "Published": ["CDR story", "Epilepsy comorbidity paper"], "Race": ["Caucasian", "Chinese", "Colombian", "Italian", "Swedish", "Taiwanese"], "Condition": ["Normal Healthy State"], "Encode_Feature_Types": ["Promoter"], "Experimental_Group": ["Physical exercised group", "Sedentary group"], "KnockoutMice": ["App transgenic"], "DiseaseState": ["Early-onset AD", "Familial Alzheimers Disease", "Late-onset AD", "Mild AD", "Moderate AD", "Sporadic Alzheimers Disease"], "FDASTATUS": ["Phase 2", "Phase 3"], "UserdefinedCellLine": ["293APPwt", "App transgenic", "CHOAPPsw", "INS-1 cells", "N2a695 cell", "NT2N cells", "Neuroblastoma cell", "primary cortical neuron", "primary neuron"], "Patient": ["AD T2DM +ve", "AD T2DM -ve", "APOE e4 +ve", "APOE e4 -ve"], "Developmental_Phase__of_patient": ["Developmental stage", "Old"], "Transcriptionally_active_region": ["3 prime UTR", "5 prime UTR"]}}, "nodes": [{"function": "Abundance", "namespace": "CHEBI", "name": "1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate", "id": "b4b62f02b25e1e2c31c12519f4eeed2baa6514c07c6bb3d0b8949e73d5708fa7ee94efa297b6a12f9719eefe04fce3aa40f95ab0efe36e13aa1d65be51cb7fe9"}, {"function": "Abundance", "namespace": "CHEBI", "name": "17beta-estradiol", "id": "3ec3515ce1ae102eb3e7c2a04838574773d0aa055d1b5caa6bcf3dd5cb5f9e86a53367450754964b23ca6f94f811ef91389f26ef491c31c505877bfd972bfd1a"}, {"function": "Abundance", "namespace": "CHEBI", "name": "Z-DEVD-FMK", "id": "78b9a9ad4275673bcde479f3f000db14882d0666a66770eb3c4ad25b2f6a75c9a6077c854d261d159a47db25e44e4926a084db815e9d410594ffa36e4f102118"}, {"function": "Abundance", "namespace": "CHEBI", "name": "amyloid-beta", "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"}, {"function": "Abundance", "namespace": "CHEBI", "name": "copper atom", "id": "b831fe5d1263fdf8554113c03cae9e7d256f0a55d30f374a55e0f3b2ff66d9b64208a47e7925e40fb7f8fb339147856ebd83b6f81f9671ff0c3ae5114ccb26d3"}, {"function": "Abundance", "namespace": "CHEBI", "name": "cyclosporin A", "id": "cc2d9386ffb706a1d62ee95b31327612e3263da9936967c06daa1c7b62c93eaf1f898d6288db7b59eae92826e3a840b321586a964d50f783936b7987a42606f6"}, {"function": "Abundance", "namespace": "CHEBI", "name": "lithium chloride", "id": "ab8f490e75ef0056abde589c607768817ca9a55f2845689fdb08a499f5843139a22df94f407a28792c0b46ea49e3215f77a59f29be4e7c8feb823718844604ce"}, {"function": "Abundance", "namespace": "CHEBI", "name": "lithium(1+)", "id": "943c096f03634b7dbc23b20c0b3cf2392d0f373b19fef3d18bbcce7b2c99dbfe759397ec294f186cb6876052de3e7177d8da019fea173f99f26c1013dc1cfd99"}, {"function": "Abundance", "namespace": "CHEBI", "name": "okadaic acid", "id": "676b3ff5997541b41ef095d98283a202a12cc877b431c8467f956ef1acf990f281c503ef40951a8135be2af35c9c46ccdfc87e4af3ac93d9f086dd911f85683c"}, {"function": "Abundance", "namespace": "CHEBI", "name": "alsterpaullone", "id": "705482bdfcfe21dad824136f3454a9dabc7e0609f463062e3701efa3fd9a6438a714c395d84a4094636f375a95e6b8e3c28c725bc8dbdf2423b9d1a3f775a94e"}, {"function": "Abundance", "namespace": "CHEBI", "name": "berberine", "id": "e57e7808372e142d1dba445b83ec643c6330f0d1bd2804c0331e332e1e26433cc8b8c9f47fa38a72ca59b1ad3651943329349f590ed90906a4c558eb9c0109ff"}, {"function": "Abundance", "namespace": "CHEBI", "name": "donepezil", "id": "e1d832febdffe3cc8c4fa21718e0b21719272a1a10c2945cdd3b36cc6ff66c3ec70289ed1ddc3a7a6b79ca44a4bc0fac6ecb12683fc043cdac26b952f7cf5223"}, {"function": "Abundance", "namespace": "CHEBI", "name": "malonaldehyde", "id": "739f31faea80a4346f93d88fb322844d4a48cedd3887e50968fbf26d7666f2cec39be3aadacf4e570e76340d40b2e860ed74d5181306d84b7ca1c26ab4443bba"}, {"function": "Abundance", "namespace": "CHEBI", "name": "paullone", "id": "b226152f3de74c11076a2c181f34cd9259fe5c6efb2835b08c93bc0596fddddfccee85c912ecf36954b5dd19b3808dafd2cce9785b9e43df76df64ad8e94bbfd"}, {"function": "Abundance", "namespace": "CHEBI", "name": "rosiglitazone", "id": "2aee1fa205419703cf2948fa6a76b2c16d6d10a12332e89ef4567ecc8833779d47b34a96054889b74ee43a97efaddbf1544f3ea24c588af930766dd6d78a7cce"}, {"function": "Abundance", "namespace": "CHEBI", "name": "wortmannin", "id": "dcc61e41e7984480a5acce6dae10d1b3e8e41867fe2cdbcc588699e1c59b9972cb453cd7d5fccdf18f0b097aca6e1fc115bd6005e81e719e2ed50eb7e82dd344"}, {"function": "Abundance", "namespace": "HBP", "name": "amyloid-beta aggregates", "id": "1d739f6eba3532950fc068e81f7aea675ce76d42a049b5a301ad8bccf2f503d6c2a79c9d417d4d35cc760c340b5db2513536b3c420156a92bda3605be3537740"}, {"function": "Abundance", "namespace": "MESHC", "name": "Amyloid beta-Peptides", "id": "d674d9b66cf1651d42f860188d796e7087b152be0c3199722af782e5fe709e4d65f7d6864feb3b91607d918bfd93db3cb2ece60f56854259ceedd233d75c415e"}, {"function": "Abundance", "namespace": "MESHC", "name": "cerebrolysin", "id": "0f7f355261a0240ebdfbfc2288628796c4cea00a77737eefc361ad06945b7e287c20ac8f88c7022ff639ff6f17c37d2d46e5aa3d23758cfa2dc326aba1be7cd1"}, {"function": "BiologicalProcess", "namespace": "ADO", "name": "loss_of_synapses", "id": "7a23b696e7f1c800eb645fcea39a2c104e7aa05a803efa16f093d82e3a40e7025050ebd9bd8b76e7f8205505607e6d9ef5c7426043b086f1ad7ee794398db123"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "TOR signaling", "id": "8ff487c9b6442254f911daaaeed49c31fbcd163e642bd0d54ee16e6808a9bea695728858487339ecdf0cd63207f4a76e09315bdc0d37d220d338b3d633c745be"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "Wnt signaling pathway", "id": "c8c2a0398723041db8c2cabac45072dfae35d37928e09da389b8b5c773cf9c29603aada9d05b5b5d5ef585ca52d9b02ab4359d98b25d311e8aaac80c64f954f1"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "apoptotic process", "id": "3b6274961b3ffdeb24d162fa8ee48994603d4263030d5015597037d4dcb0e80f2413b85d4648d2a8c56b68161162dcb95656e3637a245faa140d61a61232451d"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "axonal transport", "id": "a6dbd77b98d99bdeff16a73cc0eb417359152f341b34500e3c4afca4ae8849ad891b721737f259ff50602760f9db92f53a40910980aa476a38cbea57cf697be8"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cell growth", "id": "a55470837167d0241123066dd70468af68cf21fbbe18ad91af0926d7a29d37811520376e217370b819f73bf2706d13360bc7d995a85a292384a696ffecbc04ce"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "generation of neurons", "id": "36ee87c177d078b9b97499b54bf57f4829bb11a40327aa1a3baff6d140105c7518b22960e66bf212040b09e0ef61883318230b3eee46beeb64e47f134f062ed2"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "inflammatory response", "id": "3d95fab3ea44ace52d93f8d514ed76a13b0141d47b3fdb540a4f251104b4455dce67e0dac58c1a127df709dc3721e03aba719c2877d49fac8c3e2abab2b721cf"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "insulin receptor signaling pathway via phosphatidylinositol 3-kinase", "id": "023393352846e2409b3e2e2417011b242621ee7f0be28c2f9712516d9a2ea48bc500c8459184a513d332fe5f9de49d60384de9b847af5ddc07776da085598c3d"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "insulin receptor signaling pathway", "id": "9237fcb9f7e126e74b063bccb9a3481fbb174f2428c747cff297c660b94d239d5a1029ddc8f62afbc8ae4685c16628a78c3dbcbc9899eaccd8645509d502e16c"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "insulin-like growth factor receptor signaling pathway", "id": "2a030f16e6ae6a6e9faaf5c0ee94b2f6d1956840eab12808acc639cd5409bb85e691ff5a6553a692d7f32dd16604b86cbe427a54d99c5b833f62a0b62867a504"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "maintenance of permeability of blood-brain barrier", "id": "3e75422af248c3a84af96b4d55e90ab8c1dfae226878c3af2188fa6b85657c81730a7ce29c25e62d276ef65cbe7a054c6d087c4a1e2e4df376a9b5fdd4e6cfed"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron apoptotic process", "id": "d03e6f0803e977ca2408bd8e60f7f8872ed7a1adb3ef8bc9d8d22481bce67f9ebfc4fe9b04e693e27779c9e3aa27d37f78ff1e9751ef84f3c780e9bd4030bea7"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron death", "id": "7a2f309b1d4a7c1ab86704418e6cffe1e917c5d1d842312e825776263f2ae593e2d871381b4a4bacf2efab95f6f8e1d9264f5e025c7676621a1e72a9e74d7c85"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of cAMP-dependent protein kinase activity", "id": "652913b0aa19ecf22794ccae12c0df78af9378a7cc5cee7aa1a7b4eedfb49f3e481b71b47365e0a9b4f8905edc6767c8c6af3b56cde35097e29fa9aa7202e419"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of synaptic plasticity", "id": "20ae2e31a66e627912482dcd89c85cd4a7abdc174d25d479bf5935b69f385906a6e21e7ef6ca1503f584a3d31849b4ab2b00a5ac2ae696c877b6924acbdde86f"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of tau-protein kinase activity", "id": "d4ff6a6eb5dc84fa32a64a81d287b833b39064367f6f37fe27e234f7cbe26821e035510529ef9531b3f29c7f446b49f1ec261628dd49aac5ffcecb8aa3464d96"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "response to oxidative stress", "id": "a102c12e30559a8d58a9ad0a290b9f0830898de52dc176810348cc207194be3490f8e38df97987bea8b5827f54a61ed09445e86a065fe9b27a51db2f861de59c"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "memory", "id": "2c0be3c3d7742f81a705f9ed3b9ae8ad529994d220b57b3c46cb1641073373cb3579b3c8ac29e9512cf6f3e2fd2207d508591b3c588d51484d8f1a21d05f1c8b"}, {"function": "BiologicalProcess", "namespace": "MESH", "name": "D000066829", "id": "6ef71a95d47c5d6ce72365c206a8074d5788ffbc8eb64411f72bcedd23da07434900c470e1a48e4942c7703008d213c0ba431a923a8f6f125441640db90a98b3"}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Cell Survival", "id": "2db470a036e09f3c0488a28934ce193e0a519d030ea768e5359e055746343da97b63778d1ff329a02a132fb3922f0af8b16eada27677c9a2127d2817197adf3f"}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Energy Metabolism", "id": "5896560344758b47f273b969fcb1a36f40938e6648750ed70387c95f17c84a13ce58b0fa7b4df584cc46d5713333f29be97df9eff02b13fef7fcbfcf4e5ef648"}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Oxidative Stress", "id": "2e38d6f16f5bdfbc33da58532c5bdd2a6e47cde3f52748b83013a33fc1a076ae93e2852e3d3559e7e4b130cae695a61f746fe7fd8b5929ac3761040a5474b31a"}, {"function": "BiologicalProcess", "namespace": "PTS", "name": "Insulin receptor signaling pathway", "id": "9add1ca0d6891741a999be929183239e1efc167977ef64131220964895d187bb398415f73f8e2559c93bfe3324c740b1db5022ce84000c855d3301a58863daa4"}, {"function": "BiologicalProcess", "namespace": "PTS", "name": "PI3K/AKT signaling", "id": "0cfc6721cc8313d5b40ecb28470a68c831aa4af017743e3c6beb2466efbbbb8fe1091d2a64bdb251c761a9873e11a24c665a6fcc0b8abeb4e054f00f0c994e6c"}, {"function": "BiologicalProcess", "namespace": "PTS", "name": "Ras/MEK/ERK pathway", "id": "d5e5c4505fe40df8002b02e805750e610561a29df7a2ea0661c5ff4c1cbb4606a62afa18c55bb553f40aecaddb32f91c40ba6cfa94c9e887f24aa79c4a9187de"}, {"function": "Complex", "namespace": "GOCC", "name": "neurofibrillary tangle", "id": "a948642b45fa2268bd16073151feb34085114b9b06f83e2a29ac009cf0ad486779b946904e0d8ac85dea9b74ddb457aa750c3018eef9e457af88b50258c42773"}, {"function": "Complex", "namespace": "SCOMP", "name": "AP-1 Complex", "id": "8401ade143f7e8674198a9eb3b1a71b66d53f3d13fca598888c3e9aa92896c9f270c55e3e2e98e192c8ac8f98f1db957989374418750bf6decec6f1d716d7ce0"}, {"function": "Complex", "namespace": "SCOMP", "name": "Nfkb Complex", "id": "8ffe850de1b4281d0828fe3516a7bd4cfd2e80c7aef726f0646005c0e7ae06bd94925a6bf3d483d74dfd7d34ee2408e22dd46c0333ef62b7c70459e33b57e095"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "APBB1", "id": "a436425a19ea8343770653e9c0af7e22f677dfca5b2fc075a2692024f5096f9ea3d963aeabba287cbb076d8030f55e6aa05dbf87375d97eb4a0d86820b2ca556"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"}], "id": "342c6effb7cccb328d9ef64d571dddb294fb72a9102ed42d1d2df96e5e549c2477e85bbbb8a6d6dc158719917e41c7892f2a3a23ed06e794d070d779ef503495"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "APBB1", "id": "a436425a19ea8343770653e9c0af7e22f677dfca5b2fc075a2692024f5096f9ea3d963aeabba287cbb076d8030f55e6aa05dbf87375d97eb4a0d86820b2ca556"}, {"function": "Protein", "namespace": "HGNC", "name": "TFCP2", "id": "849ae01c3336c23934832e81fbe005a06b4b827d3b12db2b95f2565b58260bcacf9e8657c076cb48d038fc3a2ec07756cf48328f9de666d3092c08bf7c5657fa"}, {"function": "Protein", "namespace": "INTERPRO", "name": "Amyloidogenic glycoprotein, intracellular domain, conserved site", "id": "0755e0dd6509f38c335622890384e735ef1d94e443f1c1a37ba5e1a57f3be60114b17c2932a4617ca6776e876a676c015ee6aaf605a4415b909325ce752b619a"}], "id": "293222e03a2be2ed9bc2d5c474191afdbb927659a63192616d8bf1b4e0a50ae88dfa35d3fa1a026914e2fb9ee24c720c2c3cd1e56f52529ebd020295567dc3af"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "APC", "id": "8856ec29c879bb41f47ecc1aa23cfe5797ba5a10eccb2b7d9edae08bb833ff83cc39b52b861e743afe4cd24794930c4d87ca57360e8b63aded83a99bb9b32509"}, {"function": "Protein", "namespace": "HGNC", "name": "CSNK1A1", "id": "55e8f15d97f4d338e9d7ef1da2fb6908c6c79766e9d827523457d8db998308a5049b5f2a3a1c28f5538e21379e0a889b1bc17fe925572e3604cb230b3c9f59aa"}, {"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "id": "a2bc0511621c6128941ce4889e2169d5ea15cda57b26de72e4a6212856db0cf989f1fba19328a884092694e5a710c81b67198481f8060b50a2a1c0580c4fa6d3"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"}, {"function": "Protein", "namespace": "SFAM", "name": "AXIN Family", "id": "a071bada6817a3dcb26bcde4f930dc2a2d6bb3e8017edfba9b1e8c3878772e1b36114edcfbd54ba0a1bac983de1c65cc5e94b9a706417c0fd77f05914e4d26c1"}], "id": "a5bb95efb5e2c8c3503b5c4fae380898f1d7473febe2934d5416cef2c1a1b1be9e99bbd9cc84d1fc8c7a915cde015286aec071fbd632cc196742d99978f08c87"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CDH2", "id": "0bd8913974cc2e038fb2e872a267607e556cc4139ea68cee40fd4c686c4f622e4bab303f3c6d18304e07b87958eb65fb3eb3c8d766ee7dad4b165a4276e3e423"}, {"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "id": "a2bc0511621c6128941ce4889e2169d5ea15cda57b26de72e4a6212856db0cf989f1fba19328a884092694e5a710c81b67198481f8060b50a2a1c0580c4fa6d3"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"}], "id": "b6994a871bdd9f9369a96ce319cdf0784120d450fa9be463aaf2f54a558f5438d600e2fbc7a03b7c77de9fd6422a69d522bd6425cc6cf48baee044d9168b62d0"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CDH2", "id": "0bd8913974cc2e038fb2e872a267607e556cc4139ea68cee40fd4c686c4f622e4bab303f3c6d18304e07b87958eb65fb3eb3c8d766ee7dad4b165a4276e3e423"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"}], "id": "4260d0ba0e703c372e0e5dd6421ca9a962b376c835854c9da18b7f91943ed1ca18348c889ce8ed788738404eae9905414b31c694c2402e639a660f2e39e44224"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CDK5", "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"}, {"function": "Protein", "namespace": "HGNC", "name": "CDK5R1", "id": "0207787ec1a245b4edc4d61e093cfdf729180ecde8b3c7ae6644ca38fc0a28cb03b727dba6caaf192b4a98594148ceee9ff9e34195a7f8915ee6f683b8a08526"}], "id": "f4c257e967616f0f74693d60486361c7668ea8db16385c3e7dd5002889a12e3cdeaf9ebf5d1117a23aecf4b6e93d1817024b36ec26478a5d4212822cef5e88b3"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "id": "a2bc0511621c6128941ce4889e2169d5ea15cda57b26de72e4a6212856db0cf989f1fba19328a884092694e5a710c81b67198481f8060b50a2a1c0580c4fa6d3"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"}], "id": "c652513c7faa28871b0369e4cc9fa1f1faab3774e03413a3f6eaa4bbb2281e2c4fd20e38b22cfac43ccccb80da46e93bd9825aef2917663d8e2943ad5c692082"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "id": "a2bc0511621c6128941ce4889e2169d5ea15cda57b26de72e4a6212856db0cf989f1fba19328a884092694e5a710c81b67198481f8060b50a2a1c0580c4fa6d3"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"}], "id": "21856e836eee22f32c3e010139eb4fb554a54f7807af90d5abd2f6d9710e163d2c91c1d03c4dca0cb09ac173728dee279021028150470f20f53795b8bc9e5eb6"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"}, {"function": "Protein", "namespace": "HGNC", "name": "SNCA", "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3"}], "id": "1de725a729b6fb4b15e163c7e212c235c5770b65a4463ee78f55f63f736c5b043ebd4be96b7c61b1613aec6e72f185842b454a8e48e47b2768526fd495a8c54e"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"}, {"function": "Protein", "namespace": "HGNC", "name": "PPP2CA", "id": "6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1"}], "id": "b4b1eaec4f6017f5902c8c0d05ba60b085658fd8b60e522f7b7c1b322ffd7415fd8e14616161b7e5524b075722a48a9dae64313c6df738ef7967c75d7c00f904"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "IGF1", "id": "3369894fadb1dfa2a161a7804d9e5be75205b590f45176482fbb7013986d328fd7874e0e48874a6658bc4a2d90f06abaef588ce4071f2e3b42a29a7376a4e892"}, {"function": "Protein", "namespace": "HGNC", "name": "INSR", "id": "72e25187d4bd32d07aed8b4b69a5eeda3f0f4424a8103ecf2132f704ff8ff7fa57768077c1cb46b8a08d4df499cc0a5df309a3398e938ba87d237ccd476709a7"}], "id": "b312ab12c8b892e8d1fa67807771327cf562143a9200256a1b0f69e38d548b7b884b79d0431760b419a1a6fe853de1c83deb5c147631f1703666dfef20368d8c"}, {"function": "Gene", "namespace": "HGNC", "name": "GSK3B", "id": "2c67e945b648a462d81c936023d1ccff1f97155bff43951387fd8014d4549305597173cc15bbacc57d9b6c1d4b2c7f8494f61cebe20f24ac3a411f1f0af1c376"}, {"function": "Protein", "namespace": "FPLX", "name": "HSPA", "id": "c293d8f843520dae6cba835a86c0e958d54d4dad9658a8281d9540b21d8e39272f2548fe5c429cd97d5d9a3755643b8dc346c2aecf00d7d53ab3914574cbf62d"}, {"function": "Protein", "namespace": "HGNC", "name": "AKT1", "id": "459b49bb1c745041814dfc37f0d89c3d0c3db4d952402fc2ca8e986e90bb84483919e9c4a520236e0b44f7438c90f068ea34f28822e46ae58e9515fc87c89569"}, {"function": "Protein", "namespace": "HGNC", "name": "APC", "id": "8856ec29c879bb41f47ecc1aa23cfe5797ba5a10eccb2b7d9edae08bb833ff83cc39b52b861e743afe4cd24794930c4d87ca57360e8b63aded83a99bb9b32509"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "frag", "start": 672, "stop": 713}], "id": "3e5de8e845a1a7b00bc3bcb2e2ce192ad8c91a9c1beb7f894571f750d8d4cbcfb96c2dcabb2c5f461e38a63cd31bbb7233e393cfba29dea19455033cd38fbe28"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "aee5a87041a5fb729a1098a050b7c979e89d489ea04102c91e0ca979381f6efed040ee6c5a8ef87259e3b872a3b5de52268617856b8c88b6c172485e0ef7fbf3"}, {"function": "Protein", "namespace": "HGNC", "name": "BAD", "id": "ef20babd63e8d073bac5d3a82b61a82bdf8da6696cb2903a65450f2aef8100022d7c5df982eb9e654ac2a43eee09eef3fd95472ef91c20d03e50bd497bc62a74"}, {"function": "Protein", "namespace": "HGNC", "name": "BAX", "id": "8a222b014ada3e5796ac04a4889d935c609db72c1e566d43b04ec45d9bddcabebc6a3a442ed1d12a5406ef159b7180dc656d8e99c2e5623af13bf85f2931bcae"}, {"function": "Protein", "namespace": "HGNC", "name": "BAX", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "a02cc2b9342747ca8df09b4dc8cfcd96ccb0d203fac9770bdba7f86173fa510227775bc21388759a17d30fc6d572bf4564924198b341b15527bc185524ef0658"}, {"function": "Protein", "namespace": "HGNC", "name": "BTRC", "id": "88f8adb07e4a8a5e450d264f17f555bd6bf90dfa583a4645139408b6ecd2f277e790f07a934265e04bb7be15b5fafac952e2dc8c31705264c3124b5909698f4b"}, {"function": "Protein", "namespace": "HGNC", "name": "CASP3", "id": "3fc355e7c574083fad31aa9edc5d5685615c49fd58885c2fbd439371619da84fbe274bd3325695ab21c912b5ea592d8031ffa114a9147908170dc187400ba74c"}, {"function": "Protein", "namespace": "HGNC", "name": "CCL2", "id": "0ffaf8edf9d1f6deb96f353ad12fccb2cc8250da79451f2fd3f673b99f190ead3987d4e96df92f61da68955493c39c3f56507db2adeefcdf744f6c8cba24e84a"}, {"function": "Protein", "namespace": "HGNC", "name": "CCL5", "id": "a271a053df5ca334f9ec5d909ad7c5f4a1f8d4f105259c4f4e218e22ed683bc36fcfeda3429f1f08dcdfc69c28bd43329ccfc333629cb204ef50d3c11ac0efdd"}, {"function": "Protein", "namespace": "HGNC", "name": "CDK5", "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"}, {"function": "Protein", "namespace": "HGNC", "name": "CREB3L4", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "9a2a01accff92ff44dfe7fc124fe0bedfc8a6fbfa5f7c60602cbb3e1393511ef359f9ec9ae67e82623ceb8240c7e1b265d19f41ef13c813f67bac61380028451"}, {"function": "Protein", "namespace": "HGNC", "name": "CSNK1A1", "id": "55e8f15d97f4d338e9d7ef1da2fb6908c6c79766e9d827523457d8db998308a5049b5f2a3a1c28f5538e21379e0a889b1bc17fe925572e3604cb230b3c9f59aa"}, {"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "id": "a2bc0511621c6128941ce4889e2169d5ea15cda57b26de72e4a6212856db0cf989f1fba19328a884092694e5a710c81b67198481f8060b50a2a1c0580c4fa6d3"}, {"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "7d4df7a6f88651934fab7a3484d0789c9292c95735b9d55e7f5ba7fd26fed303c473b0cfc66e790f3961d773d8bb67e1a85924120e45c293dd8e0a4811e0650f"}, {"function": "Protein", "namespace": "HGNC", "name": "CTNNB1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ub"}}], "id": "8b35a3621fc2b326829d315461adf5d9dbf6817b0097dade40bd7255369cd535194fe51ed762aa0eeeb98f3d660edee32bbfadb4022f5145f6678b1aa9f13e96"}, {"function": "Protein", "namespace": "HGNC", "name": "CXCL1", "id": "6a131e726acafd4d951890ba3435b92156d5654a5df283509baa5d4ff2a9ec32a267f7d4098b1e6b0f549ea48a0091588b18d4cf4c0d461d587ca8ec53fc3728"}, {"function": "Protein", "namespace": "HGNC", "name": "CXCL10", "id": "fe00d6dde684b87c90dd3dbcddbc59d64b1a54a4afd296edb3fe99ce7e0f1b94c4e37a3696876abaa41d6ecd14890d38616b12e91d85e59d122d6779f22949ad"}, {"function": "Protein", "namespace": "HGNC", "name": "CXCL8", "id": "1d43bb6142e5802710652980dca32f0b5ae0bf401e5d279f80368982ffd1ac2adb0d667cc1170852072dd6a82b8fcfabaf1ed9869135585b804d73f99084a667"}, {"function": "Protein", "namespace": "HGNC", "name": "DKK1", "id": "43353c695c37d05100ccc4d88cfc994417614c34fe111df6314c9f4143abc3ea6c90a9bf584c4c8e811efaaa5fc268e61dbdc6ca23c67cba998a28632f6400b7"}, {"function": "Protein", "namespace": "HGNC", "name": "DPYSL2", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "c0b4a5e92a2fc66c0fd003bb1110e1e7e8c19b61cf5d1d71e8eab1c685bdc4522b32cd3ee712872dd0946444bd23542949042de6e510aeca67b13d39fdc860aa"}, {"function": "Protein", "namespace": "HGNC", "name": "DPYSL2", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 522}], "id": "4716190335f0f60abeb0596476cc0a2ff6f2e061a7c1d0423ffa7a9994abfb8f4cb4238086a0661cd2f59b681d511fa9f0d09dd447d8488ec53811ada5b8bfdf"}, {"function": "Protein", "namespace": "HGNC", "name": "FRAT2", "id": "bcdec3792b577b3f6054f640564aac796c43668404e11da5b5a6020ba37571d2d82909a282825c6fdfedbfd32a9d0304950aba0cfb3632691afb8b76ed817cb5"}, {"function": "Protein", "namespace": "HGNC", "name": "GCG", "id": "6071e7ff42285b3bfb1b3eb048afc40225cb8a196fa48e24525fb419e0eca8525b3ab5b96bf18d8196f4b9419a2c6ec8562502a28b1f7ef9847822372bf49b4c"}, {"function": "Protein", "namespace": "HGNC", "name": "GRB2", "id": "f94af8faaaccda960957759a32709642d7b4d818e8c8ba3ed97d7ba05833b4af9c016e3eb270995a8fbcd1fa75f839418fc6a71673178efd3786e4f881a3df32"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3A", "id": "4dcc5c23063ff0124b5d1cbb5234bc651bda68ab1675a7f4f5a55b966f6e2a610cd47d0b43d14895e16bc8e506da0f6d265a5d9c7490c754631596b2536de8f0"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3A", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 21}], "id": "6726345e01ca0ac81415b609466ad644468403b31f6346b5d0abf310b68ea93c81a84ef275131eed7ece8119e29a36cca94e69337c69690fd3925e9a3dd876e4"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "22a248fbd56e870f6b8bf39f7e1b4d0300ed008ef2341689ccd1d23808b9b8cc284e8176597c7033adeae01576043d8c3530c96189f1f22bb816f0f4883d6c43"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 9}], "id": "8d7ebbd9db06bfd2384321706d086542b1139faa7e1e65bfa46266a43582c9b2d1475fad41e42b54b51c5c64fe134658d3b53c01964ce52c62163f2077b4e180"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Thr", "pos": 668}], "id": "ed66a1167d12bd95b24d8ae97dc7e1456240e893e1aa96f26b6eaf605fc310f5582ed0be10b5fc200f60ab250b9c232598bea183c84a8e2fbc9088bd84f977f3"}, {"function": "Protein", "namespace": "HGNC", "name": "GYS1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "2ba6b4a2a4fa24a243358279366f2d0fbbabf0c39b1c5649db04fd5c8640fb3944f095229b86a3631246377a90179a490239b0fa59f39ac114c4f1eb868d9e1a"}, {"function": "Protein", "namespace": "HGNC", "name": "HSF1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "609f9fefa746828ae1180ab92604082e8d4f497ce0bf66fdade425244e28de0b8824ba4fa11bbb2c238f8b710f71787ba04a4b087d1ff70d416229d0a744ac76"}, {"function": "Protein", "namespace": "HGNC", "name": "IGF1", "id": "3369894fadb1dfa2a161a7804d9e5be75205b590f45176482fbb7013986d328fd7874e0e48874a6658bc4a2d90f06abaef588ce4071f2e3b42a29a7376a4e892"}, {"function": "Protein", "namespace": "HGNC", "name": "IGF1R", "id": "b31afcae01c7f92d5d2820a46e90bac3095691e49f1760c5d8cd5c6f6cce073ab81487a24e56a4bd8fa79a232691c26d4f016410e2d8be0d58024eaf77c8a85b"}, {"function": "Protein", "namespace": "HGNC", "name": "INS", "id": "bbf5c1f16cd0d6ad433776f0bfeca42c89fd769028501363322b16adc74541669b4a0e8ddaf039ade6e7341f046de2ad42cf1f110f16c8abd4666fd4ee201149"}, {"function": "Protein", "namespace": "HGNC", "name": "INSR", "id": "72e25187d4bd32d07aed8b4b69a5eeda3f0f4424a8103ecf2132f704ff8ff7fa57768077c1cb46b8a08d4df499cc0a5df309a3398e938ba87d237ccd476709a7"}, {"function": "Protein", "namespace": "HGNC", "name": "IRS1", "id": "695da0e7d607d0d8061d5373f9a98d49bc0f3b60bca1ab602f2ddb4a4b1a7c127fd71bea902b99954f596c02aff9fdf1e4cb788a6db5f90172dc8c808a3c0bf7"}, {"function": "Protein", "namespace": "HGNC", "name": "IRS1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "98803c9e9036e5d529eadab563993b60a3514eb033cb4c3881dac175ea3e65e9ae95819c8643e0ea85f6f883bcad7076002c975a4f17795aa8be53c689a17c74"}, {"function": "Protein", "namespace": "HGNC", "name": "IRS2", "id": "79d56bc18f00ae9dc237f4fe3b47c271414f61a63d62f77eab15110a056ec86cbd7588b031acdd1278b86a2d38e089e56eeb356820facb352267cd257148ef2c"}, {"function": "Protein", "namespace": "HGNC", "name": "IRS2", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "079ab3102e2d38736babe67f652c3f312623e03b9958d92a5fe914bfd482007bb3a4465738d8b4820d589f8e7ad05d076e2875ab69ef8eac9c893f75a12cfa6a"}, {"function": "Protein", "namespace": "HGNC", "name": "IRS4", "id": "1a4fc1ce12dcb5ded469c02e3618dfffc1f1ff043cd6b03c61e063fea91cb9ebfd69a3652c9e9ccec4fc016b5f9ab93677bce3cbd20cf472d2100df1103262a8"}, {"function": "Protein", "namespace": "HGNC", "name": "IRS4", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "904ef16322cd276c2d247db4f0fe1397ddd1c4188d7adbeb7db8b3f8029e864987e81b46484a9e00f36feead8beca70056e827c996cbc4381f12f6dee26e0d71"}, {"function": "Protein", "namespace": "HGNC", "name": "JUN", "id": "54cf70b0e3223232ffad00658dfdeacf4c42283c91f943562a4debab6c786a69bb8021b49d44ab47268272c5c0c28f47a456172e7a4ce508bb34c8b6bcb23358"}, {"function": "Protein", "namespace": "HGNC", "name": "LEP", "id": "0a39584a2cc655be426e343ece48d99437c516787949702ce6e68c7372f64f9953f2dd5922c0c89e8e19bb750f2f7129a881a984e690183463283a61ad651e02"}, {"function": "Protein", "namespace": "HGNC", "name": "LRP2", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "797bc73851f63f7d13d6aa29199292ba0b3f2b947d6dbb926c1a61021439408212537f3dbb5ac386548021032211d04ab343c699e8e8e0e4349cb6ac0a54b633"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPK10", "id": "2b49dda6fd0b958a60a0e33d971d92eadae0f1a4588489cc5a47209139919654e8686b7e3fef8608b14f2dd903ddd4d3650b4f486a2da7f774552e8dbb16b2cf"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPK8", "id": "e370f32babf1d093baa470210581c5aaf7fe894eb3f730dea55f7b963c45470e6ef9fdb12686d208f0f4b4fdeaf6de23c15f4d077cf1cfaafaf2243ead13f2bb"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "frag", "start": 226, "stop": 240}, {"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 10}], "id": "4d2781326b919bd4cac5bb30bb14b17bb9facd5aebe3dacf98dd27d87424d8fae316cb221fa85c94c4e04f1bebbb7a0783723cb898fda5d44cb709a97e03ca2a"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Glyco"}}], "id": "7326a8bbbe7f274931b81154ee5aff2971215e9215b9533cfe2cf13089d0743c1f32919833499afac4b90a4a228cadbc829cea12135a8b40f2a18f4a76a8ce36"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser"}], "id": "301da971dfb25c858d07f5501a0debc60f46c9718cf62fbd7bda73401a68f8d3cae20c2a6ee6789b4c971f6fa04d76947939a6f8c7ad1e6bb67cc6646a859f95"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 199}], "id": "a145df05055e4436ddc08a7d9e576954162015f2fd2fa4cdbb4e673261fe4932313e7e8984a94c3d8624252ea9edb21bb2b1a15071d766a2ce5e919d17a2735c"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 202}], "id": "49b56446b699c749fbb01c4560254bbf621f44bd52a02cb74e212fb0ef1b9b1616a31cfe6ca06023fee3689ef552a3e8fe71211987ebad4180c2d78535f4ad7a"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 235}], "id": "56b559ea103ba90d8fd62e908303bb518afc413fa2e659f3043602e7e227a4f345231987467945e1a02d74aeb5a1840ec6759bdae3109cd4836894ddd9936f95"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 262}], "id": "c20d653a77090fa48337a73d9915475bcb411eb52f7e239d287da66a8d92ac32ac84146976f90af86f112ccd6fb631b1dea88f465bf333cf545de4f9a44d07ef"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 396}], "id": "233ebce30d7505cee42acc956f9d268e5b725e14853bd56fab3b87a93a4e0c8141a6fdec062d10e9c4924f6e13a61184600872c2f5080656e3ca27227eb4cb93"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 404}], "id": "a448f901ddc919f32d50fa5284355b4eb4ed52e9ebf8705052086706d728d8ebef0cc66616b7fbfda3aeffd49db6e41134fb39996aa9b996a73bce331de95767"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 413}], "id": "36a258cb3297b4d1f2d977824fb5deef793f37f08d05d612b3a9f803bc6d1a7121faf74e7967da2fc34609a4a67f7e73ff68bf48cdf8d3be9fae68f99306e484"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Thr"}], "id": "66d9c938f4d1cbe8c06189a8302e57afc1e64bb7d606c86dcc5b82f1037a71c8e90a52c08f515e1628665361862407175ca7bc6f9575962bd031ce27185c4c57"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Thr", "pos": 205}], "id": "24f81ecd30f95a3f531b41b720220bf9d7658f3707c73433cb4f0aa57bc57aafa73ff95df5991871c0528b3a9de6d2ff36d46cd5b85e906f33d54e6b47bce815"}, {"function": "Protein", "namespace": "HGNC", "name": "MAPT", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Thr", "pos": 231}], "id": "fd67fbe5c0c0911e8bffaf415eb40748a781d8776f2e2cdf8a3f4f97f0f2f312aaa680c7b670dc27b11d220f0079b4d5e41cbcf095a568bc644b6e9eaefc50b3"}, {"function": "Protein", "namespace": "HGNC", "name": "MARK2", "id": "32e9705a2cfe2236e89f96b1de2674ed6b928f961ba06a2ee26a04d2758841c562de68ad629751e3068693935cde11d4c376ccf85a83ede814fd5b8c2721eeca"}, {"function": "Protein", "namespace": "HGNC", "name": "MARK2", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "ff80fd7c94231dc18b4a6ea31b4abbbfdc258bb0a6b4cb6ac19c8125f03ac477a411a554827660fd57128ea671d01e7484e5a172443b6a14cef6fb4dc17e856b"}, {"function": "Protein", "namespace": "HGNC", "name": "MTOR", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 2448}], "id": "b9b5a11b3da1782b0aee0237abbdb744699b8f06b9068915111ea5d62f84025d1379ebfafba7a9fd71bde9da6b6db98d2df26747e8c605230be097bdc1bdb479"}, {"function": "Protein", "namespace": "HGNC", "name": "MYC", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "5eda04757fc0794e1aa601143e238930d1990ec22acb6af394a15ddbf4050b7afdea8448217452ee01f456c4d0b60310e4f139ca519f6b5abc098aee5da78886"}, {"function": "Protein", "namespace": "HGNC", "name": "NFATC2", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "c6b521270aac1631a3f0bde5e9184135bfb61ec4d27216109c497ac63c794fa8b3ca986d2bdc09af3512ec1bd42a71363824cbc0a76421b31e331e1ee223acb4"}, {"function": "Protein", "namespace": "HGNC", "name": "NFE2L2", "id": "f707e81d79f55da8c33a4f0fad8eda52a2960c3256f2cd831a5d51542d824e4ed26a18f97cebba93ca1b75239d492efaa0acefa07f5cb15dd98f75c9078ac249"}, {"function": "Protein", "namespace": "HGNC", "name": "PIK3CA", "id": "d9ac0f90136806f4d0d7a9fbf266e573707939cae3257fd0473dccd7d18669cb3435a3f87553f00f66716b1ff6cf4d5bf6bd1e77e036817080076eb4fa6d699d"}, {"function": "Protein", "namespace": "HGNC", "name": "PIN1", "id": "a4b6cab238e3cf3e494c884c3b540f12c39b1604b07e59f53693996e4bc2658cc64c2c01ccfa634d6236037a0b85aec593bdb9b7667a3f19d8d33e93614f39c8"}, {"function": "Protein", "namespace": "HGNC", "name": "PPP1R1B", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "b5527344d7688571728fcb6e2a2574ba7ebc4add7e4084b916f56eb04daca385f69c408924ebead8ab66b01e724df50d66f8f7d9df5dff33b002292980228f59"}, {"function": "Protein", "namespace": "HGNC", "name": "PPP2CA", "id": "6baa9d09125d1244431e7a8a8d8788f573889554982a8abcbd5c5d85b5f5c28771ff34971f8ab09e92bd0d7517b229ff34958f0f1278cc23410b7141982490a1"}, {"function": "Protein", "namespace": "HGNC", "name": "PRKACA", "id": "1822e503df5a619b37063f0dabc67b9564a6e7ba2ae477dd5fb70c8996f53c0ba8242d64510a626c1b766ecdd1dd4f74cf39d7d49675cbba7d2fae2fa5c903b9"}, {"function": "Protein", "namespace": "HGNC", "name": "PRKCD", "id": "a4818ca61c5417fa6b2116e636302098bd94e615b99b74b65bff4ed2ee140730f2f0feb3f97784dbf9066d71a7f99037192f7b8f09d9ced763c49de7a84124c2"}, {"function": "Protein", "namespace": "HGNC", "name": "PRKCD", "variants": [{"kind": "frag", "missing": "?"}], "id": "dd8c88a4c246d872a4df4640dc071671d2f002c09615657dba69d74242cceac586abe39121c8c9cef6a1076baa6f4d27e587b222c05c13fec8fefce8936767d2"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "d26df78279d95ca492e2bcd14ca29c9f06370d1173f09ea8511583119e6d77847919339cb563b84643f02fc166c650e2050a22d5138e7e49dc8eec1f13966886"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 353}], "id": "3577238735755d8e9dc55188d9ed66f77e27310ea57c64bcc05286de616f789c4bc95e225d84aeabbaad88f28a0795c6118b4eb09fdc31895349ed976e374196"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}, "code": "Ser", "pos": 357}], "id": "2587347cfe5e765b546508277915a58029f35eaef627369fda0326e66aa552960efcd3d21cf7cb0eb1e16b4a97fbe6701ead93aee76e924ec56008cabbdf8055"}, {"function": "Protein", "namespace": "HGNC", "name": "RPS6KB1", "id": "dbc870612632c31c7ec03d133088ee4c07204a1b43939bafedf632d785567bdb517ebb2d68523af24ff3b83e2cbf9aac1c7540272479f513b092bab1d4f26acb"}, {"function": "Protein", "namespace": "HGNC", "name": "S100B", "id": "f7c74d78e50e9084bbd32771955eff3c412004927980d769d1edc2fba3b569af908e85437a88a7eed468bdc0b56c2c60a4bc2559ff565f010a15f1040abfc855"}, {"function": "Protein", "namespace": "HGNC", "name": "SNCA", "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3"}, {"function": "Protein", "namespace": "INTERPRO", "name": "Amyloidogenic glycoprotein, intracellular domain, conserved site", "id": "0755e0dd6509f38c335622890384e735ef1d94e443f1c1a37ba5e1a57f3be60114b17c2932a4617ca6776e876a676c015ee6aaf605a4415b909325ce752b619a"}, {"function": "Protein", "namespace": "INTERPRO", "name": "cAMP response element binding (CREB) protein", "id": "53b9b9bf796d21f247f6e9306c368c4f67a4d20d543f9a050a09dd8c75a8ad5ccdb53dc2bcee433ddea702f57fc9d95f74abc78be3b12012f717fbf68473ac75"}, {"function": "Protein", "namespace": "MGI", "name": "App", "id": "78d5e866274e31ff2b09ef6663cb084c62dad139135478daf1645a32988a8214b14330f44be626991077159244c9e35920dcc0025af376746275c215fceafca6"}, {"function": "Protein", "namespace": "MGI", "name": "App", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "031b0399cf873b2f9e5d204bc439e59994a9847c80cbd408193f7c7a26d813e8cc118b367613629437a7a0fd741c509bd2447aabd5930a0d22fd8f7f0520647c"}, {"function": "Protein", "namespace": "MGI", "name": "Cdk5", "id": "2242415e42a04751fb07681acad9f9769f79233a0a87835fe653ed5eee7c77c637074541986216571a96f3ce1b3c69824b051ac84147deb6ef24b12f4bda30f6"}, {"function": "Protein", "namespace": "MGI", "name": "Gsk3b", "id": "b736f9678213df5d00e417b39eb991aea58a169a9b2d00bc986629a81d8bc014dac30bb5e246f35a286104e3959c859ab388a6b724bbb1e7c8e6a98ca23de14f"}, {"function": "Protein", "namespace": "MGI", "name": "Mapt", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "866eb2548d3ebb8c575db22b2dbbed794da750619a04d31b30c8ffbd59b1562d89d2191f4ea30cc09874d9d44f251a203918593f4cc4e29a12eb1d52d0f58bd4"}, {"function": "Protein", "namespace": "SFAM", "name": "AKT Family", "id": "3688c50ea6bd1508059871b6c133d4ddbcc43ba60fff7f2785c1c86c5a7c6000ac6be617b23ac5df27c8f40621a0f4c24a4f0509ddc82032f9784033e7845240"}, {"function": "Protein", "namespace": "SFAM", "name": "AXIN Family", "id": "a071bada6817a3dcb26bcde4f930dc2a2d6bb3e8017edfba9b1e8c3878772e1b36114edcfbd54ba0a1bac983de1c65cc5e94b9a706417c0fd77f05914e4d26c1"}, {"function": "Protein", "namespace": "SFAM", "name": "CREB Family", "id": "cf949c73a8b86c43061f7592441187a7fb844c44b47c25633d7829b648d31b04be88a3ffa49c071d7d425bd6c88a418625aed8656724ed37209899c293d92d45"}, {"function": "Protein", "namespace": "SFAM", "name": "EGFR/ERBB Family", "id": "f08714f927f8dc517a2c9660e80e507bcb57d0743e33b9fc1c636b16174190fa74a1b1999a4bc5f2fc5028baa0e2fa92707ac11f7252dfc79cfc8a4047fda386"}, {"function": "Protein", "namespace": "SFAM", "name": "GSK3 Family", "id": "cffea66847216ebd8da555d9de94f6b4589db341395576c270e80c495463de8fbc4753df7612cf9e11ef65cd844eae0c11e1ed6683839e5822d7e2b2e15b22fb"}, {"function": "Protein", "namespace": "SFAM", "name": "GSK3 Family", "variants": [{"kind": "pmod", "identifier": {"namespace": "bel", "name": "Ph"}}], "id": "b024e1a91e6575749609e86e9fa49f6808b7c6d618c7f56d4b915663b4f1d49589b0a1e4a7b1b3e5099723a8551ba77f61f8b22df3ce36a7b04cc9d7ef765fac"}, {"function": "Pathology", "namespace": "HBP", "name": "Neurodegeneration", "id": "1e32e61de82d42fab0a4abcd15d32d3fa5b2f65883b2d99c828d4019591a465f11cd017eefe918bc5d066b7f3cef9d21f4e0988e5c23cc2c135313815478263a"}, {"function": "Pathology", "namespace": "MESHD", "name": "Alzheimer Disease", "id": "0893d59040331bc1b155187396067458820ab2635e0138b840323082d33d44b964ab1240f5aeb64c5360e1340de40545835bc744c181abb910d64c923d55ff2b"}, {"function": "Pathology", "namespace": "MESHD", "name": "Inflammation", "id": "105f4167508b4d96d8df8e04cfb3d84bd7d3af8b312f852502dede706fbd61636cfba0f29d669053a109275f0761f212596ee9f18453d168da563f716b9eaa15"}, {"function": "RNA", "namespace": "HGNC", "name": "BDNF", "id": "0716d15a357b13aac3835d0a2ebf6523d6c878a1bc6f29defea119a74c9b1ee017c1a7d31b31dcfed4b4329c85f46fdf746dfdf6ad2234ec6be6ae17d0454a67"}, {"function": "RNA", "namespace": "HGNC", "name": "GSK3B", "id": "d19d75d0ebd1faebbb84c97d5153b12b61680456833ff8a8e0d4d85da0030a7c76e304b19e4ab6f59275e8f01318d1dfe582ca5ab22368c7378dc7201ce3bf3b"}], "links": [{"line": 45200, "relation": "increases", "evidence": "Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3ÃƒÅ¸, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes", "citation": {"type": "PubMed", "name": "BMB Rep. 2010 Oct;43(10):656-63.", "reference": "21034527"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 63, "target": 90, "key": "464318281f52bd81e6e57d99443f1f498fa929ce77250c4fddd00f2dc5b7dab4cb9ea1ba078176df3a45a90e31e895d92ef0b0a499bcb34dc727db147e380d0d"}, {"line": 862, "relation": "directlyIncreases", "evidence": "Two main protein kinases have been shown to be involved in anomalous tau phosphorylations: the cyclin-dependent kinase Cdk5 and glycogen synthase kinase GSK3beta", "citation": {"type": "PubMed", "name": "Arch Med Res. 2001 Sep-Oct;32(5):367-81", "reference": "11578751"}, "annotations": {"Confidence": {"Very High": true}, "Disease": {"Alzheimer's disease": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "52774574bd7547d36311c285e86f67c23f50053fcd403289982b81aad5db8ae9a760d0b4211b2c1f1c9da0a069429a0f2d0b501112f515e67188e2d5b1bf532a"}, {"line": 3622, "relation": "increases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53\\ expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-b, may also\\ contribute to AICD-related cytotoxicity by up-regulating tau hyperphosphorylation. GSK-3b activation and collapsin\\ response mediator protein 2 (CRMP2) phosphorylation, along with downstream tau hyper-phosphorylation/aggregation,\\ neurodegeneration and memory loss", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "4dba83696413e5c05a9232eab43bef453d4c3338e224ec6df20f51d7cd5efad79c5dd1fd9ac275e00e6ae694d065d14f0cfe920fef59185a55046f490c3235ad"}, {"line": 5110, "relation": "increases", "evidence": "DYRK1A phosphorylates tau at 11 sites, including Thr212; primes tau phosphorylation by GSK-3beta; promotes tau aggregation into NFTs and the several-fold increase in the number of DYRK1A-positive NFTs. Phosphorylation of ASF by nuclear DYRK1A increases the level of 3R tau, leading to an imbalance in the 3R/4R-tau ratio and triggering neurofibrillary degeneration with a several-fold increase of 3R-tau-positive NFTs. Both cytoplasmic and nuclear pathways contribute to neurofibrillary degeneration, loss of neuron function, and neuronal death.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"CDR story": true}, "Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 90, "target": 114, "key": "10e6339c4769be61d0aeed61affe64af8fd34fc923f67cffeece1902789cc4085d5a2d7260c5b0d1ed86fc8b58ba80789df38b0c90c997668353cd27dbcd367b"}, {"line": 8040, "relation": "increases", "evidence": "Akt substrates such as mammalian target of rapamycin (mTOR; Ser2448) and decreased levels of cell-cycle inhibitors (p27kip1) are found in AD temporal cortex when compared to controls. GSK-3a has been implicated in the production of Abeta peptide while increased GSK-3beta activity has been implicated in tau hyperphosphorylation and neuronal cell death", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}, "Disease": {"Alzheimer's disease": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "b36bc24a40d04111c158b90b18f5465dd0c6c1f35e0e0c8165b4e6e7cd4e1f1fe8e8befe389b60a3492d6b5486c4f9e69aa9229d4a3e4451ce70cdf201f065f6"}, {"line": 10983, "relation": "increases", "evidence": "The phosphorylation of tau is mainly promoted by GSK-3and cyclin-dependent kinase 5 (Cdk5). Besides these kinases, activated c-Jun N-terminal kinases (JNK) and ERK-1 /-2 signaling lead to an increase in tau phosphorylation and th erefore might be of importance in AD pathogenesis.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "759f286927b9cde004c49251114d2316866dfb0124aa5b5d846b9024fdef23720ef7015cf1dff32e3d96f12e82cda37b487c0c8d0675b29d72ac0349d64764a7"}, {"line": 12625, "relation": "directlyIncreases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "17f8f5eb97a0aec6e97e65edda7d7ebabdd5bc4197d5e20e866807a1c99b4cf8d4b154e5ff6514386cc602428db8d394a83683b742d7b276ebb26194a6ccfbd6"}, {"line": 15317, "relation": "increases", "evidence": "The inhibition of this kinase can prevent the aggregation of beta-amyloid (Abeta) and hyperphosphorylation of tau protein.", "citation": {"type": "PubMed", "reference": "22718609"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "ff658cc7257b2923cfd30839bf24f4751e7f8f8d12d649a15f9bb7b7498b2969f6fef9e4eef2a9d19f508cb3aa8272f5ca42fcb2cfea76e5b5ae61b611974968"}, {"line": 15971, "relation": "increases", "evidence": "We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "reference": "19429119"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Leptin subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 114, "key": "671fa846bcecb8edf5d66159bffb96305f8bcae7ec661bcd89f95c7a084a8e5eb8224c83175eb15df51a81a8e86abe1de69a46576f46dd58d98203b2906686e9"}, {"line": 17076, "relation": "increases", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 90, "target": 114, "key": "694b01ff5fe00d6e8ef84c3afd4f300a602a84de8edc3c9aa49eae1cf2b1dd51c7577c145d384c6f1782c136e3d779b52803abc39becb4eae3544c5ee144dc19"}, {"line": 17241, "relation": "increases", "evidence": "Here we describe results that show that although MAP kinase can hyperphosphorylate tau in vitro, activation of MAP kinase in transformed fibroblasts does not result in hyperphosphorylation of transfected tau, whereas glycogen synthase kinase-3 beta (GSK-3 beta) when co-transfected with tau does result in tau hyperphosphorylation. The findings imply that GSK-3 beta may be a stronger candidate than MAP kinase for inducing tau hyperphosphorylation in vivo.", "citation": {"type": "PubMed", "name": "FEBS Lett. 1995 May 22;365(1):42-6", "reference": "7774712"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 90, "target": 114, "key": "6c4b34b728d2555efa521fb68f141a6e07ec5c5d32799061c5096f8f6edcbd0ac9d142f1c753b363f1c37dd29b5b390ff8a24ed4b86bb9338b3b7d77b112e340"}, {"line": 33700, "relation": "directlyIncreases", "evidence": "GSK3B is known to phosphorylate the microtubule protein tau (MAPT).", "citation": {"type": "PubMed", "name": "Neurochem Int2007", "reference": "16973241"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "b7d2e287e14551bc7b87b770c20441c1599e13fd59d010c608fa82790861c31719f3b6f2b96a91d934cdf3974e38b6acc6a9b4e602708a9664e5220189f5e8f7"}, {"line": 35577, "relation": "increases", "evidence": "These studies suggest that PKA, cdk5, CaM Kinase II and GSK-3 are involved in the regulation of phosphorylation of tau and that AD-type phosphorylation of tau is probably a product of the synergistic action of two or more of these kinases.", "citation": {"type": "PubMed", "name": "Neurochem Res2006", "reference": "17120162"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "9e247d09198df137c8a8cbed941a7cfb474278b7a5542686f69405dacb20f39121cc80faeb919eac88d06b3817fab10b4a1d3328043421845d805d15b6bbb703"}, {"line": 35594, "relation": "increases", "evidence": "Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2001", "reference": "11013232"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "7400d883a0b3aad776a7f4f6e134e4c02fe1c13366b3ec005aa9ecc8fa955ab5f1a9e4cf6994c76e2ebb5ac1909bcd85d73af46e5686b58d93a42e788df7d2d8"}, {"line": 35609, "relation": "increases", "evidence": "A number of kinases, including mitogen-activated protein (MAP) kinase, glycogen synthase kinase (GSK)-3 alpha, GSK-3 beta and cyclin-dependent kinase-5, phosphorylate recombinant tau in vitro so that it resembles PHF-tau as judged by its reactivity with a panel of antibodies capable of discriminating between normal tau and PHF-tau, and by a reduced electrophoretic mobility that is characteristic of PHF-tau.", "citation": {"type": "PubMed", "name": "Curr Biol1994", "reference": "7704571"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "11f170de4cb64d4176dd6e53999dd63c6d8f23a0e301805e3e573bba069cb9d3942b4b09add16afb5b90d3e57f313522f11981c9b392c399996f9ba2f57000d9"}, {"line": 35656, "relation": "increases", "evidence": "Phosphorylation of tau protein is regulated by several kinases, especially glycogen synthase kinase 3beta (GSK-3beta), cyclin-dependent protein kinase 5 (cdk5) and cAMP-dependent protein kinase (PKA).", "citation": {"type": "PubMed", "name": "FEBS letters2006", "reference": "17078951"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "b1876612f9e70624d5864944a4aa13eb9c2afc8a82b6fafde510bdc24733600630d667893b85b0223421afcff8dd13e688cfd9c40abfc7a21168b476d439d919"}, {"line": 35768, "relation": "increases", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "0d710570f819d938fdee172781ebc7084a9eac862cb5d04bf4c5bef238987b42097d00fd389f71fa9f82a9b416a35e74a90fa48879e8f1beb054bb7ab0d31afe"}, {"line": 35991, "relation": "increases", "evidence": "Thirdly, GSK-3beta has many substrates, such as beta-catenin, APC, Axin, Tau protein, etc.", "citation": {"type": "PubMed", "name": "Eur J Pharm Sci2011", "reference": "21352912"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "e71b62e5294867e7e6777ce63ecb184912ec698bbac9db2346f582c1d6ba096f2ba734b1d722fc9c3ebaf69a476b44ca01e4542b4f56423f3009eff76cc6d5c2"}, {"line": 36544, "relation": "increases", "evidence": "In experimental pmodels of AD, GSK3B has been shown to hyperphosphorylate Tau, leading to microtubule disassembly and loss of function", "citation": {"type": "PubMed", "name": "J Psychiatr Res2011", "reference": "20576277"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "84e9c51d06c070fb2d272e37b330096cdade691698f9457fa958574eb0293d3cea81aecabcb546bfafa6e9916dadea376103c23603316933a03a529e8119f596"}, {"line": 36553, "relation": "increases", "evidence": "Glycogen synthase kinase 3beta (GSK3beta) is a proline-directed kinase generally considered as one of the major players that (hyper)phosphorylates Tau.", "citation": {"type": "PubMed", "name": "J Biol Chem2010", "reference": "20679343"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "beffc6bb3e4220824f182840c489a6304a4cacd64384ae394025add9b4d437a227ddae3662a4591e1e85f95abacd1f93dd8420fb0d19f0dd6a35e44c2936ba8f"}, {"line": 36564, "relation": "increases", "evidence": "The results provide initial evidence that TPKI/GSK-3 beta/FA after heparin potentiation may represent one of the most potent systems possibly involved in the abnormal phosphorylation of PHF-tau and neuronal degeneration in Alzheimer disease brains.", "citation": {"type": "PubMed", "name": "J Protein Chem1995", "reference": "7786411"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "20abd6acadf90cb79d3a9db8b4ee17c3126eb0cb73e6a10ebb146410c33b8559eaaf1d9c2a814f3daf1c986dbf72a723779a8e1ab5c43aa6f87580272a7ccf7d"}, {"line": 36573, "relation": "increases", "evidence": "A mixture of recombinant human tau isoforms phosphorylated by GSK-3 beta gave similar results to those obtained with control human brain tau.", "citation": {"type": "PubMed", "name": "FEBS Letters1994", "reference": "8050597"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "6291aa3c01913310e469ed795a022c48b55652297b831a845028417613f60a225e94c90a101c47f6dd3b44d516683d6d6cdb845aa739a4c8b7de197a441a02d7"}, {"line": 36609, "relation": "increases", "evidence": "Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2000", "reference": "11007782"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "85870d2dd457835c5f1531c48958053d87098a473b7319ff8fb7820ff53fd8eb01e8dd0e2718562a11e8b86f29f01b29587358d0edea1c2b3e418805d595584a"}, {"line": 36618, "relation": "increases", "evidence": "Recent studies have shown that GSK-3beta phosphorylates the microtubule-associated protein tau in vitro and in cell culture.", "citation": {"type": "PubMed", "name": "Genomics1999", "reference": "10486203"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "4d8e0366fe07d0ae4ef30203196571b4b28aab0d15897098af42d6e1303495695dab04c0fb0c4303cc6ddf04485501ad10ddb2a79b5909ab0ba1d8999f7c3264"}, {"line": 36652, "relation": "increases", "evidence": "Colocalization of these epitopes suggests that tau protein kinase I/glycogen synthase kinase-3 beta abnormally phosphorylates tau and is in a position to disrupt neuronal metabolism in anatomical areas vulnerable to Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res1996", "reference": "8930358"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "ef45c6a8d12d05274c4706bfb2e9fefc4afc363fadbff84bae1bf6dc847873f29c7fe75f86917028c68d57c19451cfb57aeb93e3b26006b42d1f2cd005edd775"}, {"line": 36676, "relation": "increases", "evidence": "Two protein kinases, tau protein kinase I (TPK I or GSK 3beta) and tau protein kinase II (TPK II; cdk5/p20), have been isolated from bovine brain microtubules", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2001", "reference": "11181841"}, "annotations": {"Confidence": {"High": true}, "Species": {"9913": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "7aa07303e0a89be28df25bf7af92275465879531b508e524427cb298ab96d85dd0a6a5c50a8e467c46f38897e0b58673dd1368c616b5160fef9be3c0d21fac7f"}, {"line": 36688, "relation": "increases", "evidence": "In situ, FRAT-2 significantly increased GSK3 beta-mediated phosphorylation of tau at a primed epitope while not significantly affecting the phosphorylation of unprimed sites.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "15522877"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "75bece2961258efaf4beb6db0456ecbcaab36a98c91257aeaae3dbb1c0ec0ea84c10bdfadd8fdc58c24f74ea8ed7c80983c47d76dadbed327b6dc9802884ab9c"}, {"line": 39200, "relation": "increases", "evidence": "Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2003", "reference": "12191990"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "MAPK-JNK subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "5e3c594dccda08b967f046a033f4a2c53d5b1e195aca4954ca39027cf7b7b0b2ea5e9ff3c5afaa0114edb32640b5a4345a5ddd1e9814519910b8ffacc7b8af7b"}, {"line": 39214, "relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "f58795e87d3641a2b465883ad7194eb050550ee316223f74ee7a1dc140a8f47371a271c58cf107546f9313ad6f75a8cd41860219f0eac9f45662bd5ea6631488"}, {"line": 39278, "relation": "increases", "evidence": "Glycogen synthase kinase-3beta (GSK-3beta) and cyclin-dependent kinase 5 (CDK5) have been implicated as two major protein kinases involved in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles.", "citation": {"type": "PubMed", "name": "Acta neurologica Scandinavica2009", "reference": "19154537"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "11cbac14105f668690a4de571427d6845990514b765a4fbc215fd5e4c8bf6f9097e88e1df11e833d322b97ee31bdbf2ab5d0e54a358437b0e0952a039e156af2"}, {"line": 39593, "relation": "increases", "evidence": "This interaction is regulated by the phosphorylation of Tau at selected sites, by glycogen synthase kinase-3beta (GSK3beta) and cyclin-dependent kinase 5 (Cdk5), and requires an intact microtubule network.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2005", "reference": "15686969"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Tau protein subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "b582a28f8d27d2ec5f0fb53cfde7669a6563ff87fd3ca7711981110536d230ba187f545dfde7bea6c8789bdad82238b9289ea2af48c66ee4222e2251224bdb65"}, {"line": 39967, "relation": "increases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 114, "key": "cbdc37404ac99d84b8636b3141f81c60ca7c9e11049798436ac622970af8c021f36b09cefecca5b9d8b1a1c8facf85e7b3a390f3972d1c601d907f49e39594b7"}, {"line": 2532, "relation": "increases", "evidence": "In the absence of Wnt ligand, axin recruits CK1 causing the initiation of the beta-catenin phosphorylation cascade by glycogen synthase kinase-3 beta (GSK-3beta). Phosphorylated beta-catenin is recognized by beta-transducin repeat-containing protein (beta-TrCP) and degraded by the proteosome, reducing the level of cytosolic beta-catenin.", "citation": {"type": "PubMed", "reference": "22496686"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "3c3df638bf766ffb2de3def1bae1fb10053cd115be9fc02ec4771bfc0525a5d65d4f1e9bcb71df0d7d8d0049b93a73b0f2b725cf2a52346681594cc17bc7b45e"}, {"line": 2560, "relation": "increases", "evidence": "It was reported that beta-catenin interacts with PSs, and that PS1 promotes beta-catenin degradation regulating phosphorylation by cyclin-dependent kinase 5 (CDK5) and GSK-3beta. Importantly, GSK-3beta was implicated in various neurological disorders, including AD.", "citation": {"type": "PubMed", "reference": "22496686"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "c15dde0dcb3b5f814765672d1d0a908ff1bd885450e6b2363352bef9240a28d49abbaddf2712d1d089d6f67104473d0d58bdb70fd5e099d09f87ac43a698e61a"}, {"line": 35917, "relation": "increases", "evidence": "It was shown recently that axin negatively regulates beta-catenin by bridging beta-catenin and GSK-3beta together in the same complex and thereby facilitating the phosphorylation of beta-catenin by GSK-3beta ", "citation": {"type": "PubMed", "name": "J Neurosci1999", "reference": "10341227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "9a1dacd877d2411d1cdc461175894e43584591f3c368c362f4921a04a2de422dc7345355d616f94442b1f3cdabb3389a660ec4b3a7674ae3bbff20b63c86c2bb"}, {"line": 35950, "relation": "increases", "evidence": "These results reveal an antiapoptotic function of tau hyperphosphorylation, which likely inhibits competitively phosphorylation of beta-catenin by GSK-3beta and hence facilitates the function of beta-catenin.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360687"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "96abf9e15b2dd2b1b64b1b7f766e86ce67cbab344d13900895a4041f1dd57f426a963034e04657285a2f0309f65b84b2d60dd82fa3221ce1cc919c88cdd75f89"}, {"line": 35992, "relation": "increases", "evidence": "Thirdly, GSK-3beta has many substrates, such as beta-catenin, APC, Axin, Tau protein, etc.", "citation": {"type": "PubMed", "name": "Eur J Pharm Sci2011", "reference": "21352912"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "0219341965f87fdc62c2a9eacb036bf3b6656baa52cd2363cd3760d01336bbb69acb00a27c485d02b39397bacace4f2cbb868ce7a1ecf784642d5ec5b3258b8f"}, {"line": 36031, "relation": "increases", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "fa5f8921f8e255cc879418e4e8a7500508222bb6cc7d76390be9881c07119050c1d2f86b2537314ddc26661a54c4c132789440171faf9c58e0984886b8e83147"}, {"line": 36075, "relation": "increases", "evidence": "Interestingly, GPCs from AD patients exhibited elevated levels of glycogen synthase kinase 3beta (GSK-3beta, an enzyme known to phosphorylate beta-catenin), accompanied by an increase in phosphorylated beta-catenin and a decrease in nonphosphorylated beta-catenin compared with HC counterparts.", "citation": {"type": "PubMed", "name": "J Neurosci2009", "reference": "19458225"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 77, "key": "27fdea3bdbc92114ccbcf6b329f0d581af84b66525930e1a1b46f1825cc71b089e0733a508e7d7c858bb37fb79356cedc44a027c7363f72d4bdeb1427b53da3b"}, {"line": 39879, "relation": "increases", "evidence": "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation.", "citation": {"type": "PubMed", "name": "Cellular and Molecular Life Sciences1999", "reference": "11212302"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "66045fa5451e1869d2a1f970ea643717a9d8838a6657c2890d022ca8679fc91e0dd43c52567cbdd2590c65147287d636e318b4cca8e9344e34e8e08e0615628f"}, {"line": 40426, "relation": "increases", "evidence": "This pool of beta-catenin exists in the cytosol and is normally rapidly degraded through phosphorylation by GSK 3beta, leading to its subsequent degradation. ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2001", "reference": "11504726"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 77, "key": "7f94c34eb424d240a95bdb57f7aa8b7b8a07b649fc06fdab399f028a9d0ad15c60331c27911cba61d96f42d124dd35521af8542c5533b21d53c59cba884914d2"}, {"line": 42093, "relation": "increases", "evidence": "It was reported that beta-catenin interacts with PSs, and that PS1 promotes beta-catenin degradation regulating phosphorylation by cyclin-dependent kinase 5 (CDK5) and GSK-3beta. Importantly, GSK-3beta was implicated in various neurological disorders, including AD", "citation": {"type": "PubMed", "reference": "22496686"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 77, "key": "bef79c104a29f1cc1c4a2d1a760626396edfca4ee47b39a5b1dd9c12f074c179a8a0c9dda61f3a64aabfda3676dddd2edd7a83d2d3e335ca551806bae37f6c10"}, {"line": 3584, "relation": "increases", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 31, "key": "bfa19f07067ef0e2662bf33bbf925d4f5001d64772603fdadaf21d6279500412da2d3322a082e691257ecde3743e2c61fb8afc469888561ae5f009e3bcde72f3"}, {"line": 42226, "relation": "increases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53 expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-beta, may also contribute to AICD-related cytotoxicity by upregulating tau hyperphosphorylation. GSK-3beta activation and CRMP-2 phosphorylation, along with downstream tau hyper-phosphorylation/aggregation, neurodegeneration and memory loss, are observed in an AICD C59 transgenic mouse line in which Fe65 is co-expressed", "citation": {"type": "PubMed", "reference": "22122372"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Apoptosis signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 31, "key": "54ba9853678a83767aad2378619c756aa7e0ac731ccc238e539c25ff4bcff086d82e93b6b02f9e58a94ab96bf6eb863fe2a096a1419c58ec711d0faed3419e16"}, {"line": 43764, "relation": "positiveCorrelation", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 31, "key": "e18b238ebe398b923078862b2b169bd6380703b2245acefe4dec2870f14c6624cbd3ec45c5f4543bb3c2c15cf9f6eb0c40cad8a806275588682886f43d281bb9"}, {"line": 3586, "relation": "decreases", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 90, "target": 147, "key": "ccc2fb0da8e2857733312b8cc59b25682e56b0c8e524cda19605249f600c1dc01a5f89b75e9ace5a7087920584ec42558a0a9fbdaeb99227e643db63c73c2dc5"}, {"line": 3628, "relation": "decreases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53\\ expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-b, may also\\ contribute to AICD-related cytotoxicity by up-regulating tau hyperphosphorylation. GSK-3b activation and collapsin\\ response mediator protein 2 (CRMP2) phosphorylation, along with downstream tau hyper-phosphorylation/aggregation,\\ neurodegeneration and memory loss", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 25, "key": "df4c6cdf6eb8c833d294b12ce6b448b6ac4fa181746dfb95033f92de05b80c3874438fe9532072732644a96f9796df28155fdc631e14e8671569adbe130eb104"}, {"line": 3629, "relation": "decreases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53\\ expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-b, may also\\ contribute to AICD-related cytotoxicity by up-regulating tau hyperphosphorylation. GSK-3b activation and collapsin\\ response mediator protein 2 (CRMP2) phosphorylation, along with downstream tau hyper-phosphorylation/aggregation,\\ neurodegeneration and memory loss", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 37, "key": "27f93945ee8e01053db2fe09c96a90e7be00b4dc44a8c7fd5ce5e324619e3367c3207d1fac92962bb84fe926a958e6ed63fc67c118e91eeac0126915efd93cca"}, {"line": 39218, "relation": "decreases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 90, "target": 37, "key": "2aae94141ec7578eeb5751036f8ca154314ce54d9498b986c2377f999aebfc38358064a652918500d11948f215e8019b3319e9a106f3de642b683c787c1c1551"}, {"line": 6782, "relation": "increases", "evidence": "In this study, we found the AICD to strongly inhibit Wnt-induced transcriptional reporter activity, and to counteract Wnt-induced c-Myc expression. Loss of the AICD resulted in an increased responsiveness to Wnt/beta-catenin-mediated transcription. Mechanically, the AICD was found to interact with glycogen synthase kinase 3 beta (GSK3beta) and promote its kinase activity. The subsequent AICD-strengthened Axin-GSK3beta complex potentiates beta-catenin poly-ubiquitination.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2012 Aug;1823(8):1233-41. Epub 2012 May 18.", "reference": "22613765"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Confidence": {"Medium": true}, "Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 50, "key": "cd153772bc48d6503c648f0bb28e50f322d7b91ed957274e6ec501776ed0dded594485451cb73654d60c7372a8244b474423f9a2f3e2754291cff08fd85ab3b3"}, {"line": 7279, "relation": "association", "evidence": "Alzheimer's disease (AD) is a neurodegenerative disease with progressive dementia accompanied by three main structural changes in the brain: diffuse loss of neurons; intracellular protein deposits termed neurofibrillary tangles (NFT) and extracellular protein deposits termed amyloid or senile plaques, surrounded by dystrophic neurites. Recent studies have suggested that the trafficking process of membrane associated proteins is modulated by the FAD-linked presenilin (PS) proteins, and that amyloid beta-peptide deposition may be initiated intracellularly, through the secretory pathway. Current hypotheses concerning presenilin function are based upon its cellular localization and its putative interaction as macromolecular complexes with the cell-adhesion/signaling beta-catenin molecule and the glycogen synthase kinase 3beta (GSK-3beta) enzyme. Developmental studies have shown that PS proteins function as components in the Notch signal transduction cascade and that beta-catenin and GSK-3beta are transducers of the Wnt signaling pathway. Both pathways are thought to have an important role in brain development, and they have been connected through Dishevelled (Dvl) protein, a known transducer of the Wnt signaling pathway. In addition to a review of the current state of research on the subject, we present a cell signaling model in which a sustained loss of function of Wnt signaling components would trigger a series of misrecognition events, determining the onset and development of AD.", "citation": {"type": "PubMed", "name": "Brain Res Brain Res Rev. 2000 Aug;33(1):1-12.", "reference": "10967351"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 160, "key": "81862ed826faeba59e95d495e89721efb9b16fbba566761782637a430ae2ae2e27741b6d95f6b5eb27d58b35a0aed6eaa984058a4d4dae54f0f09c30eeb1e064"}, {"line": 17077, "relation": "association", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 90, "target": 160, "key": "4f8af6419a7d3813c2cc7a5878ab6a069656b92aa56058974f452e7c963ac85c5e8d0feb42217fd8ac34ec86d9e53680ca2e75773f52482cdec643a2c4e7e02c"}, {"line": 35224, "relation": "association", "evidence": "Our findings indicate that the abnormal activation of glycogen synthase kinase 3beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 160, "key": "a1badad993775a61eff5007e2aca009a3c674a8255c1267245f1e015830ce72a414f0af62cf9b7fc921b7da7ad066adc5d0b7ed4941f794328c8b5975d650db8"}, {"line": 7529, "relation": "increases", "evidence": "Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Inflammatory response subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 26, "key": "735afb33cfcd3223ef7bb413d09f6928cdbf50e8f6cfe051c55215bd2c069fd14a2c41f9125169736a5fe2b9e6e3b36395e56a50d6b784a73c50d6c021a9885c"}, {"line": 7541, "relation": "increases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Inflammatory response subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 26, "key": "b6312a0fd9e34234cb67aba54a9d723a3c6b4c0b6ded1389a711f851714210f6d5da234627ca015950bf83a5bc33ec0349f81ce74a49a6596f4ecb8024c45c46"}, {"line": 7543, "relation": "increases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Chemokine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 80, "key": "d68cea83bdb077b7468ca411a66476d6805b701979bb44aca8e5f0003b1dd8b8b5fed90d449870ee7db8b3c0507efe8e6252442635ceb6f58938b067d3abdc09"}, {"line": 7544, "relation": "increases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Chemokine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 71, "key": "1b959f0b9235c545dcf2a4493e6534b76c51d6683b78ce06fe071aec51fb85870502427a8dfae95baf67f33c27faf20aa3004bea09151966d1f2f2ee41a16418"}, {"line": 7546, "relation": "increases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Interleukin signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 81, "key": "54f03e5e8040d23fbbca80a1a99924f10f1aa1ee0abdcfeb165c87ca9e92a0fbd3043e924184f6d05b07f4b53ca8fe77057288e2639a7982b01fa3bed57c4975"}, {"line": 7548, "relation": "increases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Chemokine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 72, "key": "9c4b95779716fd51be2dd790c52b43656c920de897654498340dfe70cf904d61895ce2d8aa0333dee858a7f855567f1ac6a9d9c08eb882539e141298e8203354"}, {"line": 7549, "relation": "increases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Chemokine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 79, "key": "e6bc15672fe7237ce046a0bd611ac5dc3660993b878730e1c23688ae78b02063061379408570716730878c0ac723f6022582987d9838a325878581764d4a3fdf"}, {"line": 7555, "relation": "decreases", "evidence": "Genes known to contribute to neuroinflammation that were most negatively affected by GSK3beta inactivation included IP-10/CXCL10, MCP-1/CCL2, IL-8/CXCL8, RANTES/CCL5, and Groalpha/CXCL1. Interactions of monocytes with TNFalpha-activated BMVECs led to barrier disruption, and GSK3beta suppression in the endothelium restored barrier integrity. GSK3beta inhibition in vivo substantially decreased leukocyte adhesion to brain endothelium under inflammatory conditions. In summary, inhibition of GSK3beta emerges as an important target for stabilization of the blood-brain barrier in neuroinflammation.", "citation": {"type": "PubMed", "name": "Am J Pathol. 2010 Feb;176(2):881-92. Epub 2010 Jan 7", "reference": "20056834"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 30, "key": "edec1b1c9b9b714a670536b8bacd3c619c3d5264fdf7b4e9a720d7f689f5f158a1f775fba5efd878b54fbbdf6f0ffdf6befcccd2d8c6d116ff277286a622b5ae"}, {"line": 8046, "relation": "increases", "evidence": "Akt substrates such as mammalian target of rapamycin (mTOR; Ser2448) and decreased levels of cell-cycle inhibitors (p27kip1) are found in AD temporal cortex when compared to controls. GSK-3a has been implicated in the production of Abeta peptide while increased GSK-3beta activity has been implicated in tau hyperphosphorylation and neuronal cell death", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Apoptosis signaling subgraph": true}, "Disease": {"Alzheimer's disease": true}, "Confidence": {"High": true}, "MeSHAnatomy": {"Neurons": true}}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "source": 90, "target": 22, "key": "19ea5c77c789d464f3f40dc4fc4094c76949c334f0c35f6e70f25cb265e95bf321aa7631122bb462348a146b74b771326428f36007f7b2ec2a6a83f553d3f3de"}, {"line": 35968, "relation": "association", "evidence": "Here, we show that cells overexpressing tau exhibit marked resistance to apoptosis induced by various apoptotic stimuli, which also causes correlated tau hyperphosphorylation and glycogen synthase kinase 3 (GSK-3) activation. ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360687"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 22, "key": "38bfa381e09a64f2b28e0bf6db40bdc365851cca0d74ac5175171232b5b2f7b8b3dfa296a5f409079fcbe3977d2492d141079153fe587c385ef627be2f07fabb"}, {"line": 8964, "relation": "regulates", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 40, "key": "0826a790e9e0056a7e86a898b3bd6c047b45d6976e57b834c03bc67b649dea2e6f8e88baf6894bf51b44f0fde61d4782db4f3a350da9f7beb7d7a312c703b267"}, {"line": 10718, "relation": "increases", "evidence": "CerebraiiR/IGF-1 signaling in APP metabolism. Binding of insulin and IGF-1 to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3 and the tau phosphatase PP2A. InterÂ­ estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK cascade regulate different transcription factors involved in transcriptional regulation of metabolism and clearance of Â­ amyloid. APP is cleaved by a.-, -secretase (BACE-1) and y-secretase (presenilin). - and subsequent y-cleavage of APP leads to generation of -amyloid 1 -4o/ t-42â€¢ IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest that not only BACE-1 is int1uenced by IRIIGF- IR mediated signals but also a.Â­ secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 90, "target": 58, "key": "abdaf6e3ece261f74ee4fa5440cad12c9f1db012372616df4974e5321e3d62e49ef9ce6cbe5e2ee80471f6fdd52cbeb05f4b6ca6a1ac9c19d385ab45cf28d924"}, {"line": 10731, "relation": "association", "evidence": "CerebraiiR/IGF-1 signaling in APP metabolism. Binding of insulin and IGF-1 to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3 and the tau phosphatase PP2A. InterÂ­ estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK cascade regulate different transcription factors involved in transcriptional regulation of metabolism and clearance of Â­ amyloid. APP is cleaved by a.-, -secretase (BACE-1) and y-secretase (presenilin). - and subsequent y-cleavage of APP leads to generation of -amyloid 1 -4o/ t-42â€¢ IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest that not only BACE-1 is int1uenced by IRIIGF- IR mediated signals but also a.Â­ secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "mTOR signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 20, "key": "f44333d66c207788dfd8d9ac402f197a51b6bfb886350d87778a1259e5fe60405119a8f52848b69826879482154db83913b17cc1fea58addf31d6584508fe519"}, {"line": 11084, "relation": "negativeCorrelation", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 132, "key": "6cc3e3f65d873d49679be962409c4bfb9e71505d3b72c8612c300a40007c77ea25b38a0573e1d70787a4452f430a5c50ec1e783aae2330fe948b1a21df32596c"}, {"line": 11086, "relation": "isA", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 57, "key": "55bb3e16e5c0f495d93b77d20529c2a6172bd05af38bbf9b119ae29ef8201ae8f107f006d47067a24f7e3f2c4250c7c6da10abd17fb5efec061deb943b2ea8cd"}, {"line": 12584, "relation": "increases", "evidence": "Alzheimer disease, the most common tauopathy, is characterized by neurofibrillary tangles that are mainly composed of abnormally phosphorylated Tau. Tau phosphorylation occurs mainly at proline-directed Ser/Thr sites, which are targeted by protein kinases such as GSK3beta and Cdk5. We reported previously that dephosphorylation of Tau at Cdk5-mediated sites was enhanced by Pin1, a peptidyl-prolyl isomerase that stimulates dephosphorylation at proline-directed sites by protein phosphatase 2A. Pin1 deficiency is suggested to cause Tau hyperphosphorylation in Alzheimer disease. Up to the present, Pin1 binding was only shown for two Tau phosphorylation sites (Thr-212 and Thr-231) despite the presence of many more hyperphosphorylated sites. Here, we analyzed the interaction of Pin1 with Tau phosphorylated by Cdk5-p25 using a GST pulldown assay and Biacore approach. We found that Pin1 binds and stimulates dephosphorylation of Tau at all Cdk5-mediated sites (Ser-202, Thr-205, Ser-235, and Ser-404). Furthermore, FTDP-17 mutant Tau (P301L or R406W) showed slightly weaker Pin1 binding than non-mutated Tau, suggesting that FTDP-17 mutations induce hyperphosphorylation by reducing the interaction between Pin1 and Tau.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2013 Mar 15;288(11):7968-77. doi: 10.1074/jbc.M112.433326. Epub 2013 Jan 28.", "reference": "23362255"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 115, "key": "821461d15822bd01287f8e272482ed205404898a6dae1c2e4f214708e8ec8adfefce26cac6850053dffbbabf17dd7119655f1f3829febdb3fbfa2faac1c0b4c4"}, {"line": 12592, "relation": "increases", "evidence": "Alzheimer disease, the most common tauopathy, is characterized by neurofibrillary tangles that are mainly composed of abnormally phosphorylated Tau. Tau phosphorylation occurs mainly at proline-directed Ser/Thr sites, which are targeted by protein kinases such as GSK3beta and Cdk5. We reported previously that dephosphorylation of Tau at Cdk5-mediated sites was enhanced by Pin1, a peptidyl-prolyl isomerase that stimulates dephosphorylation at proline-directed sites by protein phosphatase 2A. Pin1 deficiency is suggested to cause Tau hyperphosphorylation in Alzheimer disease. Up to the present, Pin1 binding was only shown for two Tau phosphorylation sites (Thr-212 and Thr-231) despite the presence of many more hyperphosphorylated sites. Here, we analyzed the interaction of Pin1 with Tau phosphorylated by Cdk5-p25 using a GST pulldown assay and Biacore approach. We found that Pin1 binds and stimulates dephosphorylation of Tau at all Cdk5-mediated sites (Ser-202, Thr-205, Ser-235, and Ser-404). Furthermore, FTDP-17 mutant Tau (P301L or R406W) showed slightly weaker Pin1 binding than non-mutated Tau, suggesting that FTDP-17 mutations induce hyperphosphorylation by reducing the interaction between Pin1 and Tau.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2013 Mar 15;288(11):7968-77. doi: 10.1074/jbc.M112.433326. Epub 2013 Jan 28.", "reference": "23362255"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 123, "key": "c641ac9113c4a084fc79ce3ed910391d06f7d24737b2f558589f03f6921ad1f700e91279a35924b00b5443da068950c507208750bbe804e09894493c4eebf834"}, {"line": 12628, "relation": "positiveCorrelation", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 145, "key": "9bf20cf20fafbebb1be9e78e1f6e8826988a32259454d07432d2c256e84901d32481a9a10f8e6eb4199be4a6c85b298dae22ded7d9804774f958e9757236d502"}, {"line": 14063, "relation": "negativeCorrelation", "evidence": "This decrease in insulin-PI3K-AKT signalling could lead to activation of glycogen synthase kinase-3beta, the major tau kinase.", "citation": {"type": "PubMed", "reference": "21598254"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"Insulin signal transduction": true, "Tau protein subgraph": true, "GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 27, "key": "445b90195e1fc5fa16dab8867a3cd8e6d53cee84d614c3e83c92de9897cf8ee4df42280c135da8fd71b6878ce1681d5c245e3fedc2d2ee26e4ddc31513b8536f"}, {"line": 14064, "relation": "increases", "evidence": "This decrease in insulin-PI3K-AKT signalling could lead to activation of glycogen synthase kinase-3beta, the major tau kinase.", "citation": {"type": "PubMed", "reference": "21598254"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"Insulin signal transduction": true, "Tau protein subgraph": true, "GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 35, "key": "bfacc3dc6c1f40c4aa61efe1f2f6152685ca4382b6d20ead0a834c29714bde17a0acb51e3a11dfd19de4aa35dc032baf4a79e9e8e13959935d6c32f92bc01d03"}, {"line": 15325, "relation": "increases", "evidence": "The inhibition of this kinase can prevent the aggregation of beta-amyloid (Abeta) and hyperphosphorylation of tau protein.", "citation": {"type": "PubMed", "reference": "22718609"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 16, "key": "3c1544093f0d47dea9dc66ef9c75282c3da3f3c5630bd36253502ead98076bf1a731594c1b280d113086643e3ef4d91cf6e2e74eb2d99b9fdc81834ca478705c"}, {"line": 23055, "relation": "association", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Inflammatory response subgraph": true}, "Confidence": {"High": true}, "MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 161, "key": "0e14ac3357ad890bf79322bf2a3d24640267b37e4815a7729c7820d6a573be1e6a008dad636a996388ffa35a6366a42044a6baf12e4ab5c8ab9d111971f2a7b8"}, {"line": 23067, "relation": "association", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}, "Subgraph": {"GSK3 subgraph": true, "Inflammatory response subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 90, "target": 131, "key": "cf17bcf5fa8468663afa8897f47f833fb7755062499fd1f3b3bbcd2a8061e5f7bb448c422f7f20a7efa77929b6e7719f9149b94c42ae80679a31b76db712dee8"}, {"line": 47808, "relation": "association", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}, "Subgraph": {"Response to oxidative stress": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 131, "key": "7a084af72f4ccae49ab121f833e7a78f4ad967551913905df2e38c8c7df31e908c1ba2024b2db82de886de17ed7f2851722aadc02a64418fb5e6f219cfd75724"}, {"line": 24303, "relation": "association", "evidence": "In addition, cdk5/p25 might also interact with other pathways such as glycogen synthetase kinase 3beta (GSK3beta) and c-JUN kinase.", "citation": {"type": "PubMed", "reference": "17160145"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GSK3 subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 53, "key": "fe46a210891670f014f517959e778cc18a15484390a3cca99a9eb647e5d3b3af965d77a1a6ab5eded8d0adde1bcf72a1e3a22d41b79f822bf0f7a127cc55cc31"}, {"line": 29665, "relation": "increases", "evidence": "Activation of PI3K after CsA treatment appeared to trigger opposite effects. First, CsA induced PI3K-dependent activation of Akt, which mediated cellular responses against cell injury. Akt activation led to transient phosphorylation and inhibition of the pro-apoptotic GSK3beta and Bad, thus preventing GSK3beta-mediated phosphorylation and activation of the pro-apoptotic Bax, and Bad-sequestering of Bcl-2.", "citation": {"type": "PubMed", "name": "Xenobiotica. 2005 Jul;35(7):737-53", "reference": "16316932"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 68, "key": "d3e93890c80e0e90a94dc3d2adeaa364206edfb39bc68499cee07a0ab3df82a72d73468512428f4988c80ab75dab5154fcd6d7c5859d8c593cb7b387e2949f07"}, {"line": 29779, "relation": "increases", "evidence": "Here, we show that GSK-3beta phosphorylates and regulates the activity of Bax, a pro-apoptotic Bcl-2 family member that stimulates the intrinsic (mitochondrial) death pathway by eliciting cytochrome c release from mitochondria.", "citation": {"type": "PubMed", "reference": "15525785"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 68, "key": "1bf52b267b9197539d5e42026d15d1419981485a001691fb45cde9f871f0a31844a02515cd9ed88f735498e5e2050ec37e67f1639378d1d464c0856c5eb9ca06"}, {"line": 29783, "relation": "regulates", "evidence": "Here, we show that GSK-3beta phosphorylates and regulates the activity of Bax, a pro-apoptotic Bcl-2 family member that stimulates the intrinsic (mitochondrial) death pathway by eliciting cytochrome c release from mitochondria.", "citation": {"type": "PubMed", "reference": "15525785"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 90, "target": 67, "key": "8c4981bb99218d730c9e1f44744476df3ff0bd86adacebfdf303216e4c754643890ec95e7165780c0431c42b8effa724e00ee886e1066644d4fe53d960fa6c31"}, {"line": 35190, "relation": "increases", "evidence": "Presenilin 1 interacts with N-cadherin/beta-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues (serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3beta.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 141, "key": "dcdeeeb342a37f7aa2442a9aa2a403f31335d4382f3d74517461c15150b2906195f140c6de519153a9ec586572fa196c58221e6ac8fcf202664d22c025a3243d"}, {"line": 36708, "relation": "increases", "evidence": " The physiological relevance of the association between PS1 and beta-catenin remains controversial. In this study, we report the identification and functional characterization of a highly conserved glycogen synthase kinase-3beta consensus phosphorylation site within the hydrophilic loop domain of PS1. Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357) are glycogen synthase kinase-3beta targets.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11104755"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 141, "key": "811e3aaf0562f843ec6a54a4c1f0e70feda284be297476da248335be7aeb4d952fc30fbbd346580067425cfe44667a11add4cd055d50d7d4c9c7584f7f67db17"}, {"line": 36737, "relation": "increases", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 141, "key": "d00129274a07b1b0f1c787350b2a06faf18f43fd451da344b0fc4d9207ca871593444909def8d94ebfc41810efa3f794d852a30b31417f2149dd4fb6268a6f3a"}, {"line": 38291, "relation": "increases", "evidence": "Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357) are glycogen synthase kinase-3beta targets.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11104755"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 141, "key": "5ec87be19083f4188950fc358915fe1fba99da50cac0bde323d1f129d54fe8122b89dc83077e4f5253d3f070b800ab6432b82060346a4d2459c98a7601811396"}, {"line": 35191, "relation": "increases", "evidence": "Presenilin 1 interacts with N-cadherin/beta-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues (serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3beta.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 142, "key": "57c6814f583e38c48cfc367fdfd31f103bf49cc889af39af6519b198365c785e1cc432972c360fd5d5edbf6d16c0df33a0021a5a97fcc961c9e41293d5531780"}, {"line": 36709, "relation": "increases", "evidence": " The physiological relevance of the association between PS1 and beta-catenin remains controversial. In this study, we report the identification and functional characterization of a highly conserved glycogen synthase kinase-3beta consensus phosphorylation site within the hydrophilic loop domain of PS1. Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357) are glycogen synthase kinase-3beta targets.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11104755"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 142, "key": "3565608f21a00339f24381ee14749ee0ffdfeb45f951e69e0cb8c395ec532647aa7101629f5a6a226d5a69b2bf798373170d59197f91ac378b53a3956d81b275"}, {"line": 36738, "relation": "increases", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 142, "key": "f94785d9a04c19914d98800808dd6b8edb2a65168f1493b7f2b72f6856a21c71b08f833ed37a279e393005ffadc4029c657f64acb0ac156259526b4fb47e8878"}, {"line": 38292, "relation": "increases", "evidence": "Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357) are glycogen synthase kinase-3beta targets.", "citation": {"type": "PubMed", "name": "J Biol Chem2001", "reference": "11104755"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 142, "key": "b838407730f00328e8fbae5f9999b8cd797cb1125c3b9e518b942ccdc92414acfdf7f98a64ee5ad5a794d13c710c26e7b220ba20e03986dac500b5ad2e624bd0"}, {"line": 35215, "relation": "increases", "evidence": "Our findings indicate that the abnormal activation of glycogen synthase kinase 3beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 32, "key": "6a146c4ac07a7c4a75763f66cd39c0f37f7c2d6725eb2ad61a566849bcdcc4fb4f2d7a5c632dc4a66e9f88e9d7bccaa7514cfd407dde34ab1b155a38ee6a2490"}, {"line": 39216, "relation": "association", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 90, "target": 32, "key": "397ce80087172f74eab3931c26cce6d6f660898ccbe37849c910c9e659774bb005277f2ee786dd0031a9895a49ffcba51477862e6549e32dd751598006b92c49"}, {"line": 35216, "relation": "decreases", "evidence": "Our findings indicate that the abnormal activation of glycogen synthase kinase 3beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 34, "key": "210c7f25f4dfb52bf93c033f2df63f405e09c9fec00edb90d2f21928fe3e13257c135ade0e8d4c92402e0f0660abd8ffb97d5323ad3c05b7de2a174270f6c964"}, {"line": 35220, "relation": "regulates", "evidence": "Our findings indicate that the abnormal activation of glycogen synthase kinase 3beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 51, "key": "fd194fa6f0c320e8ebc5964e6c3faf611c5caa3584f62a9694af59a54f611470aff82d73639210ff76554a5bc618068cbdd38e78fef0bdf56bb01dfb1d41eb6f"}, {"line": 35350, "relation": "increases", "evidence": "In addition, the sequential phosphorylation of CRMP2 by Cdk5 and GSK3beta is an important process of Sema3A signaling.", "citation": {"type": "PubMed", "name": "Nihon Shinkei Seishin Yakurigaku Zasshi2006", "reference": "16866215"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 83, "key": "f4b0beb52b51c8272e7bfe5e7f0db1a432393c6cd7259ac707f4af418d68fbb958310266fa657b711e0bad297eaeceb8a54b1e572a36a79c6e069c1298d536d6"}, {"line": 35375, "relation": "increases", "evidence": "This function of CRMP2 is regulated by phosphorylation by glycogen synthase kinase 3 (GSK3) and cyclin-dependent kinase 5 (Cdk5).", "citation": {"type": "PubMed", "name": "J Neurochem2007", "reference": "17683481"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 83, "key": "6480816993dd35e72ca7d1fff7c211059553b2be833fd8e79a40fc64a29bb0f5332a268cf0149a5b5debff20ce77d85e5938b859fb5b151531b38a8a5070895e"}, {"line": 36186, "relation": "increases", "evidence": "Both GSK-3alpha and 3beta phosphorylate purified pig brain CRMP-2 and significantly alter its mobility in SDS-gels, resembling the CRMP-2 pmodification observed in AD brain.", "citation": {"type": "PubMed", "name": "J Cell Biochem2008", "reference": "17902168"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Species": {"9823": true}, "Confidence": {"High": true}}, "source": 90, "target": 83, "key": "5b73e9eaf0e6da00d70798a1724ac23a219977a8779f686c2b2de27fe23275ca0ef5f621bda05e6aeecd9bd15a37abd57b9b64d919a70681e54a107b74e9de4f"}, {"line": 36215, "relation": "positiveCorrelation", "evidence": "Phosphorylation by GSK3beta was exclusively observed in Cdk5-phosphorylated CRMP2, but barely in CRMP2T509A.", "citation": {"type": "PubMed", "name": "Genes Cells2005", "reference": "15676027"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 83, "key": "b39cbb4d36f21704465f5a543e5edb991e68b7fee94ce82dccfe58c006b4f90e3206dd47bd8e7004a6da1d9f9ae14aeed0d92dc62d3e0d339c2d6a5f94a39083"}, {"line": 36216, "relation": "increases", "evidence": "Phosphorylation by GSK3beta was exclusively observed in Cdk5-phosphorylated CRMP2, but barely in CRMP2T509A.", "citation": {"type": "PubMed", "name": "Genes Cells2005", "reference": "15676027"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 83, "key": "7c95c5c6d676fb6e3947899113d612bb6bad786fc9ab6d3ec677aa7e05e6b859c10068a38e4bc976000df3e22c43b48fb02d16f28f03007b863ac193ca512a87"}, {"line": 35722, "relation": "increases", "evidence": "GSK-3beta transfection showed the phosphorylation at Ser-199, Thr-231, Ser-396, and Ser-413.", "citation": {"type": "PubMed", "name": "Biochimica et biophysica acta1998", "reference": "9565682"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 116, "key": "d0f99901da0ddc40d9ba4200b3a95abb2678f4e6c9902b0f445177f6ae6aa951a460fdef5a1710532068b0352496349ca097323294fd2ca670063b6cbb83b48d"}, {"line": 35723, "relation": "increases", "evidence": "GSK-3beta transfection showed the phosphorylation at Ser-199, Thr-231, Ser-396, and Ser-413.", "citation": {"type": "PubMed", "name": "Biochimica et biophysica acta1998", "reference": "9565682"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 125, "key": "a55e1d13f9603967e5d4421b86eee6f5616ac7adf3c168a659fb77e64054d36de23c8c8ff2fc2476ee37b451e0308ac20dc2680525b100c0207207dc55935e0b"}, {"line": 35724, "relation": "increases", "evidence": "GSK-3beta transfection showed the phosphorylation at Ser-199, Thr-231, Ser-396, and Ser-413.", "citation": {"type": "PubMed", "name": "Biochimica et biophysica acta1998", "reference": "9565682"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 120, "key": "d8f991df6994493446ab4f9ca7471ac0b31e985d973a980fd2b48f42d3cab127d5588f8fa679f2e98fdf1f2f3f97c41935e1a692adfded9ac99f6283927b55fe"}, {"line": 35725, "relation": "increases", "evidence": "GSK-3beta transfection showed the phosphorylation at Ser-199, Thr-231, Ser-396, and Ser-413.", "citation": {"type": "PubMed", "name": "Biochimica et biophysica acta1998", "reference": "9565682"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 122, "key": "9d3f84c20fff1aad6e82dd7bc6727fcb0da954425bd591f67aa5002ec9cdca1d95ccdd5a0b556fd5133b2a700b3a9caf0c1add1f6a0ee9d5dab004106daf9efc"}, {"line": 35765, "relation": "negativeCorrelation", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 9, "key": "cc045388489851232ae360d501aeef288be869572c255a68c9410345b6f26eeef5ae4be480b8676a9a1ba44686161347369d4d7b8f4ef4883cec87aa1bf27492"}, {"line": 35993, "relation": "association", "evidence": "Thirdly, GSK-3beta has many substrates, such as beta-catenin, APC, Axin, Tau protein, etc.", "citation": {"type": "PubMed", "name": "Eur J Pharm Sci2011", "reference": "21352912"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 154, "key": "5a95f7252c748f8b5f83c4027aa699227ae2a765a350bde4aa35a85d334ef9606382b8624c1ee47f1ec9be22a4b573621d3aa3ee8403d883ea12468b4028690c"}, {"line": 35994, "relation": "association", "evidence": "Thirdly, GSK-3beta has many substrates, such as beta-catenin, APC, Axin, Tau protein, etc.", "citation": {"type": "PubMed", "name": "Eur J Pharm Sci2011", "reference": "21352912"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 62, "key": "c57e2926cf97c569fd844652339d2add1c884f8d7c8896cf95f4cf0655d22f4a5b9f5147db9cd7b3e4d0d38e26611c352beb0e30941278ad506458439a53acb8"}, {"line": 36006, "relation": "increases", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 46, "key": "771ee62373bdf3bf8981f8014dc3bbab6cc633eeec25ab91d623d4ea503fe2cf2d762825923ad1fa472d86a4490dbe43e87de0b645f841243136eb8834f9b7a0"}, {"line": 36012, "relation": "increases", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "CREB subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 74, "key": "67a7770c7151e07ed59930ba609c7d56dd8745d119f30446e3887f7d9fc1ce72d3acae308fec801d41772940bc0a56647311e6b9dcd6da47ef41b24a799f31ea"}, {"line": 36018, "relation": "increases", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Chaperone subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 95, "key": "2b2984c0f2486c6a3228a086d6531cb4dde5fad18073ccfd595f3af1c343c2756b72c448d7e41de32dd58781920fd9310fed967592fe258ca916bac44fb47551"}, {"line": 36019, "relation": "increases", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Chaperone subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 129, "key": "e28a41418659cad66ed234392aaac732f5f9da37fecb6ea5e020ae6618a308322b0ed8766a1ec15c4538bf5618e4450e803f277286e744c5ec892e73d9a127da"}, {"line": 36025, "relation": "increases", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "T cells signaling": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 130, "key": "ebcf7f61bf07edcbe9c16936cc754977c8be45e60206d17b3cdf446b2310b95d89c607e178ee62c17495d032d9792918675389bbfb10f098000395f28bcd3792"}, {"line": 36039, "relation": "regulates", "evidence": "Notable among the signaling proteins regulated by GSK3beta are the many transcription factors, including activator protein-1, cyclic AMP response element binding protein, heat shock factor-1, nuclear factor of activated T cells, Myc, beta-catenin, CCAAT/enhancer binding protein, and NFkappaB. ", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Nuclear factor Kappa beta subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 47, "key": "bcb20ffb3fae2a7bc6048674f1a646c70ba48676904594bc8c99489d1945c8a5210ae4c37a848463c0342accba1794668aebff13e3bc1d992d7a0721873be69a"}, {"line": 36048, "relation": "decreases", "evidence": "This mechanism was shown to allow local inhibition of GSK3beta, leading to stabilization of beta-catenin levels due to reduced GSK3beta-facilitated degradation of beta-catenin, a necessary step in embryo development", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 76, "key": "88f8c144f8fd3ce939c755d1df0613f92f23b0da6007785b1377b412a747b884230b64b03c88aab2138535f6d21f105e5b80be9afbf611607e87b456165b5737"}, {"line": 43773, "relation": "negativeCorrelation", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 76, "key": "7fc8f50ccb3e9858317699dbdad1249df0678e9c523ed0fd74b3d932176f552f77ce2ad68a565874e51f63e437d4b9995c754c55ca66a910dcf521b6c6687bfc"}, {"line": 36535, "relation": "increases", "evidence": "In vitro kinase reaction revealed that recombinant GSK-3beta indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "16257959"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 127, "key": "c4d1ea39e4b2665ef586c2d71fb23099e66e1176cb9e2c4112a122eefbb06c33e9c854e579e1286a0c2c4668b4b3909a58afb3e0f38618c39319505d8e34f87e"}, {"line": 36597, "relation": "increases", "evidence": "These results, respectively, indicated that GSK-3beta is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3beta-MARK2 pathway.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "16257959"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 127, "key": "ea82b9305eba0b230cb0ef6b4af82ae5e4fabb06010fa981f102ac56481f457d1841350e1065905911df895770c9855bf4793a6e273715a6bc2f5a22226af2d2"}, {"line": 36596, "relation": "increases", "evidence": "These results, respectively, indicated that GSK-3beta is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3beta-MARK2 pathway.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "16257959"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 119, "key": "14efd3bafc872b4ccb0b60b4d51a37d1a23d6f48e83f88405316c6a45b48deea6fdc91e7e340a4b0fe5acddf6d198df8428726dd0fc19ae17b76fdc59cda832d"}, {"line": 36642, "relation": "increases", "evidence": "Treatment of PSer262 peptide or GSK 3 beta phosphorylated tau with alkaline phosphatase increased Ab262 immunoreactivity, indicating that Ab262 is a reagent useful for studying tau phosphorylation at the Ser262 residue.", "citation": {"type": "PubMed", "name": "J Neurochem1996", "reference": "8769876"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 119, "key": "ebceb261994ba2a92be21722ae972d0607222108ea25d7dce7daa902e0511ad0722cb5fb119a3f413705e01ef79f333f626b50451920b05333fafe1ac8c7edc3"}, {"line": 36720, "relation": "increases", "evidence": "Previously we described presenilin-1 (PS1) as a GSK-3beta substrate.", "citation": {"type": "PubMed", "name": "FEBS Lett2006", "reference": "16814287"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Low": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 140, "key": "7494678dec34887e49c6338f7b6190a87b3ad5b180e805be5bffc424b1930bf1f3e48883a0c62a7450733c57455e872cc0d1a5a850ae8aea187b8f510b728b4f"}, {"line": 37502, "relation": "increases", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 140, "key": "5b895aaafb168f3dfd1b719ddc225bd668d534d06b54fdbe8f987de378a13d25a515e14ac0ae80772ef2743e8844804644fa6ba0b3ce0c8c0b32772fbd4c1abb"}, {"line": 37501, "relation": "decreases", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 52, "key": "55708ab63f562fe48ee744a9156fbf0c4b8f7dce6624b795a8e008c5d0f94c3bbb058f98df3705efa4ac4dd73f137ad7297b657e18e09205a0069614f0454472"}, {"line": 37505, "relation": "decreases", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "cell surface"}}}, "source": 90, "target": 139, "key": "4d967577bb4d98ce181446ec600bbc669a8e58c8431712da8a0cface99747da6031c916849ac6b1b676b7313e3065fd20544cce0733be9bdf5427a38ad97efc5"}, {"line": 38628, "relation": "association", "evidence": " PS1 directly binds tau and a tau kinase , glycogen synthase kinase 3beta", "citation": {"type": "PubMed Central", "reference": "PMC21391"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 139, "key": "901ca2b411191908f416ebfac309659cbab1ce87c13f671d11bdd1a4d966211e6aff848d7aaa348597129e4be4b73ba895365f034652027af5fae4c2650894a7"}, {"line": 39215, "relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 90, "target": 45, "key": "f16d35ff7888af8f15a32a71c37460f449c65439fb447490a97ff13c0488ba751bfb3707d84e609f9757f9de41666521691c8931aff746caa91ce5e81a7ee110"}, {"line": 39217, "relation": "association", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 90, "target": 19, "key": "1d4d50a2b55555b2771ed7adfd231e0120b65e307cbf2cdf8f3b774cf6925e8c1313aed5663455281860b7ff569df8706aba3f4fef59172aba1ea53100eed011"}, {"line": 39228, "relation": "increases", "evidence": "In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta.", "citation": {"type": "PubMed", "name": "J Neurochem1996", "reference": "8764598"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 65, "key": "3e39003b067f1b7b800aa1eeeaf42c9f3a0330bcbccaeed52b17a8a726cce780fb7007f062eb2fe4395fa883d0ee111a765161a626a17dc70e70a438c5f45e65"}, {"line": 39594, "relation": "association", "evidence": "This interaction is regulated by the phosphorylation of Tau at selected sites, by glycogen synthase kinase-3beta (GSK3beta) and cyclin-dependent kinase 5 (Cdk5), and requires an intact microtubule network.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2005", "reference": "15686969"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Tau protein subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 48, "key": "0824149a315d6219c388d9b41a8fafed459c9cdaa6ba66460666ba0fdcaa4789c8ea1dd38157bcbbec8900c6203faf9d817d8c61cb3f9da5191ebbc10f9de644"}, {"line": 42169, "relation": "decreases", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "reference": "21945540"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 90, "target": 162, "key": "9418232a315f63f58723e6b55300885081749cd3a4bd3c840b0c72b3b4bf6bb08258da5e4e6adad240c2c7ffe020a4365c2c90a461d0d0ae26f6aa4bbb6599c2"}, {"line": 843, "relation": "increases", "evidence": "In Alzheimer disease, it has been proposed that the peptide beta amyloid promotes GSK3 activation, resulting in tau phosphorylation", "citation": {"type": "PubMed", "reference": "19782073"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Confidence": {"Very High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "object": {"modifier": "Activity"}, "source": 3, "target": 157, "key": "15c3244daff529c4e7b21b9fd714e06e5f48a573f528fc585392c7dbbebb70569625fcd4d71786b751671e3259e51aa594220116c340a38a8954826584c63a64"}, {"line": 39707, "relation": "increases", "evidence": "Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.", "citation": {"type": "PubMed", "name": "Neurobiology of Disease2009", "reference": "19038340"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 3, "target": 157, "key": "8df24018d6a804db826fbc96b85a53018358c077241987df107a59890180dfc31c6ebaec795335d4b6645cdff9229e5972200c92b4097d540543f295364c35ec"}, {"line": 3582, "relation": "increases", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 3, "target": 90, "key": "905fbb469899cbd801355bfa4156c40cc9fd4085c80da8269a7c0e3f23359167168a2be5bf5a434ec8ba422b3284413d06f115c2b85afbf2e9587a2afb4a1b1c"}, {"line": 39213, "relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "object": {"modifier": "Activity"}, "source": 3, "target": 90, "key": "1b8ca17af5225a71bddfb96cb64d262954f671aff5d35adb02f9d27e8111d52c381a97fb078bc9536db061536c6a5bbaf8fc11923c60c603fe22ff827dcf99b2"}, {"line": 3583, "relation": "increases", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "name": "Neurobiol Dis. 2012 Jan;45(1):425-37. Epub 2011 Sep 13.", "reference": "21945540"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 3, "target": 31, "key": "6b51ea056880243e48ce85d8ef014c3fb01684dd7b67a44fb3e94072f9521054366015fc3f51d2cdfd693faf09d1d1fb4d6c6c7dad234949618b29ec419a3797"}, {"line": 844, "relation": "directlyIncreases", "evidence": "In Alzheimer disease, it has been proposed that the peptide beta amyloid promotes GSK3 activation, resulting in tau phosphorylation", "citation": {"type": "PubMed", "reference": "19782073"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Confidence": {"Very High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 157, "target": 114, "key": "91ff4c54d94a44888d29334c6031d577f5bd958007d3b05225d6e0cada960e30626c2ccd57f4c3c8c8dd5ea0c98be38f03e245cec4e437b27d7239f97000dd01"}, {"line": 26872, "relation": "increases", "evidence": "Recent findings from our and other groups have suggested glycogen synthase kinase 3 and p70 S6 kinase as main tau kinases and protein \\ phosphatase 2A as the main tau phosphatase involved in the formation of these processes.", "citation": {"type": "PubMed", "name": "Curr Opin Psychiatry. 2008 Nov;21(6):555-61", "reference": "18852562"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 157, "target": 114, "key": "db88dba46a740078320cf6a9b6d3429e917a0cd9be0d2c2e35e9f330d9c8f92af157369ff908609c1b92e502f0e892144c1b2b1d90d5c092b19441f51134ac59"}, {"line": 35505, "relation": "increases", "evidence": "A large body of biochemical, genetic, and cell biological evidence implicate two major serine-threonine protein kinases, glycogen synthase kinase 3 (GSK-3) and cyclin-dependent kinase 5 (CDK5) as major kinases responsible for both normal and pathological phosphorylation of tau protein in vivo.", "citation": {"type": "PubMed", "name": "Neuromolecular Med2002", "reference": "12428805"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 157, "target": 114, "key": "3c98d3774ab58724748c8d7a6d34b67a8df99cbd300feec8920d32a2004e5e0838b85c0df6b17cb51cc94c33c7aae0993112408661683975c7cb9e0c027b1d7e"}, {"line": 6932, "relation": "regulates", "evidence": "The availability of megalin at the cell surface is controlled by several regulatory mechanisms, including the phosphorylation of its cytoplasmic domain by GSK3, the proteolysis of the extracellular domain at the cell surface (shedding), the subsequent intramembrane proteolysis of the transmembrane domain by the gamma-secretase complex, and exosome secretion", "citation": {"type": "PubMed", "name": "Biol Res. 2011;44(1):89-105. doi: 10.4067/S0716-97602011000100012. Epub 2011 May 11", "reference": "21720686"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Low density lipoprotein subgraph": true}, "Confidence": {"Medium": true}}, "source": 157, "target": 108, "key": "4bfa646f58c3bf660b52b1a37d42bcb8fa70f8bfe5c61d7cee734fb130b3e35baebb915381832c8468347336b4141e98d5dd9907013160eeb335fc18612b7184"}, {"line": 15309, "relation": "increases", "evidence": "As a constitutively active kinase, glycogen synthase kinase 3 (GSK3) is a kinase which regulates body metabolism by phosphorylation of glycogen synthase (GS) and other substrates.", "citation": {"type": "PubMed", "reference": "22718609"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 157, "target": 94, "key": "41f44d7f2109b9eaa70b9a99bdbe6d144417a9ebe7e10f8a90d78e06a2ae80719e35140eed83ad97ce2430dc2b9cd61380c7439a6622b626cdb89621b093c56e"}, {"line": 15334, "relation": "association", "evidence": "The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification.", "citation": {"type": "PubMed", "reference": "22718609"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Glucagon subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 157, "target": 86, "key": "ae9d341aad2abf4b546f7080d2621d9b31e5078092196c9791706bec0f6b3f264d6006b7f1a4777c8aac70d3a02a5aefaf1c90ce17612fba37544bcba1a4f728"}, {"line": 35514, "relation": "regulates", "evidence": "Interestingly, some of these kinase and phosphatase activities have recently merged as key regulators of fast axonal transport (FAT). Specifically, CDK5 and GSK-3 have been recently shown to regulate kinesin-driven motility. ", "citation": {"type": "PubMed", "name": "Neuromolecular Med2002", "reference": "12428805"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal transport subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 157, "target": 23, "key": "b1c0860b1eeb018483e5d35957b38cb19ab25e441197661056a723f78cb7a963fc6d2fb24ce02b63dd6ff9c57eb75ffb3e89d103ba4016c2fb0af31ca61815df"}, {"line": 43764, "relation": "positiveCorrelation", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 31, "target": 90, "key": "a768e4c190454a1df264e6e2c9b556ad2b59b65ff9f479f794949fba706d6e67004614512bca0da94f461c2c9d0f70b86adcdec7d20982feb0d99933cd338813"}, {"line": 42146, "relation": "increases", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "reference": "21945540"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 64, "target": 90, "key": "38fe3cfd8442a7a95f64d8b936f8d80593475bc1728cedc4e3522bc4e8189d88dff675c3048102c650a3e36ffa9286fd857a4fede067c7e84913b3e60403cbc1"}, {"line": 43768, "relation": "increases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 64, "target": 92, "key": "270e664fc8c7751e0a51bff2cc8069656487c35760905c3a00639ba24b2e157d6acd5051e3ef7d89e6cbb7b5ba95e8a6c834bac9258f9837c570398e22f86378"}, {"line": 8963, "relation": "decreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 92, "target": 90, "key": "7802a46239a6a4923066d1afde7b6ed6bffe7672a3cbd517feea114f5f989edebaad9fd4e3b8bc12a794514addd26a56521629dc04d997a62fddd762030d42d4"}, {"line": 11021, "relation": "decreases", "evidence": "GSK-3 is a serine/threonine kinase, modulated by insulin/IGF-1 signaling. When the IRIIGF-IR pathÂ­ way is activated, GSK-3is phosphorylated by AKT at Scr 9 leading to its inactivation [I 06-109]. However, PP2A dephosphorylates GSK-3(review in [II 0]), which then phosphorylates tau at several sites leading to an equilibrium of phosphorylation and dephosphorylation of tau (Overview : see Fig. 1). Thus, impaired IRIIGF-1 R signaling might lead to hyperphosphory lation of tau protein and an in creased forÂ­ mation of neurofibrillary tangles.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 92, "target": 90, "key": "34f4e86c686905b75d8b13d81f825856d90227e95d3572f438fd389f842a570c0f184600c4c46f623b6f422473c6f1022c21aeacfbba6f7aa8b6bb6def40a7f0"}, {"line": 17078, "relation": "decreases", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 92, "target": 90, "key": "ea98874682d72ac24444c005576b1a42c42e9a86646b882b633a65593eb8c651172115e5a1cd7e0fb77bc9eaf4044db1f90bd6c4b975d586ad101205314ba8e9"}, {"line": 39975, "relation": "decreases", "evidence": "Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Estrogen subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 92, "target": 90, "key": "c09c9d50db039601d981c92916a0325bed6975560946889818f7efcc8220136139be9dfc6b77a75ef11ae7185a28d73d6a0c031d1780b8eb6c15a4aa4f1160af"}, {"line": 43744, "relation": "decreases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 92, "target": 90, "key": "728b2792b15d5905775c60602a5a13853ad6b0263e7913acf778a56c9692ed54aabc04259f9ffddec73fba8c50eedee8c14574933c2948a5ab211d022b3a4f01"}, {"line": 17079, "relation": "positiveCorrelation", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 92, "target": 160, "key": "92091b65993b8b1a91584ba847366ad945a773d95b4683970ffa67717c9d6823aa0caa78becc3329f0a6e4bc26181415c762c688c680df5d003fe128a40a7d1d"}, {"line": 39936, "relation": "positiveCorrelation", "evidence": "In concordance, significant increases in the levels of phosphorylation of total Akt substrates, including: GSK3beta(Ser9), tau(Ser214), mTOR(Ser2448), and decreased levels of the Akt target, p27(kip1), were found in AD temporal cortex compared with controls.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2005", "reference": "15773910"}, "annotations": {"MeSHDisease": {"Alzheimer Disease": true}, "Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "source": 92, "target": 160, "key": "430e44b62eb269eb19c10165c6e868b6dbf5d9bb0628acba1d8b92aa277bfb8f1e84ba4313f6341192baad5c547337691b38ce42169c27ebb94d95e4e6e31df8"}, {"line": 43762, "relation": "decreases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "source": 92, "target": 114, "key": "55df2f7b8357f157038209654514669ad6e2964cb2b37e24d5200d74e5d372adc143694209cb070c1fd58f61d70127090fc13eca44edb8a9e1b0bf0b8f68339e"}, {"line": 43763, "relation": "decreases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "source": 92, "target": 31, "key": "25748a7a88a2ccd5f4ee6766331ce953e7a75b260fbf9c9b2fc5a9860d9c00e997d1f3336e88d9162eccf1af4796d5a13de42456b6b1c1f8232e3875ca07e575"}, {"line": 3621, "relation": "increases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53\\ expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-b, may also\\ contribute to AICD-related cytotoxicity by up-regulating tau hyperphosphorylation. GSK-3b activation and collapsin\\ response mediator protein 2 (CRMP2) phosphorylation, along with downstream tau hyper-phosphorylation/aggregation,\\ neurodegeneration and memory loss", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Amyloidogenic subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 146, "target": 90, "key": "cdd16a7775e4b3aa4ab0d8c88c05febfa950b116ddb44477c812f02cb25c6d26c3bc36d9989f469c19a00aa73f64f9287abf055e6096f4404df5f04e0abb75da"}, {"line": 6779, "relation": "directlyIncreases", "evidence": "In this study, we found the AICD to strongly inhibit Wnt-induced transcriptional reporter activity, and to counteract Wnt-induced c-Myc expression. Loss of the AICD resulted in an increased responsiveness to Wnt/beta-catenin-mediated transcription. Mechanically, the AICD was found to interact with glycogen synthase kinase 3 beta (GSK3beta) and promote its kinase activity. The subsequent AICD-strengthened Axin-GSK3beta complex potentiates beta-catenin poly-ubiquitination.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2012 Aug;1823(8):1233-41. Epub 2012 May 18.", "reference": "22613765"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Confidence": {"Medium": true}, "Subgraph": {"GSK3 subgraph": true}}, "object": {"modifier": "Activity"}, "source": 146, "target": 90, "key": "11920266791ff5b2f2a1236fec4dff31c0624e8961e3972bf4a11ca06b6d9513d6ca7a211d1dd408015bf530d52f91db204e23e030c8e6fd14d6daac23995577"}, {"line": 6783, "relation": "increases", "evidence": "In this study, we found the AICD to strongly inhibit Wnt-induced transcriptional reporter activity, and to counteract Wnt-induced c-Myc expression. Loss of the AICD resulted in an increased responsiveness to Wnt/beta-catenin-mediated transcription. Mechanically, the AICD was found to interact with glycogen synthase kinase 3 beta (GSK3beta) and promote its kinase activity. The subsequent AICD-strengthened Axin-GSK3beta complex potentiates beta-catenin poly-ubiquitination.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2012 Aug;1823(8):1233-41. Epub 2012 May 18.", "reference": "22613765"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Confidence": {"Medium": true}, "Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}}, "source": 146, "target": 50, "key": "65fe0755c706d701727ff6b1a33156ad4e126f11f9e9fe61e5ba3237a52b0f46ff5672d4cf747910cf5b30d905b8a73cf2bd874ec91ba54a2f6c882940faf7ba"}, {"line": 42201, "relation": "increases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53 expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-beta, may also contribute to AICD-related cytotoxicity by upregulating tau hyperphosphorylation. GSK-3beta activation and CRMP-2 phosphorylation, along with downstream tau hyper-phosphorylation/aggregation, neurodegeneration and memory loss, are observed in an AICD C59 transgenic mouse line in which Fe65 is co-expressed", "citation": {"type": "PubMed", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Species": {"10090": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 146, "target": 151, "key": "3ca193374d53ac75bd6cf914010cb24f276b900937809414094d1c294249aa5d937651ce42c0fd763b27d946506836d0413d511d382c8d579b0ea34a0590e1df"}, {"line": 45992, "relation": "positiveCorrelation", "evidence": "Tip60, a histone acetyltransferase, is a component of a larger nuclear complex with DNA binding, ATPase and DNA helicase activities. Although Tip60 does not bind to AICD directly, an indirect interaction between AICD and Tip60 is mediated by Fe65. Upon forming this complex, AICD is stabilized and can be translocated into the nucleus to regulate expression of genes such as KAI1, Neprilysin, LRP1, p53, GSK-3b and EGF receptor", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cytoplasm"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Nucleus"}}}, "object": {"modifier": "Activity"}, "source": 146, "target": 146, "key": "817ab16ccaca49aa2b7971c43d90c65f23c3d513edbb72d6f632bafad7b837fcdfa8e5a90078120c0d2c6e2e4fba93f91e922d722061654080899c971503e097"}, {"line": 45992, "relation": "positiveCorrelation", "evidence": "Tip60, a histone acetyltransferase, is a component of a larger nuclear complex with DNA binding, ATPase and DNA helicase activities. Although Tip60 does not bind to AICD directly, an indirect interaction between AICD and Tip60 is mediated by Fe65. Upon forming this complex, AICD is stabilized and can be translocated into the nucleus to regulate expression of genes such as KAI1, Neprilysin, LRP1, p53, GSK-3b and EGF receptor", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cytoplasm"}, "toLoc": {"namespace": "MESHCS", "name": "Cell Nucleus"}}}, "source": 146, "target": 146, "key": "d70ac25080320aff457c8c633342ed51c658dd9204aaadc8284b8f4c657ab806ed7c3b76f9965858de65c79ab3e3231959ffa8cb545df314570c1edc8dd87af8"}, {"line": 45993, "relation": "regulates", "evidence": "Tip60, a histone acetyltransferase, is a component of a larger nuclear complex with DNA binding, ATPase and DNA helicase activities. Although Tip60 does not bind to AICD directly, an indirect interaction between AICD and Tip60 is mediated by Fe65. Upon forming this complex, AICD is stabilized and can be translocated into the nucleus to regulate expression of genes such as KAI1, Neprilysin, LRP1, p53, GSK-3b and EGF receptor", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 146, "target": 163, "key": "6de10650f4d5199442f87bbe3b952bcca43a1a2be50181f33857c7af49d5a00d8ff1525aa1d0af0ed9b6651b335971784ee41251cc6a6b91571c070e00f9b30b"}, {"line": 45994, "relation": "regulates", "evidence": "Tip60, a histone acetyltransferase, is a component of a larger nuclear complex with DNA binding, ATPase and DNA helicase activities. Although Tip60 does not bind to AICD directly, an indirect interaction between AICD and Tip60 is mediated by Fe65. Upon forming this complex, AICD is stabilized and can be translocated into the nucleus to regulate expression of genes such as KAI1, Neprilysin, LRP1, p53, GSK-3b and EGF receptor", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 146, "target": 156, "key": "0255905918049db59a934faf744c19adae18e2cb032103697da2982abd024957e9891b12dadf2927c500e1c7a887c05e88ffcd3afdba96874e85001c3b7d45c3"}, {"line": 2531, "relation": "increases", "evidence": "In the absence of Wnt ligand, axin recruits CK1 causing the initiation of the beta-catenin phosphorylation cascade by glycogen synthase kinase-3 beta (GSK-3beta). Phosphorylated beta-catenin is recognized by beta-transducin repeat-containing protein (beta-TrCP) and degraded by the proteosome, reducing the level of cytosolic beta-catenin.", "citation": {"type": "PubMed", "reference": "22496686"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 50, "target": 90, "key": "b198d05d6daebf30e016b187e367ac1e8e5922a439c85a85e1f68b9ed4134f189a32a66535f3cefd64b3b3afdb9acb32534f28d44faf04961b70813d856b1764"}, {"line": 39878, "relation": "increases", "evidence": "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation.", "citation": {"type": "PubMed", "name": "Cellular and Molecular Life Sciences1999", "reference": "11212302"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 50, "target": 90, "key": "02dc74bfe767c4ee92614a5eebfdb7082e5d2917803f5c89acc01a6db5fec07b71012fb0e6b8c1d65ae2cd3cc52a2a99bb3045da651eeba503e9afb9f0845191"}, {"line": 6784, "relation": "increases", "evidence": "In this study, we found the AICD to strongly inhibit Wnt-induced transcriptional reporter activity, and to counteract Wnt-induced c-Myc expression. Loss of the AICD resulted in an increased responsiveness to Wnt/beta-catenin-mediated transcription. Mechanically, the AICD was found to interact with glycogen synthase kinase 3 beta (GSK3beta) and promote its kinase activity. The subsequent AICD-strengthened Axin-GSK3beta complex potentiates beta-catenin poly-ubiquitination.", "citation": {"type": "PubMed", "name": "Biochim Biophys Acta. 2012 Aug;1823(8):1233-41. Epub 2012 May 18.", "reference": "22613765"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Confidence": {"Medium": true}, "Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}}, "source": 50, "target": 78, "key": "9509a7ccc96618d65a0a446a90560e3904a6b30766912924528928cc61de681dd8e579cb11a931c5bf852e5dc95413dd465046e3bf78bd69bf2f85efa2e78af4"}, {"line": 16245, "relation": "increases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "source": 151, "target": 149, "key": "da6a86730fb64c84e69b8b05a2202eae1ddc493b2d816b0c3373f33e97dcab75098babdfd75d3e88a1950dfe6093c4a6534eb673ba16c6c06653e283550656b7"}, {"line": 42171, "relation": "negativeCorrelation", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "reference": "21945540"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 151, "target": 155, "key": "3a7e6b57d83bfa0913ba530d755dda8727ccab4c0b95b5115353bb600697e49e4316024ef5c8f3f94f2ec339c7a7147852a0b0e89c474c042d0e94261d6cb6ea"}, {"line": 42206, "relation": "increases", "evidence": "In addition, AICD-induced cytotoxicity may be mediated by its regulation targets. For example, P53 expression, as well as p53-mediated apoptotic process, can be enhanced by AICD. Another AICD target gene, GSK3-beta, may also contribute to AICD-related cytotoxicity by upregulating tau hyperphosphorylation. GSK-3beta activation and CRMP-2 phosphorylation, along with downstream tau hyper-phosphorylation/aggregation, neurodegeneration and memory loss, are observed in an AICD C59 transgenic mouse line in which Fe65 is co-expressed", "citation": {"type": "PubMed", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Species": {"10090": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 151, "target": 152, "key": "d710ddeb80b3a3de23f8d787459e0b2f3a5cd5fe40e5f19778c69c1150f5afa0ad36cc6a2bef69788bff421278ed965442de7adb2707a6a494af91dfbf00ecc6"}, {"line": 7278, "relation": "association", "evidence": "Alzheimer's disease (AD) is a neurodegenerative disease with progressive dementia accompanied by three main structural changes in the brain: diffuse loss of neurons; intracellular protein deposits termed neurofibrillary tangles (NFT) and extracellular protein deposits termed amyloid or senile plaques, surrounded by dystrophic neurites. Recent studies have suggested that the trafficking process of membrane associated proteins is modulated by the FAD-linked presenilin (PS) proteins, and that amyloid beta-peptide deposition may be initiated intracellularly, through the secretory pathway. Current hypotheses concerning presenilin function are based upon its cellular localization and its putative interaction as macromolecular complexes with the cell-adhesion/signaling beta-catenin molecule and the glycogen synthase kinase 3beta (GSK-3beta) enzyme. Developmental studies have shown that PS proteins function as components in the Notch signal transduction cascade and that beta-catenin and GSK-3beta are transducers of the Wnt signaling pathway. Both pathways are thought to have an important role in brain development, and they have been connected through Dishevelled (Dvl) protein, a known transducer of the Wnt signaling pathway. In addition to a review of the current state of research on the subject, we present a cell signaling model in which a sustained loss of function of Wnt signaling components would trigger a series of misrecognition events, determining the onset and development of AD.", "citation": {"type": "PubMed", "name": "Brain Res Brain Res Rev. 2000 Aug;33(1):1-12.", "reference": "10967351"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 160, "target": 76, "key": "5a65d87d825e5870a203c33c98df356773fd35186883a3892d91989456c90e371987b2a21027fdd5df506cc5184916df71da337008780e03520255c1afb9b3b3"}, {"line": 7279, "relation": "association", "evidence": "Alzheimer's disease (AD) is a neurodegenerative disease with progressive dementia accompanied by three main structural changes in the brain: diffuse loss of neurons; intracellular protein deposits termed neurofibrillary tangles (NFT) and extracellular protein deposits termed amyloid or senile plaques, surrounded by dystrophic neurites. Recent studies have suggested that the trafficking process of membrane associated proteins is modulated by the FAD-linked presenilin (PS) proteins, and that amyloid beta-peptide deposition may be initiated intracellularly, through the secretory pathway. Current hypotheses concerning presenilin function are based upon its cellular localization and its putative interaction as macromolecular complexes with the cell-adhesion/signaling beta-catenin molecule and the glycogen synthase kinase 3beta (GSK-3beta) enzyme. Developmental studies have shown that PS proteins function as components in the Notch signal transduction cascade and that beta-catenin and GSK-3beta are transducers of the Wnt signaling pathway. Both pathways are thought to have an important role in brain development, and they have been connected through Dishevelled (Dvl) protein, a known transducer of the Wnt signaling pathway. In addition to a review of the current state of research on the subject, we present a cell signaling model in which a sustained loss of function of Wnt signaling components would trigger a series of misrecognition events, determining the onset and development of AD.", "citation": {"type": "PubMed", "name": "Brain Res Brain Res Rev. 2000 Aug;33(1):1-12.", "reference": "10967351"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 160, "target": 90, "key": "f67cdbbde79dd04a4d594c58218cd0de473fb97a566489dcd58209f6442637812cddef78b80a0c5d4c572f084b5a8fc0cc9ef23ee00e8eba5bfaafbb8b47d4bd"}, {"line": 17077, "relation": "association", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 160, "target": 90, "key": "698eaff1964462e2844fbbd317faf040602c5fbd12551338507ac5ec697539d02f34ad65d91952b1d6a6842595fc784acf93ab56967c39852e44471631d4a8f3"}, {"line": 35224, "relation": "association", "evidence": "Our findings indicate that the abnormal activation of glycogen synthase kinase 3beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 160, "target": 90, "key": "dd320687289373bb887f6a2642af8f6ef2b324475148e614cd72adf2e49332ffb80c5d1cf4235115132d11ac35453094b043384a9c5777bceae31493b5f85c17"}, {"line": 14172, "relation": "decreases", "evidence": "Here we review the role of insulin signaling in brain aging and AD, concluding that the signaling pathways downstream to neurotrophic and insulin signaling are defective and coincident with aberrant phosphorylation and translocation of key components, notably AKT and GSK3beta, but also rac> PAK signaling.", "citation": {"type": "PubMed", "reference": "17049785"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 160, "target": 42, "key": "4378f2d144e1e6bb2b4911e9ff02898f7fe594e7505553103754baf1b9f3f4f071b3649b83a9e74a7be40436cc7da4d1a79ded419d156df0a658b99d112b3082"}, {"line": 17079, "relation": "positiveCorrelation", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 160, "target": 92, "key": "7fb75b4f523b4ca7b97822af8f00c0744c71d2edc23a13aa8e0d0d81649716363a8af76602d97936e37022f08c8f0e06527d37972e333cd8333eaf7d66b925dc"}, {"line": 39936, "relation": "positiveCorrelation", "evidence": "In concordance, significant increases in the levels of phosphorylation of total Akt substrates, including: GSK3beta(Ser9), tau(Ser214), mTOR(Ser2448), and decreased levels of the Akt target, p27(kip1), were found in AD temporal cortex compared with controls.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2005", "reference": "15773910"}, "annotations": {"MeSHDisease": {"Alzheimer Disease": true}, "Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "source": 160, "target": 92, "key": "0901de5cbbb95922b9e2b2210959174518f6bb6f8d2b7e62c739fd38f25e3364300744559e1a533359d2b39959fec84f436c3a21615885fd429edc10b9fc2741"}, {"line": 17080, "relation": "positiveCorrelation", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 160, "target": 77, "key": "eda1c3e2ab03a35582a06677d52cca968b10b99ede8f37dd24d40b7cd890337e673a636b874abee913715c67d049323938abf61ea9950dd2b0c832d72d10bf6d"}, {"line": 39951, "relation": "positiveCorrelation", "evidence": "In concordance, significant increases in the levels of phosphorylation of total Akt substrates, including: GSK3beta(Ser9), tau(Ser214), mTOR(Ser2448), and decreased levels of the Akt target, p27(kip1), were found in AD temporal cortex compared with controls.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2005", "reference": "15773910"}, "annotations": {"MeSHDisease": {"Alzheimer Disease": true}, "Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true, "mTOR signaling subgraph": true}, "Confidence": {"High": true}}, "source": 160, "target": 128, "key": "9691386f37d47bf66a9ddf1fe50412c5759aed840563dc0835b55ca5f43e99201906d277600bb9387acbcbdb830cdf6886a1a14a7c2ba832bd770de946bc842b"}, {"line": 7278, "relation": "association", "evidence": "Alzheimer's disease (AD) is a neurodegenerative disease with progressive dementia accompanied by three main structural changes in the brain: diffuse loss of neurons; intracellular protein deposits termed neurofibrillary tangles (NFT) and extracellular protein deposits termed amyloid or senile plaques, surrounded by dystrophic neurites. Recent studies have suggested that the trafficking process of membrane associated proteins is modulated by the FAD-linked presenilin (PS) proteins, and that amyloid beta-peptide deposition may be initiated intracellularly, through the secretory pathway. Current hypotheses concerning presenilin function are based upon its cellular localization and its putative interaction as macromolecular complexes with the cell-adhesion/signaling beta-catenin molecule and the glycogen synthase kinase 3beta (GSK-3beta) enzyme. Developmental studies have shown that PS proteins function as components in the Notch signal transduction cascade and that beta-catenin and GSK-3beta are transducers of the Wnt signaling pathway. Both pathways are thought to have an important role in brain development, and they have been connected through Dishevelled (Dvl) protein, a known transducer of the Wnt signaling pathway. In addition to a review of the current state of research on the subject, we present a cell signaling model in which a sustained loss of function of Wnt signaling components would trigger a series of misrecognition events, determining the onset and development of AD.", "citation": {"type": "PubMed", "name": "Brain Res Brain Res Rev. 2000 Aug;33(1):1-12.", "reference": "10967351"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 76, "target": 160, "key": "05fb58adb7d9a82a6be9b284bf720d0cf556666faaa047aae513a835431620c6066e9f745e67aa5f1da6b6a472d22d4fb5ad82a88fe02abb93ccfeb1ccc7e881"}, {"line": 46853, "relation": "positiveCorrelation", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Calcium-dependent signal transduction": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 76, "target": 21, "key": "d088df13eaa9aeadba7ed30c05f5d3e5099cbd2b27a39f4a2b2a34d9d14049571d41730d86e8518dfd9018c074870715f4051b276664bd8aae9dcf68f2bfa5c4"}, {"line": 43773, "relation": "negativeCorrelation", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 76, "target": 90, "key": "ef0e4f98871f11fdca4337cdb4e7ea0a307e122c79b5c0a57ca912e403c458efbf8f536561905a0438a2cf5cd2ede5fea1e272d7d8c006fab75b65a12254323c"}, {"line": 46838, "relation": "negativeCorrelation", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 76, "target": 114, "key": "69218d0205cee9cb93465d3c33448266ff583c728d31c7ae9044d389f432aa37aae6976bfedace0e78cd50ea9efd854b2dceb9f5390c4261706b2e7a985d059c"}, {"line": 14173, "relation": "increases", "evidence": "Here we review the role of insulin signaling in brain aging and AD, concluding that the signaling pathways downstream to neurotrophic and insulin signaling are defective and coincident with aberrant phosphorylation and translocation of key components, notably AKT and GSK3beta, but also rac> PAK signaling.", "citation": {"type": "PubMed", "reference": "17049785"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 42, "target": 91, "key": "a322a44276aa091c24d3777d80ddf6d7888d989866d4e5cb540d76147e9faa679c6dbb06afd534f9b44c3c26241db27bbad4a154d8e82b3ba0285942cbe1c58e"}, {"line": 2533, "relation": "increases", "evidence": "In the absence of Wnt ligand, axin recruits CK1 causing the initiation of the beta-catenin phosphorylation cascade by glycogen synthase kinase-3 beta (GSK-3beta). Phosphorylated beta-catenin is recognized by beta-transducin repeat-containing protein (beta-TrCP) and degraded by the proteosome, reducing the level of cytosolic beta-catenin.", "citation": {"type": "PubMed", "reference": "22496686"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 77, "target": 69, "key": "a6669aca251cedc61cb182c73adef9599b9d2e98b2ba4b137d3f909d8b64e511c8ae0e7841fd71d96e45dc47ac317083bdef24d3b80cacc9094c8e2c5658a7dd"}, {"line": 39880, "relation": "increases", "evidence": "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation.", "citation": {"type": "PubMed", "name": "Cellular and Molecular Life Sciences1999", "reference": "11212302"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 77, "target": 69, "key": "99eab38446252103e6cbe4a74f4e3947c8a4285967b8e7530a5bb3db9148dfbc91fec36ca02376709f967eb3cccea074a4fad1304c1f4b0069270664077735e8"}, {"line": 35918, "relation": "decreases", "evidence": "It was shown recently that axin negatively regulates beta-catenin by bridging beta-catenin and GSK-3beta together in the same complex and thereby facilitating the phosphorylation of beta-catenin by GSK-3beta ", "citation": {"type": "PubMed", "name": "J Neurosci1999", "reference": "10341227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 77, "target": 76, "key": "7219a304fd446ba26cf38ebf06284c8bbce28aac7beb0e9e878b9f5bcc1c6a60e06170b3a8551535aaa5c2e65ff31a59ae1d16c3c2201a4b81270ad005d06f7a"}, {"line": 40427, "relation": "decreases", "evidence": "This pool of beta-catenin exists in the cytosol and is normally rapidly degraded through phosphorylation by GSK 3beta, leading to its subsequent degradation. ", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2001", "reference": "11504726"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "source": 77, "target": 76, "key": "8280884efc930450e2b66892e2db8e1586378d0b161e0f6f599044d115e1dd9c2f0b0920efea1747e03cf957bada8e3ad4075ae9f6717431beffe1c85c9f7c55"}, {"line": 17080, "relation": "positiveCorrelation", "evidence": "Glycogen synthase kinase-3beta (GSK3beta) is recognized as one of major kinases to phosphorylate tau in Alzheimer's disease (AD), thus lots of AD drug discoveries target GSK3beta. However, the inactive form of GSK3beta which is phosphorylated at serine-9 is increased in AD brains. This is also inconsistent with phosphorylation status of other GSK3beta substrates, such as beta-catenin and collapsin response mediator protein-2 (CRMP2) since their phosphorylation is all increased in AD brains. ", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 77, "target": 160, "key": "6bbd3c1a8e7eb7675ddb56751f2798b7f5af3a0cb4976122b3a2ee611119d227f7fb987a14dec1d4357bf7105513cfdaeba78fdad42da2749371eef67316f36e"}, {"line": 35967, "relation": "association", "evidence": "Here, we show that cells overexpressing tau exhibit marked resistance to apoptosis induced by various apoptotic stimuli, which also causes correlated tau hyperphosphorylation and glycogen synthase kinase 3 (GSK-3) activation. ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360687"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 77, "target": 22, "key": "f05613e81cee03cfade90b4af98b5d68f0387a043667bf6e9dbcbb234dbc45dfefe957fed9ec06f0a707780f1d7e44bddc58e1c30b17373146b6a308e915476a"}, {"line": 36741, "relation": "positiveCorrelation", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "source": 77, "target": 55, "key": "24d09466bf799533a4bed43024cbd21bb4f1e62a1214ed89f1d059476a99b8cf26d5770e753c553b0b35d3f7a0c560757e5961a767dc93c075454152b74de845"}, {"line": 39951, "relation": "positiveCorrelation", "evidence": "In concordance, significant increases in the levels of phosphorylation of total Akt substrates, including: GSK3beta(Ser9), tau(Ser214), mTOR(Ser2448), and decreased levels of the Akt target, p27(kip1), were found in AD temporal cortex compared with controls.", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2005", "reference": "15773910"}, "annotations": {"MeSHDisease": {"Alzheimer Disease": true}, "Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true, "mTOR signaling subgraph": true}, "Confidence": {"High": true}}, "source": 128, "target": 160, "key": "e5f4381960fca5e78a7a1911bb8dcb4bcf43f604d34038a007637d387b660465a92e314327d55337e05a1da3d38f2b89714577126c1dcdb8fbce5a5d0d32b486"}, {"line": 36724, "relation": "increases", "evidence": "Previously we described presenilin-1 (PS1) as a GSK-3beta substrate.", "citation": {"type": "PubMed", "name": "FEBS Lett2006", "reference": "16814287"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 90, "key": "1e6b2f1519a67041642ebed4944634a726fbb4658801ec356f2f0687ec5c9bc1dbf2d85ff47260ef65e32a34df12d317438985d8eb95a347beac07aefb7af785"}, {"line": 38628, "relation": "association", "evidence": " PS1 directly binds tau and a tau kinase , glycogen synthase kinase 3beta", "citation": {"type": "PubMed Central", "reference": "PMC21391"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 139, "target": 90, "key": "3b3f1e79602ceedcb6948e5fa892cc3003bee3fe81e0e213ce59d1df3630a65e6f9b494cc08d290516682ef465ba60bd9990e646066d3e5a824d7f6666f7b23e"}, {"line": 35189, "relation": "increases", "evidence": "Presenilin 1 interacts with N-cadherin/beta-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues (serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3beta.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"High": true}}, "source": 139, "target": 51, "key": "ff4703daa6c22d92e3e2a386d6b895d4866e3fbf5a67b22c956d1b1799542b7ae5ef5a4dafa2b4a3b3a1f3e10751f20486812b63be2f40b30b9db53367d6a6dc"}, {"line": 37504, "relation": "positiveCorrelation", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "cell surface"}}}, "source": 139, "target": 52, "key": "a9cd3163921b5496579857b2549b554355ea299b04f8a1c352a382819019a03811df82c6c262e70d53da5bd6607c3dfe3785f08a94c466c3930609d18b9ba151"}, {"line": 37504, "relation": "positiveCorrelation", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "GOCC", "name": "intracellular"}, "toLoc": {"namespace": "GOCC", "name": "cell surface"}}}, "source": 52, "target": 139, "key": "23e45dafc07e32f9647fa866602ff770c5447895c98648af800e86e7e44aa6bcda91c1e1d6f9ca314c1a0ba81c885262e0ea0eb87cae1306b93031884c104e63"}, {"line": 37503, "relation": "negativeCorrelation", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 52, "target": 140, "key": "f7107571d6e84e678e8313a5a4c44a732bb70c5232538a022753a72a5df47aee262ba99fb3e53d26e52c237d7b50c78ced5b45ab83e7eb3ef04351c00b29f8a2"}, {"line": 12629, "relation": "increases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "source": 36, "target": 145, "key": "10bc1efa55d01b887ac1898ee6a56b4b947e85f73e86e15d3cbcc846d07bbc5e4502071339f54273503944ec316a9ef3e70c5ae200638e1b7447d2243414d2e1"}, {"line": 12631, "relation": "increases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "source": 36, "target": 114, "key": "e5ed02b201bba217a00a472b6724fa932ff11935cb51a87bdcdbf7f575e5ab80cb95c9c21d9e1f0b5bda88de25199d7560b80dd1b395785d480f646a7efc20f2"}, {"line": 12628, "relation": "positiveCorrelation", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 145, "target": 90, "key": "f9f74c229b8fdefe0b82830504756b6898b54affa38ae3580f6a44dbfa83204ab1bb68d1dd496b9b3194d07beacced17b0235fb7d24b81981e3e81f8cabd0ac5"}, {"line": 12630, "relation": "directlyIncreases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "source": 145, "target": 114, "key": "983a7aa393c94d5e38837fb8ec477021962447929d0984dd15666d628d5d5ac2db64085482d1e4cbda6aff407738b99ab4c3846a007fe213719d6fae2f89b5d9"}, {"line": 5111, "relation": "increases", "evidence": "DYRK1A phosphorylates tau at 11 sites, including Thr212; primes tau phosphorylation by GSK-3beta; promotes tau aggregation into NFTs and the several-fold increase in the number of DYRK1A-positive NFTs. Phosphorylation of ASF by nuclear DYRK1A increases the level of 3R tau, leading to an imbalance in the 3R/4R-tau ratio and triggering neurofibrillary degeneration with a several-fold increase of 3R-tau-positive NFTs. Both cytoplasmic and nuclear pathways contribute to neurofibrillary degeneration, loss of neuron function, and neuronal death.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"CDR story": true}, "Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 114, "target": 45, "key": "981cfabc6a5be78107c8d75ef93c0de500d347c0b84dd0281084298101d2a645555ca6f70086b2477f119d761d2d6bf122880074117cd7f63e5231200770290c"}, {"line": 39279, "relation": "increases", "evidence": "Glycogen synthase kinase-3beta (GSK-3beta) and cyclin-dependent kinase 5 (CDK5) have been implicated as two major protein kinases involved in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles.", "citation": {"type": "PubMed", "name": "Acta neurologica Scandinavica2009", "reference": "19154537"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 114, "target": 45, "key": "1a576f636193313e2df1f5046ad3b3b335dee7ce7dfd75f7c738651c2ddc11373fb647466e46dc9f04455b0ed5a328ffbb53c93aeca90a041a6e4196b239ca55"}, {"line": 11088, "relation": "association", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "source": 114, "target": 57, "key": "2e7ef2786671dd716adfa593c412962a0ddea21293767f98c6e96439520d967129132ac58f1967bb393324fccf9a0ae929c817e82a9595a9830db7a5f218c8c2"}, {"line": 14065, "relation": "association", "evidence": "This decrease in insulin-PI3K-AKT signalling could lead to activation of glycogen synthase kinase-3beta, the major tau kinase.", "citation": {"type": "PubMed", "reference": "21598254"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"Insulin signal transduction": true, "Tau protein subgraph": true, "GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}}, "source": 114, "target": 35, "key": "90ed01f7cf28aa4bbfbc8e95e0079a122dd9cfb3ea2dcf3856b2c04703224baee3a87da5dde7ecb1d5ac2a189fc10357c9a001467153d1aace1879a460a76f6c"}, {"line": 46838, "relation": "negativeCorrelation", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 114, "target": 76, "key": "32fef803033f73b2f3d6dac07f3a3d7d45b9d9905cca84bb95a1c6e17a03b1ea731859cd500126760734dc8e2e7ff34513a72b7ec9203a1271445cbb3c4ec0e4"}, {"line": 26592, "relation": "increases", "evidence": "It is suggested that fragmentation of protein kinase C delta during the process of apoptosis results in the phosphorylation and the inactivation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 138, "key": "5517c5325a1f095f44707d193fe98da7be36bba5030efea92ef995f81e6eef40867af1aa32bd3801a17210b975a67fcf2e85069570a9fbcf57b86eb045a96220"}, {"line": 35967, "relation": "association", "evidence": "Here, we show that cells overexpressing tau exhibit marked resistance to apoptosis induced by various apoptotic stimuli, which also causes correlated tau hyperphosphorylation and glycogen synthase kinase 3 (GSK-3) activation. ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360687"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 22, "target": 77, "key": "c0c098b434d812a8665f84972d49488ec7ebb1aab7fd19db69151cecb2df5447033f68c852b519efeb7d8ad8cc4f58ea32829d9a7155f59f6d2b773e739eacf1"}, {"line": 35968, "relation": "association", "evidence": "Here, we show that cells overexpressing tau exhibit marked resistance to apoptosis induced by various apoptotic stimuli, which also causes correlated tau hyperphosphorylation and glycogen synthase kinase 3 (GSK-3) activation. ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360687"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 90, "key": "79ca9737566fbb4721209befc74c209d7dc421204d81a42ff88f65b36de44ecc458eaad8599b579bcac6bf7eb7ebd5e11a62edeb99a9cf91a6f5b6ff152d84c0"}, {"line": 26593, "relation": "increases", "evidence": "It is suggested that fragmentation of protein kinase C delta during the process of apoptosis results in the phosphorylation and the inactivation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 138, "target": 158, "key": "00c581f47708f3781d208f0a63dd724d0075cc68958d12be9b94a964691acec8770a5f5e39c84f2627b672b3aa6268233529db5020a6f15d46abc74baa919b45"}, {"line": 26594, "relation": "decreases", "evidence": "It is suggested that fragmentation of protein kinase C delta during the process of apoptosis results in the phosphorylation and the inactivation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 138, "target": 157, "key": "ccf0ca031f4acee31232dd22bdaae0ed4c24e0a817450ee30c0b55c9195c366418b299c40c0f9c60e9bfe6ba5efe377bf4be64fa60bdff8bf311e1e0bb750ab1"}, {"line": 35963, "relation": "decreases", "evidence": "Here, we show that cells overexpressing tau exhibit marked resistance to apoptosis induced by various apoptotic stimuli, which also causes correlated tau hyperphosphorylation and glycogen synthase kinase 3 (GSK-3) activation. ", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17360687"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 111, "target": 22, "key": "3993534a43727c9d90c582d9454a26053292fbfc9f1b746e992f48efd7b8c057a7b72a4a40a24e1786001825e68366ab3d160690947cf9a1eb70437fac20921c"}, {"line": 8958, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 66, "target": 22, "key": "09c4484b5a4e27c6da585699fa011273054ca7bb750ed7119cdb05ffd87ea9fe826bb435ce661c1556dab81403196d5b37c49ae42449f503ef59f5f46ca4381f"}, {"line": 42170, "relation": "positiveCorrelation", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "reference": "21945540"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 155, "target": 162, "key": "051cfab86ef417e32c6f3da376263514d055540375f7f978c6ada6ef106b40acae008c821943ff81403d658838788b0b723b7da8be7ef02980412ac87b2fc2c5"}, {"line": 42171, "relation": "negativeCorrelation", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "reference": "21945540"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 155, "target": 151, "key": "3a18bdfca44c7ae91a02b0265b9db152ca0573ed6a5425469fdfc83183897bb526242c0def29a1cb4d6e962d03f953da0f52c30daaa5c5275a48e34f458ace79"}, {"line": 42170, "relation": "positiveCorrelation", "evidence": "Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3beta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3beta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3beta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3beta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3beta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3beta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3beta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.", "citation": {"type": "PubMed", "reference": "21945540"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 162, "target": 155, "key": "fa1e1a134ed7e32924af66cf52b5cfd24cfe5fb5e8d19b436ae8de89a4c1ca60c36d04a24f559a2f1f601cccc6c06420cca4c718d5f76d295b73b81111ea34bd"}, {"line": 36585, "relation": "increases", "evidence": "Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2001", "reference": "11013232"}, "annotations": {"Confidence": {"Low": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 114, "key": "9e0902aae7b17c8ab95f20e50601b0cc15ec1a94e6fecc77f32f1ba9cf607edec3a653e346e6bc5a4577948d1ace0d13ca769f62eab054726e77759ca017c5fb"}, {"line": 36662, "relation": "increases", "evidence": "Phosphorylation of tau protein is regulated by several kinases, especially glycogen synthase kinase 3beta (GSK-3beta), cyclin-dependent protein kinase 5 (cdk5) and cAMP-dependent protein kinase (PKA).", "citation": {"type": "PubMed", "name": "FEBS letters2006", "reference": "17078951"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 114, "key": "1a450f128828bc8776079e67a22c29f7dc62e77f15fea2572225f14c13737876c750ff1d81748ca4c8e91e82d0f0416e80f9fea3a569402a66893254170c6fea"}, {"line": 36675, "relation": "increases", "evidence": "Two protein kinases, tau protein kinase I (TPK I or GSK 3beta) and tau protein kinase II (TPK II; cdk5/p20), have been isolated from bovine brain microtubules", "citation": {"type": "PubMed", "name": "Journal of Neurochemistry2001", "reference": "11181841"}, "annotations": {"Confidence": {"High": true}, "Species": {"9913": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 114, "key": "db675d1767abf6ebdda31b1f3dcb946527237269dd0584e972c2396fe83724267cb1428d6048ffa8f625ffa6a17fe0219a9d87901db151baa4c06953d85a94aa"}, {"line": 39277, "relation": "increases", "evidence": "Glycogen synthase kinase-3beta (GSK-3beta) and cyclin-dependent kinase 5 (CDK5) have been implicated as two major protein kinases involved in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles.", "citation": {"type": "PubMed", "name": "Acta neurologica Scandinavica2009", "reference": "19154537"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 114, "key": "cdc25718e9c35ce37fea51694b85da3a2fbe419be320f8b55fd7bc303fbe560fb685654c208348749c93779e694ad5ba9ce4bce7b5ab67148e28415e703a3dd9"}, {"line": 36214, "relation": "increases", "evidence": "Phosphorylation by GSK3beta was exclusively observed in Cdk5-phosphorylated CRMP2, but barely in CRMP2T509A.", "citation": {"type": "PubMed", "name": "Genes Cells2005", "reference": "15676027"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 83, "key": "acf846a02a736bec221e3ab937cfbfb8620d5f984fa885dee8698ac57a36a22eb07e5e5dff50ae0d02d1d60908099cfb486093f6d2aa957c39f68a783518bb3e"}, {"line": 35515, "relation": "regulates", "evidence": "Interestingly, some of these kinase and phosphatase activities have recently merged as key regulators of fast axonal transport (FAT). Specifically, CDK5 and GSK-3 have been recently shown to regulate kinesin-driven motility. ", "citation": {"type": "PubMed", "name": "Neuromolecular Med2002", "reference": "12428805"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal transport subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 23, "key": "f226a0c574f34d83fbeea7cf2760e40c7c7b51fe7c02756bb7e9f1e300b4cc7d829951d714c04a17dabfb3aab2c3d9587b861db0db94d0d2ade6e0bf49132466"}, {"line": 35766, "relation": "negativeCorrelation", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 9, "key": "b637cd54cf90005da66da2e0bf9176bcbcf80d56ba373e36f018ff45da33e74576c6e296779f89659c9aeba1b912799bbe7aae92ea143029636524ce28a23675"}, {"line": 35767, "relation": "increases", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 73, "target": 134, "key": "590cbd094cd384f2164bcf722ddb98e84ca4e9a84e3fa44a2ec63238dbf13d2e4044b752ed8ba39a434c865e40f862c9bb45a4b687bc70262f90b004cfc8ab44"}, {"line": 36215, "relation": "positiveCorrelation", "evidence": "Phosphorylation by GSK3beta was exclusively observed in Cdk5-phosphorylated CRMP2, but barely in CRMP2T509A.", "citation": {"type": "PubMed", "name": "Genes Cells2005", "reference": "15676027"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 83, "target": 90, "key": "d0e1e31cbf280de6669d0c0215dd8a6f7b3a3d5d00f0cf6b82edfeee442417216d610d5e1371be1341a7c69dab4be2e3284ce25277be2036dfaa5a512d33b777"}, {"line": 35764, "relation": "decreases", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "source": 9, "target": 114, "key": "3fadf1caa385b3b6f3e4a4b44b068728f349a5cf9a1721c06caecb4393635a86e2ba1354b86347cb6ad7d45538ae9d8356a8032b809ca60f4f022a19ae2de4ba"}, {"line": 35765, "relation": "negativeCorrelation", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 9, "target": 90, "key": "a65b8306d0bf9b251e8836c6f7fdd090a3c3740440e3adb807a437eebb14bbbada355be091f95c18471336d7d375e8390329bb64282a83bf8e3d9c7cc2de3316"}, {"line": 35766, "relation": "negativeCorrelation", "evidence": "We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3beta and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. ", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 9, "target": 73, "key": "52e75961a03417bb08292693d6161092d710f91b23844efc63ec0f90204c33bd4d9a8c1933321e920fa3fb397786890ca73aaa534585ee8e1dcd475ba6ddb73f"}, {"line": 5112, "relation": "increases", "evidence": "DYRK1A phosphorylates tau at 11 sites, including Thr212; primes tau phosphorylation by GSK-3beta; promotes tau aggregation into NFTs and the several-fold increase in the number of DYRK1A-positive NFTs. Phosphorylation of ASF by nuclear DYRK1A increases the level of 3R tau, leading to an imbalance in the 3R/4R-tau ratio and triggering neurofibrillary degeneration with a several-fold increase of 3R-tau-positive NFTs. Both cytoplasmic and nuclear pathways contribute to neurofibrillary degeneration, loss of neuron function, and neuronal death.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.", "reference": "21156028"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Published": {"CDR story": true}, "Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "source": 45, "target": 32, "key": "6e479dddd485be3e10a3fa3b660c4e429d4fdc7a24bd548ab3e0b43a3dd3e0576906bd27d287a16913fe37f49814a3dcc11b0898a429c2fa4cdc33cc154ed464"}, {"line": 11088, "relation": "association", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "source": 57, "target": 114, "key": "c74aa2f647a9cb53c53083d209c917667524bb1da04b684f3bffcb163eaa1a3af7bff8595b43ea61c6d5621e3d520ddd7a550ad9f8f03d4ac7aec411f8d97aeb"}, {"line": 14065, "relation": "association", "evidence": "This decrease in insulin-PI3K-AKT signalling could lead to activation of glycogen synthase kinase-3beta, the major tau kinase.", "citation": {"type": "PubMed", "reference": "21598254"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"Insulin signal transduction": true, "Tau protein subgraph": true, "GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}}, "source": 35, "target": 114, "key": "93072df8f17379d8e4c1628a99dcd81f10a183635c714a5737559e5cede64d1f62973dcc538887d9c5feafa50e4b7b48716e2df2174ee7461628e99279c2404f"}, {"line": 15334, "relation": "association", "evidence": "The neuroprotective effects of novel drugs developed to treat T2DM, glucagon-like peptide 1 (GLP-1) and its long-lasting analogs, have a possible link to GSK3 modification.", "citation": {"type": "PubMed", "reference": "22718609"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Glucagon subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 86, "target": 157, "key": "c1cb3834c0c71cb66375c1f04b51f66f8241c29d7ffdcf6cfa36f25e05d485b942e43ebbc955890bf05eeb96425f9e174b3595e432712075af1a4db4643fc428"}, {"line": 10731, "relation": "association", "evidence": "CerebraiiR/IGF-1 signaling in APP metabolism. Binding of insulin and IGF-1 to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3 and the tau phosphatase PP2A. InterÂ­ estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK cascade regulate different transcription factors involved in transcriptional regulation of metabolism and clearance of Â­ amyloid. APP is cleaved by a.-, -secretase (BACE-1) and y-secretase (presenilin). - and subsequent y-cleavage of APP leads to generation of -amyloid 1 -4o/ t-42â€¢ IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest that not only BACE-1 is int1uenced by IRIIGF- IR mediated signals but also a.Â­ secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "mTOR signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 20, "target": 90, "key": "53d68dce68ee76601959ef1a4b10c477222abddc9a1b7d0dec0cfd61ed68937a3337be09da2649c4f1b24b5829c0603cd6b589c4787c18d71e56df73240d0ac0"}, {"line": 11084, "relation": "negativeCorrelation", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 132, "target": 90, "key": "8d2ee38fbae8cbaf1aec972ae1b06b0ef95f0ddd006ef2cf3c5369a2cd0fe7d288818d52ba1e222fe54f94d67e3b795a66ae16892171afbd4ada614f7dbe401e"}, {"line": 11085, "relation": "negativeCorrelation", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 132, "target": 135, "key": "3ac779523c196a9f8b176f5edfa141cd01dfa6b04ea433cb8c027bfdf0ef23d9ef4a258df56e0bd866b96227c1a5598790d444233ab9bc673acdf415fd3f8a90"}, {"line": 14063, "relation": "negativeCorrelation", "evidence": "This decrease in insulin-PI3K-AKT signalling could lead to activation of glycogen synthase kinase-3beta, the major tau kinase.", "citation": {"type": "PubMed", "reference": "21598254"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"Insulin signal transduction": true, "Tau protein subgraph": true, "GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}}, "object": {"modifier": "Activity"}, "source": 27, "target": 90, "key": "df3a132e5be62b66ec1413b17f5131d0e4d4534c08606af4d1fd7b5f4de98b1f5e7fb7d13970b58e709674f76a80d3d5e0cd88718fe421d871506025069c444a"}, {"line": 23055, "relation": "association", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Inflammatory response subgraph": true}, "Confidence": {"High": true}, "MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}}, "object": {"modifier": "Activity"}, "source": 161, "target": 90, "key": "5e67239d75f42a197bac806d0c4f9a2fbfc1d12c7b17fe7120e7aa64b1e462aa2bf5e6528cc591f851a6b6c0631ef4bff7f065b7daa318c3debb7066a1921b95"}, {"line": 23067, "relation": "association", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}, "Subgraph": {"GSK3 subgraph": true, "Inflammatory response subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 131, "target": 90, "key": "5bd49841659984602523c15681c494e44a32aa2cafea13f8045f89e76de2498c2e97b2377bb44831acbe88c9cc4e56d9b80c27719af752a66cb7898dca66e2ea"}, {"line": 47808, "relation": "association", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}, "Subgraph": {"Response to oxidative stress": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 131, "target": 90, "key": "611f642e95859f94b6750824a43c640c2e620d8ed04e808474ee3055df52ca9bfd3f64b334535df08bf690052286f86d8dabcfa02cd254fda651946b6db117d6"}, {"line": 47809, "relation": "increases", "evidence": "We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury.", "citation": {"type": "PubMed", "reference": "24262633"}, "annotations": {"MeSHDisease": {"Inflammation": true, "Wounds and Injuries": true}, "Subgraph": {"Response to oxidative stress": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 131, "target": 36, "key": "a3039edeb94f0c2dd21741e6bd27d31055cb035a1dbba991b0681075778204e50d62a6ad3ab2e997b2c3e9d3f8dab189816ea8684217f9ea48be06f6e76f299f"}, {"line": 24303, "relation": "association", "evidence": "In addition, cdk5/p25 might also interact with other pathways such as glycogen synthetase kinase 3beta (GSK3beta) and c-JUN kinase.", "citation": {"type": "PubMed", "reference": "17160145"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GSK3 subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "source": 53, "target": 90, "key": "39f81f1c45310718e0894ec7ab0127864839c9d1724fe902548f175da74cda3410d1521e28f38acc629add4e62f64085eb2fd02e2c53b12d48bf31f51861805a"}, {"line": 24304, "relation": "association", "evidence": "In addition, cdk5/p25 might also interact with other pathways such as glycogen synthetase kinase 3beta (GSK3beta) and c-JUN kinase.", "citation": {"type": "PubMed", "reference": "17160145"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GSK3 subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "source": 53, "target": 106, "key": "31d497bf45e0c61c331a7899786902eaa8ee3052736ffcd3097f96cf992c6a29fe21bc9f1bab211d47134a175ecb0530516351c9d1d4ccde27a0c727ba8a6008"}, {"line": 29666, "relation": "increases", "evidence": "Activation of PI3K after CsA treatment appeared to trigger opposite effects. First, CsA induced PI3K-dependent activation of Akt, which mediated cellular responses against cell injury. Akt activation led to transient phosphorylation and inhibition of the pro-apoptotic GSK3beta and Bad, thus preventing GSK3beta-mediated phosphorylation and activation of the pro-apoptotic Bax, and Bad-sequestering of Bcl-2.", "citation": {"type": "PubMed", "name": "Xenobiotica. 2005 Jul;35(7):737-53", "reference": "16316932"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 68, "target": 67, "key": "5028f1f352916234070cade9be6d19d351c5bf260974fecee4d5fd79bdbe8610cba5742c1c3841159f86ed915f367cde1be663c8d46325c455ddf90024750b71"}, {"line": 29787, "relation": "increases", "evidence": "Here, we show that GSK-3beta phosphorylates and regulates the activity of Bax, a pro-apoptotic Bcl-2 family member that stimulates the intrinsic (mitochondrial) death pathway by eliciting cytochrome c release from mitochondria.", "citation": {"type": "PubMed", "reference": "15525785"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 67, "target": 22, "key": "3e58b4cce315a85117b4bf2179e365a72ac1f58499d01b93100f8a9761574459a4dd2f6a18553e903d2863688a35b356e67099e7e01bcb24a20197a7817db08f"}, {"line": 36739, "relation": "decreases", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "source": 141, "target": 55, "key": "ce1985f94bd4066385f8a6b2e798294bd4b57f2bd772e8349135a629f5bb69ec9fd134c25a552fa404706e898905be6aff4e7e8d3038bb963c128a7125dcc577"}, {"line": 36740, "relation": "decreases", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "source": 142, "target": 55, "key": "bed98efd524c1c01c56e9417f49614f36dce93d02bc8aaca32614569baa8a6b2267b1d3d8b39f6ac61be654a706d97a0098218af746ee1f3c8d054cd6c5bf61c"}, {"line": 39216, "relation": "association", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 32, "target": 90, "key": "40f3f9222a1cfecbe6e38cca963b0cdc041f8d93f9e228f26dc686e25f1574218d534048d57a291368da1b7796610ab418944c16dbbdaeed9687c2552fcecadd"}, {"line": 39866, "relation": "increases", "evidence": "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation.", "citation": {"type": "PubMed", "name": "Cellular and Molecular Life Sciences1999", "reference": "11212302"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"Medium": true}}, "source": 154, "target": 50, "key": "adbe61d130114d54d79cf68ab776b72c6d559d6c7badcb2e4d1c80438dcc6d5553bc1d47d08e3952a958698dd8b335469e12ebdca897613777823afec3631616"}, {"line": 35911, "relation": "decreases", "evidence": "It was shown recently that axin negatively regulates beta-catenin by bridging beta-catenin and GSK-3beta together in the same complex and thereby facilitating the phosphorylation of beta-catenin by GSK-3beta ", "citation": {"type": "PubMed", "name": "J Neurosci1999", "reference": "10341227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 154, "target": 76, "key": "70c11a9198a5f61298b518319883ab9e28f2798d303683a705444b2b1bbdd93dc0b4a9f8debca3484dd9202dbe7d36c936a75e274b39a32372603a7e589cada9"}, {"line": 35912, "relation": "increases", "evidence": "It was shown recently that axin negatively regulates beta-catenin by bridging beta-catenin and GSK-3beta together in the same complex and thereby facilitating the phosphorylation of beta-catenin by GSK-3beta ", "citation": {"type": "PubMed", "name": "J Neurosci1999", "reference": "10341227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 154, "target": 54, "key": "8c5abca5e70d11b2e28490245d5983ee36ac8e398061b183271bd6746506b674bc2ea3a67f7d49be6b7fb629abbdf7c4ecc277ad8aee0398e69c0f64cbd9e0f0"}, {"line": 35916, "relation": "increases", "evidence": "It was shown recently that axin negatively regulates beta-catenin by bridging beta-catenin and GSK-3beta together in the same complex and thereby facilitating the phosphorylation of beta-catenin by GSK-3beta ", "citation": {"type": "PubMed", "name": "J Neurosci1999", "reference": "10341227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 154, "target": 90, "key": "cedd7e9d1964a01d015d141b6c9701956efb2fd756aa06dff9fbe944d641d20bb5b523524298876b0550b24002c9d2e8e11c41be7b825b60298edbfe683d6b8f"}, {"line": 35993, "relation": "association", "evidence": "Thirdly, GSK-3beta has many substrates, such as beta-catenin, APC, Axin, Tau protein, etc.", "citation": {"type": "PubMed", "name": "Eur J Pharm Sci2011", "reference": "21352912"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 154, "target": 90, "key": "be1187d884a6854c165ec94284cb7fbdd1bf5b0a2c38230609a7cda07356f7abbf183a30e1063980a858f583eef7e0df8e3d8f203dead6f02d3f3f6cc6d4727f"}, {"line": 35994, "relation": "association", "evidence": "Thirdly, GSK-3beta has many substrates, such as beta-catenin, APC, Axin, Tau protein, etc.", "citation": {"type": "PubMed", "name": "Eur J Pharm Sci2011", "reference": "21352912"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 62, "target": 90, "key": "ace107d20560b80ead52ab03deac5029b796a9b299792520b92d309a873e6e83dfa4860f12b4af5a8f55de64728e91fac71f787d8f409dec2523996fc7e41797"}, {"line": 36598, "relation": "increases", "evidence": "These results, respectively, indicated that GSK-3beta is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3beta-MARK2 pathway.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "16257959"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 127, "target": 126, "key": "1a5fa25eeae9beec4078ecf783272d986d30315448113bedfef93b199faac6c2ed64d43b2104dae67a69570ab62004da530415667a265fe042f630414bce4f8b"}, {"line": 36599, "relation": "positiveCorrelation", "evidence": "These results, respectively, indicated that GSK-3beta is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3beta-MARK2 pathway.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "16257959"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 119, "target": 126, "key": "b89b8ef13980ac964b39124a246c0a0359ca4f4ac04584d62530e590755dd517de0f03bbf8c76c0b8a29bef8c86868761d24024c53e37dadd5b8cc66eab814a0"}, {"line": 37503, "relation": "negativeCorrelation", "evidence": "Glycogen synthase kinase 3beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17389597"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Gamma secretase subgraph": true}, "Confidence": {"High": true}}, "source": 140, "target": 52, "key": "5b6855bafffc119774456f18cca8ca5608e2defdda8b2241c2cb8f3a841c8583a4ff4cb941eafc23a015717dc3d235164de53d89153daf612c90172f79a2a0bb"}, {"line": 39217, "relation": "association", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 19, "target": 90, "key": "28355c820fc1759fe167e1a02a56bcfbaa60dd695b204a51e206538fae1b626d4b9e89b051bd1d2b45cd689a7141e9c33f23693bcc2604622ad7d3a1968719e6"}, {"line": 39594, "relation": "association", "evidence": "This interaction is regulated by the phosphorylation of Tau at selected sites, by glycogen synthase kinase-3beta (GSK3beta) and cyclin-dependent kinase 5 (Cdk5), and requires an intact microtubule network.", "citation": {"type": "PubMed", "name": "Neurobiol Dis2005", "reference": "15686969"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Tau protein subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 48, "target": 90, "key": "0bed284be2b71c45480e2f9e6d47eea7386fc11e356f0ec24b0533da4f28c7ad2eb3615d732718812aaf8404834e4d2a07e93ae021318da2151c78a21c7b2a74"}, {"line": 39238, "relation": "increases", "evidence": "Several kinases, such as glycogen synthase kinase 3 beta (GSK3beta) and c-Jun N-terminal kinase (JNK), phosphorylate tau at sites that are phosphorylated in PHF.", "citation": {"type": "PubMed", "name": "Molecular Psychiatry2002", "reference": "11803455"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "MAPK-JNK subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 110, "target": 114, "key": "978cc5f8e9e40d0105c199fdc579c412be09fb213ee5f798dcaf73f357ad8b3237d410d9d0d8559c5c70c0261e42682c40ddfcb5ccbfb0512e99d22701e89312"}, {"line": 36742, "relation": "positiveCorrelation", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "source": 78, "target": 55, "key": "78098930330eb50b5be18c0530a647c05812d1a18eb74e5c70ac44ff0ecad275dd42c9e1e8650fc347aed62adee78c218a0cc2b0b7ed6de519eba2e5994f27ae"}, {"line": 39872, "relation": "increases", "evidence": "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation.", "citation": {"type": "PubMed", "name": "Cellular and Molecular Life Sciences1999", "reference": "11212302"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true, "Beta-Catenin subgraph": true}, "Confidence": {"Medium": true}}, "source": 75, "target": 77, "key": "e23d0333df84e5ef88fe0f5b6f5a866257f9fe71e4235deee2be890d5716fa6f1692b0e791ce2161d13c183c3d8b07851fe36a3d750406475a77baf1aa863ae2"}, {"line": 46853, "relation": "positiveCorrelation", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Calcium-dependent signal transduction": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 21, "target": 76, "key": "37c5ac996b32fce1a957c2590eb160e0242e2923e8c95a825d13c75fbc4561d49a59e716ab6d0bd62fb1621eaf693d0e1d40e16a0f5e1686907bc1b3c03f527b"}, {"line": 9645, "relation": "positiveCorrelation", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPARgamma leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against Abeta neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in beta-catenin and inhibition of GSK-3beta is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPARgamma by a potent ligand leads to beta-catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPARgamma activation in neuroprotection, PPARgamma agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPARgamma activation . A recent report demonstrates that overexpression of PPARgamma in cultured cells leads to a dramatic decrease in the production of Abeta, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing Abeta secretion, PPARgamma protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 21, "target": 38, "key": "a0c19b05e14ce8317961e691c21105dd1edb98a0e572163987accdbd4157c9438b8d7ae5eba24cd36beb106808f4bd017d909681e91a4ea15c4ec86f5d41daba"}, {"line": 2534, "relation": "decreases", "evidence": "In the absence of Wnt ligand, axin recruits CK1 causing the initiation of the beta-catenin phosphorylation cascade by glycogen synthase kinase-3 beta (GSK-3beta). Phosphorylated beta-catenin is recognized by beta-transducin repeat-containing protein (beta-TrCP) and degraded by the proteosome, reducing the level of cytosolic beta-catenin.", "citation": {"type": "PubMed", "reference": "22496686"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 69, "target": 76, "key": "636c91ddd27018016eea1d19adcedcc4465273aecf59310ad87e291bc3ad1586e0b3fff320fa232430020038827538b0122ee18b748e6670b09c3002b1db1bcc"}, {"line": 39881, "relation": "decreases", "evidence": "In the absence of an activating signal, phosphorylation of beta-catenin by glycogen synthase kinase 3 (GSK3) acting in conjunction with adenomatous polyposis coli and axin/conductin causes beta-catenin to interact with the beta-transducin repeat-containing protein which results in its ubiquitination and degradation.", "citation": {"type": "PubMed", "name": "Cellular and Molecular Life Sciences1999", "reference": "11212302"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 69, "target": 76, "key": "c859b6ce6e66b9bceee193b8c4529469a4522e3fe480559650792e89f73dfbc4bacb69785979bbea8bbd5cf62f36e318901d3f337ffddba5ebca0617eb3fa483"}, {"line": 36741, "relation": "positiveCorrelation", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "source": 55, "target": 77, "key": "b0d24823be797202f094ace23f37c3842402c4f5a54abbb42142c9e8626a08862b435cce36b664f13d190b92e5e99f6c1cbccb58c5572f3baa5583dce00e864e"}, {"line": 36742, "relation": "positiveCorrelation", "evidence": "We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin.", "citation": {"type": "PubMed", "name": "J Biol Chem2007", "reference": "17360711"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Gamma secretase subgraph": true}}, "source": 55, "target": 78, "key": "d6013f4bf1150d40ce6347d54f8c6e9feaa50486127dda78bc371f0d6635c265b18b1eba0953e8294cb4caf34a26f907bcbaa3465910e4d4975a6b4a776349ca"}, {"line": 3417, "relation": "decreases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid-beta (Abeta) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3beta (GSK3beta) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3beta to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3beta activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3beta, or at Thr-668, the GSK3beta phosphorylation site in APP, abolished the regulation of GSK3beta activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3beta kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 133, "target": 90, "key": "45f5fb3dbf47347b4a0935910b0e15cbf6bffe7356473ac12c1f20e1bd65b6e865f24b8c725f56c13087a26e9663ee9ecfb766cd3458aec6e1e6f78a297fe8e7"}, {"line": 3418, "relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid-beta (Abeta) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3beta (GSK3beta) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3beta to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3beta activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3beta, or at Thr-668, the GSK3beta phosphorylation site in APP, abolished the regulation of GSK3beta activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3beta kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Degradation"}, "source": 133, "target": 63, "key": "cd8f525cd5a05ea49f2a7c7fad89d5ba07c0e148ce4b4fda1eef0899079c54ad92eaf1b2990ba8bdd71213dfa8edcaa1aef1cdc2d3aa1f34adfdb7fc5974bb99"}, {"line": 3419, "relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid-beta (Abeta) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3beta (GSK3beta) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3beta to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3beta activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3beta, or at Thr-668, the GSK3beta phosphorylation site in APP, abolished the regulation of GSK3beta activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3beta kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "source": 133, "target": 3, "key": "7844c9d7d6c6ae56ed1857315785b8afb40a43b7a1b689ed53ce28d99102abc10c12bd8b7370d17e18dc1fec0574017b17f477535bb8d93cbd57c3ab8b1c7e5e"}, {"line": 3420, "relation": "increases", "evidence": "Alzheimer disease (AD) is characterized by the presence of senile plaques of amyloid-beta (Abeta) peptides derived from amyloid precursor protein (APP) and neurofibrillary tangles made of hyperphosphorylated Tau. Increasing APP gene dosage or expression has been shown to cause familial early-onset AD. However, whether and how protein stability of APP is regulated is unclear. The prolyl isomerase Pin1 and glycogen synthase kinase-3beta (GSK3beta) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD. However, nothing is known about their relationship. In this study, we found that Pin1 binds to the pT330-P motif in GSK3beta to inhibit its kinase activity. Furthermore, Pin1 promotes protein turnover of APP by inhibiting GSK3beta activity. A point mutation either at Thr-330, the Pin1-binding site in GSK3beta, or at Thr-668, the GSK3beta phosphorylation site in APP, abolished the regulation of GSK3beta activity, Thr-668 phosphorylation, and APP stability by Pin1, resulting in reduced non-amyloidogenic APP processing and increased APP levels. These results uncover a novel role of Pin1 in inhibiting GSK3beta kinase activity to reduce APP protein levels, providing a previously unrecognized mechanism by which Pin1 protects against Alzheimer disease.", "citation": {"type": "PubMed", "name": "J Biol Chem. 2012 Mar 2;287(10):6969-73. Epub 2011 Dec 19.", "reference": "22184106"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"GSK3 subgraph": true, "Amyloidogenic subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Degradation"}, "source": 93, "target": 63, "key": "218e0289b1e06c8002fd86493c1b3936f2fbde7f8e5d5f4e8fabf4e4075d583f1c71608eeadab04dcb01aa2935c336d85c145c347bab2ae802c2883748c7bf8c"}, {"line": 8955, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 92, "key": "b4c0dfb61fd268c6469a597b703fe85c7d775127f03b1e528bd1cb1f44844499052cbe768e7884b6be6fd23a14e7a75db11db5361a53c0b0c36b4aef61b1871e"}, {"line": 43743, "relation": "increases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 92, "key": "ccb83701631590c2b1a2693626f1a7822b741ae12554a836b9ee940c3a0178bc82655e7cd660ba323eddb1f75eb93d29a00ace0890f4303624d4e3514446b0c1"}, {"line": 8956, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 89, "key": "f54b5cf2d3e9873c4a3dc1a7c57a6f0a8e00ef48f87d5a781911cf5791aacdacece5af7a403011c5eb4e5961c4ac1b42dffd2efcfaec70b70b94e26d017ddcbd"}, {"line": 43756, "relation": "increases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 89, "key": "b0c6e2d868b64694950fd8408558cb6bd061700977c82a555276c176099eec4ff3e0e7646b6009613de1fe344371002c0301d0d70d09e451509a37532db92617"}, {"line": 8957, "relation": "decreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 153, "target": 66, "key": "4c4c70911c66effb943510e52c34ba42a6d5b7bfb94a7cfbbadf9e5f684ea586b2b2708181a54f13caf62144a91554f25152489ddc2d614234fe3178919458ff"}, {"line": 29668, "relation": "decreases", "evidence": "Activation of PI3K after CsA treatment appeared to trigger opposite effects. First, CsA induced PI3K-dependent activation of Akt, which mediated cellular responses against cell injury. Akt activation led to transient phosphorylation and inhibition of the pro-apoptotic GSK3beta and Bad, thus preventing GSK3beta-mediated phosphorylation and activation of the pro-apoptotic Bax, and Bad-sequestering of Bcl-2.", "citation": {"type": "PubMed", "name": "Xenobiotica. 2005 Jul;35(7):737-53", "reference": "16316932"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 66, "key": "f22eb0a261aa2469fb858838d13da729cf482c74d51c144f32c0c8c77727903f1974bdcb4e70e7c25bce0004bef4826b0e5fbc38c240b6c25f4aefd83b1ade58"}, {"line": 8959, "relation": "decreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 22, "key": "9b30b5eab3b3037443735e7f215acb6224e9790c1045edea6a9744529d1b8ca86fd925fd93c0d04ba9ed400c8d7a28f45ba33d975e514eac3b68ed78eb447777"}, {"line": 29664, "relation": "decreases", "evidence": "Activation of PI3K after CsA treatment appeared to trigger opposite effects. First, CsA induced PI3K-dependent activation of Akt, which mediated cellular responses against cell injury. Akt activation led to transient phosphorylation and inhibition of the pro-apoptotic GSK3beta and Bad, thus preventing GSK3beta-mediated phosphorylation and activation of the pro-apoptotic Bax, and Bad-sequestering of Bcl-2.", "citation": {"type": "PubMed", "name": "Xenobiotica. 2005 Jul;35(7):737-53", "reference": "16316932"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 153, "target": 90, "key": "32b51cf42c3e8ee5c3f8bd3777cee702a8d66f100dcbafe22bbb1dc91e45abcd6580da6ec411500dead345c6dbd290b9c3a49776ef819562a14fb976132cde9a"}, {"line": 43742, "relation": "decreases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 153, "target": 90, "key": "025245d76f7e603a88a4d29b00beb53e755ec2629bb50028cbce39b90433d3a9120f8c95ad707b644a6d8fc6f60b1d0bb68a78f4fafddad0a0443376681bdcae"}, {"line": 29667, "relation": "decreases", "evidence": "Activation of PI3K after CsA treatment appeared to trigger opposite effects. First, CsA induced PI3K-dependent activation of Akt, which mediated cellular responses against cell injury. Akt activation led to transient phosphorylation and inhibition of the pro-apoptotic GSK3beta and Bad, thus preventing GSK3beta-mediated phosphorylation and activation of the pro-apoptotic Bax, and Bad-sequestering of Bcl-2.", "citation": {"type": "PubMed", "name": "Xenobiotica. 2005 Jul;35(7):737-53", "reference": "16316932"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 153, "target": 67, "key": "bcfdeeccc069398f92ab24becce077c642e0fbbbdf7cbb8a2fceeba37ce7cb4e26a7039444cdb986013bdf0d9564c6716066dc7ff548a3ff58e8371188eef780"}, {"line": 43755, "relation": "decreases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 153, "target": 88, "key": "5f40af6dcc83eb3e9d73814c9675c2f5679abd12c13002e700c0f5e99255c6b5196a536781b63cfb10f03925ad0948e8a72eaa0cb528c7d1a867485e675cc3d0"}, {"line": 43757, "relation": "decreases", "evidence": "The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta¸42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3ÃƒÅ¸, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3ÃƒÅ¸ by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3ÃƒÅ¸, suppresses GSK-3ÃƒÅ¸-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta¸42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3ÃƒÅ¸ [97]. Inhibition of GSK-3ÃƒÅ¸ promotes cell survival through a variety of mechanisms including a reduced degradation of ÃƒÅ¸-catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 89, "target": 88, "key": "31e7d82d59596deb93c1b77820c6e91b43fab329799a74ae932c7839280a941914cae4126704fa8ca351e5632840a43b13a6d4289379488ef5b02c21a76532a5"}, {"line": 8036, "relation": "increases", "evidence": "Akt substrates such as mammalian target of rapamycin (mTOR; Ser2448) and decreased levels of cell-cycle inhibitors (p27kip1) are found in AD temporal cortex when compared to controls. GSK-3a has been implicated in the production of Abeta peptide while increased GSK-3beta activity has been implicated in tau hyperphosphorylation and neuronal cell death", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Amyloidogenic subgraph": true}, "Confidence": {"Medium": true}, "Disease": {"Alzheimer's disease": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 3, "key": "90f6906bba47a08333fed5867ac1891be387feb1ae07aa60de4dedacf69e77a65f7d44cd9fcfd1e4c3709c99600ca56b080e941dddde923142390afb52b0e8f7"}, {"line": 39219, "relation": "increases", "evidence": "In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis2006", "reference": "16914869"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Amyloidogenic subgraph": true}}, "source": 88, "target": 3, "key": "16c0170262448da89a1dcdb8a522c2e0434f8da82010c8993aad7ec1b1053fd0417376826a978c7a46bba22e566a9a6de4493ec44d3c670fbf0ead7786fd21ff"}, {"line": 36185, "relation": "increases", "evidence": "Both GSK-3alpha and 3beta phosphorylate purified pig brain CRMP-2 and significantly alter its mobility in SDS-gels, resembling the CRMP-2 pmodification observed in AD brain.", "citation": {"type": "PubMed", "name": "J Cell Biochem2008", "reference": "17902168"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Axonal guidance subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Nerve growth factor subgraph": true}, "Species": {"9823": true}, "Confidence": {"High": true}}, "source": 88, "target": 83, "key": "e396210fc7ed3555709887be932974c994eef521abfcc8c84110cbd44fa74b3a0c8783c29cd40b89b8060297369cae23815961c3a06804c6d2d2d87c8981d370"}, {"line": 36205, "relation": "increases", "evidence": "Ser-522 prephosphorylated by Cdk5 is required for subsequent GSK-3alpha-mediated phosphorylation of CRMP-2 in vitro.", "citation": {"type": "PubMed", "name": "J Cell Biochem2008", "reference": "17902168"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 83, "key": "0f4889e609543b6a75118bfafc41f546348142e21cdefbbff83c6dc38c45a3be674df82f4279826402db173ffbce6313ae7cc36b577e1a85febc76794d970f64"}, {"line": 36204, "relation": "positiveCorrelation", "evidence": "Ser-522 prephosphorylated by Cdk5 is required for subsequent GSK-3alpha-mediated phosphorylation of CRMP-2 in vitro.", "citation": {"type": "PubMed", "name": "J Cell Biochem2008", "reference": "17902168"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 84, "key": "099611689a8880d23718dab61523f5c2cbd284674916c37890c1b5482aad916e8157f843caeae24b15e31616940030c7b41d0f5e8768baa76a36e9d7715b6661"}, {"line": 36513, "relation": "increases", "evidence": "In sharp contrast, when Ser-10 of this peptide was replaced by a phosphoserine, the phosphopeptide fragment (VAVVRTPPKS(p)PSSAK) became an excellent substrate for kinase FA/GSK-3 alpha.", "citation": {"type": "PubMed", "name": "Biochem Biophys Res Commun1993", "reference": "7505567"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 112, "key": "4ffbff1c6bbb8232ee88a63bef992d741c22ca911bdd3ad8e1e9ef14127ab7d8ba9a7fd65cab0ec1e0da8aa9a98a456591c3f14a8a3065267c3533320b0de9d7"}, {"line": 36524, "relation": "increases", "evidence": "Previously, we identified protein kinase FA/glycogen synthase kinase-3 alpha (GSK-3 alpha) as a brain microtubule-associated tau kinase that phosphorylates Ser235 and Ser404 of tau and causes its electrophoretic mobility shift in gels, a unique property characteristic of paired helical filament-associated pathological tau (PHF-tau) in Alzheimer's disease brains.", "citation": {"type": "PubMed", "name": "J Neurochem1994", "reference": "7931292"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 118, "key": "af51e4d6601884a77785429b523872f0fc2a14c435820eaf014921f49f52f21fc6868126fc117a4b220e373e03d7f3901c1f56b023ad5555b1c3ad5c41d29232"}, {"line": 36525, "relation": "increases", "evidence": "Previously, we identified protein kinase FA/glycogen synthase kinase-3 alpha (GSK-3 alpha) as a brain microtubule-associated tau kinase that phosphorylates Ser235 and Ser404 of tau and causes its electrophoretic mobility shift in gels, a unique property characteristic of paired helical filament-associated pathological tau (PHF-tau) in Alzheimer's disease brains.", "citation": {"type": "PubMed", "name": "J Neurochem1994", "reference": "7931292"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 121, "key": "863b448b4095b432eb33dab82d2bdb8bd663849accb3bbdc1418ea5295c9a788041a51fbe2b785df58b38e3383c31ebe2c9b7955733ce84dca205ba2eb7caf06"}, {"line": 36599, "relation": "positiveCorrelation", "evidence": "These results, respectively, indicated that GSK-3beta is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3beta-MARK2 pathway.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "16257959"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 126, "target": 119, "key": "1ebf4eb3dc8b31aa1aea8e5a7019d58574ac410771b22014b80c896b703c777910c024a28f7bee8a6018ae10c2e3617094eecf45e6f0712bc646f10860d2e2c2"}, {"line": 9645, "relation": "positiveCorrelation", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPARgamma leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against Abeta neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in beta-catenin and inhibition of GSK-3beta is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPARgamma by a potent ligand leads to beta-catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPARgamma activation in neuroprotection, PPARgamma agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPARgamma activation . A recent report demonstrates that overexpression of PPARgamma in cultured cells leads to a dramatic decrease in the production of Abeta, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing Abeta secretion, PPARgamma protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 38, "target": 21, "key": "7fab133f5b16125702b82b7682608bc4dcc8bd2f0e5b3facf6b809624bfba050a42297c4fab02f131dc74000fda59a3460331f01ef67b1b684090de602468e45"}, {"line": 46830, "relation": "increases", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "DKK1 subgraph": true, "Calcium-dependent signal transduction": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 144, "target": 91, "key": "f167fb96d1a90a112932d99024c5d2d55733eb60d1881915da698de9abbbb053d82ea2e57f72a2720e3ed47f300aec1eab58de53d07b2f987d79f33cf298702b"}, {"line": 46831, "relation": "increases", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "DKK1 subgraph": true, "Calcium-dependent signal transduction": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 144, "target": 82, "key": "abbf4420685a4284ff6dfeffe94493ce090fe7f4038dfc02ea598675b38d163713b7581f15c77076ac079f6c0ab770ace3bdfd570f55f685c9643618edb44eb2"}, {"line": 10547, "relation": "decreases", "evidence": "Activation of the catalytic subunit of the PI3-kinase results in phosphorylation of phosphatidylinositide-diphosphate (PI4,5P) to generate phosphatidylinositide-triphosphate (PI3,4,5P). This leads to activation of several downstream targets, such as phosphoinositide-dependent protein kinase (PDK)-1, protein kinase B (PKB, AKT), p70S6kinase, glycogen synthase kinase(GSK)-3 and BAD a proapoptotic member of the Bcl-2 family. Phosphorylation of GSK-3 and BAD inactivates these proteins and thereby inhibits further signaling leading to apoptosis. Activated AKT phosphorylates the forkhead transcription factor Foxo, which triggers its nuclear exclusion and thereby regulates transcription of genes involved in development, growth, stress resistance, apoptosis, metabolism and aging [29-31]. Several Foxo target genes might play an important role for the pathogenetics of AD (review in [32]): Catalase and MnSOD (manganese superoxid dismutase) are crucial in promoting longevity by possibly acting as antioxidants due to reduced insulin-like signaling in various species such as drosophila [33] and C. elegans [34]. ", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 91, "target": 90, "key": "e5768e2ee919f8932931942681444762afa3296c74519499807d574510e9ede1d20dd47e16a81d3e5af8fc53618888d68df0e60d48c38613c94ddc1729a13f1e"}, {"line": 10548, "relation": "increases", "evidence": "Activation of the catalytic subunit of the PI3-kinase results in phosphorylation of phosphatidylinositide-diphosphate (PI4,5P) to generate phosphatidylinositide-triphosphate (PI3,4,5P). This leads to activation of several downstream targets, such as phosphoinositide-dependent protein kinase (PDK)-1, protein kinase B (PKB, AKT), p70S6kinase, glycogen synthase kinase(GSK)-3 and BAD a proapoptotic member of the Bcl-2 family. Phosphorylation of GSK-3 and BAD inactivates these proteins and thereby inhibits further signaling leading to apoptosis. Activated AKT phosphorylates the forkhead transcription factor Foxo, which triggers its nuclear exclusion and thereby regulates transcription of genes involved in development, growth, stress resistance, apoptosis, metabolism and aging [29-31]. Several Foxo target genes might play an important role for the pathogenetics of AD (review in [32]): Catalase and MnSOD (manganese superoxid dismutase) are crucial in promoting longevity by possibly acting as antioxidants due to reduced insulin-like signaling in various species such as drosophila [33] and C. elegans [34]. ", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 22, "key": "83364e5c41d2ff8ee92c0320dec5e4dc3d0e585da2c3305955579367269e4dcbaefe93fdded5ffb8b52aa081fcef91c15f1be90f7ff0bc723c999d8069a65323"}, {"line": 46832, "relation": "positiveCorrelation", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "DKK1 subgraph": true, "Calcium-dependent signal transduction": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 82, "key": "9dc02764d8a2095f55913eeb9554d740d05017feebd89482802e932abe93ffaf7093eecd02b425ac44edda3681110ad8a9ec9b796a1b45c72adbb345ccc05c0b"}, {"line": 46837, "relation": "increases", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 91, "target": 114, "key": "d28240fb5692e62ddc75dba8350388dbeb8be9119c229bd40cf1a9f732334474e9c54c53d3f362228b335b1c7dcbebdd7d2b94385c0aec657b191c130f4aad0d"}, {"line": 46832, "relation": "positiveCorrelation", "evidence": "it has been demonstrated that micromolar S100B concentrations stimulate c-Jun N-terminal kinase (JNK) phosphorylation through the receptor for advanced glycation ending products, and subsequently activate nuclear AP-1/cJun transcription, in cultured human neural stem cells. In addition, as revealed by Western blot, small interfering RNA and immunofluorescence analysis, S100B-induced JNK activation increased expression of Dickopff-1 that, in turn, promoted glycogen synthase kinase 3beta phosphorylation and beta-catenin degradation, causing canonical Wnt signaling pathway disruption and tau protein hyperphosphorylation. These findings propose a previously unrecognized link between S100B and tau hyperphosphorylation, suggesting S100B can contribute to NFT formation in AD and in all other conditions in which neuroinflammation may have a crucial role.", "citation": {"type": "PubMed", "name": "J Cell Mol Med. 2008 Jun;12(3):914-27. doi: 10.1111/j.1582-4934.2008.00159.x.", "reference": "18494933"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "DKK1 subgraph": true, "Calcium-dependent signal transduction": true, "Wnt signaling subgraph": true}, "Confidence": {"High": true}}, "source": 82, "target": 91, "key": "a42f11b1807947e020e26487355eeb59972108607631563ba4888a3d1428fe3d56595f56861ca1d0140fe57602292df6752064a6c6759c411ed6e1a5fbf2586a"}, {"line": 39199, "relation": "increases", "evidence": "Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2003", "reference": "12191990"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "MAPK-JNK subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 109, "target": 114, "key": "11fe5794c8644242f29321f103d2052d790eb66f117109f321347fa611aeab5fb0d695b08a4baef462e79f8c2bdf01b4adf50dbc8d4803804d8c5bc9b45d337b"}, {"line": 36204, "relation": "positiveCorrelation", "evidence": "Ser-522 prephosphorylated by Cdk5 is required for subsequent GSK-3alpha-mediated phosphorylation of CRMP-2 in vitro.", "citation": {"type": "PubMed", "name": "J Cell Biochem2008", "reference": "17902168"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 84, "target": 88, "key": "1d5843f532d504790f9e2feeb07b2c6b1fd05a42ad10c1cd733baf003f60dfe61170bff8f8dc565435819c563d85fadc85c6372b3b02a01fe9c931b52b269d1e"}, {"line": 35578, "relation": "increases", "evidence": "These studies suggest that PKA, cdk5, CaM Kinase II and GSK-3 are involved in the regulation of phosphorylation of tau and that AD-type phosphorylation of tau is probably a product of the synergistic action of two or more of these kinases.", "citation": {"type": "PubMed", "name": "Neurochem Res2006", "reference": "17120162"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "source": 136, "target": 114, "key": "b5db89eb8cc3c76e7369192e7fb63e76a55e59fb18fd4392809e9220f5333314cc7377c73b4b0ba7b1b35c552e32f92e9bbad64c12c4139343d45a847532961c"}, {"line": 35657, "relation": "increases", "evidence": "Phosphorylation of tau protein is regulated by several kinases, especially glycogen synthase kinase 3beta (GSK-3beta), cyclin-dependent protein kinase 5 (cdk5) and cAMP-dependent protein kinase (PKA).", "citation": {"type": "PubMed", "name": "FEBS letters2006", "reference": "17078951"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "subject": {"modifier": "Activity"}, "source": 136, "target": 114, "key": "8eb8b501f2c697d119a87e936aa0c890405eb813d210f760a38f1db9f2ca2992e6bde1cfe9fd211cbdcee1fa6e01dfd5e527ae946dcd50747fad55e040d654d3"}, {"line": 11020, "relation": "increases", "evidence": "GSK-3 is a serine/threonine kinase, modulated by insulin/IGF-1 signaling. When the IRIIGF-IR pathÂ­ way is activated, GSK-3is phosphorylated by AKT at Scr 9 leading to its inactivation [I 06-109]. However, PP2A dephosphorylates GSK-3(review in [II 0]), which then phosphorylates tau at several sites leading to an equilibrium of phosphorylation and dephosphorylation of tau (Overview : see Fig. 1). Thus, impaired IRIIGF-1 R signaling might lead to hyperphosphory lation of tau protein and an in creased forÂ­ mation of neurofibrillary tangles.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Akt subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 61, "target": 92, "key": "4b5d04a51f24daf2d38b294289d01d0530d5c920be574a9d8c5b2a368e2c3aabecde3f42f75de5d31c69be58a0e70af9894b8ff9984c4484411a3886ea070c7c"}, {"line": 17150, "relation": "decreases", "evidence": "Thus, we addressed this paradoxical condition of AD in rat neurons treated with okadaic acid (OA) which inhibits protein phosphatase-2A (PP2A) and induces tau hyperphosphorylation and cell death. Interestingly, OA also induces phosphorylation of GSK3beta at serine-9 and other substrates including tau, beta-catenin and CRMP2 like in AD brains. In this context, we observed that GSK3beta inhibitors such as lithium chloride and 6-bromoindirubin-3'-monoxime (6-BIO) reversed those phosphorylation events and protected neurons. These data suggest that GSK3beta may still have its kinase activity despite increase of its phosphorylation at serine-9 in AD brains at least in PP2A-compromised conditions and that GSK3beta inhibitors could be a valuable drug candidate in AD.", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Species": {"10116": true}, "MeSHAnatomy": {"Neurons": true}, "Disease": {"Alzheimer's disease": true}, "Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true}}, "source": 6, "target": 90, "key": "33d11381e6bf2d41cd13b289be252407523109c84055045fcd9456a676a3e13b9983b1c6f804883c23f67a6e3db0b6f5a233de426c7a1ad72ddeec91cfb9ff67"}, {"line": 8941, "relation": "directlyIncreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 98, "target": 99, "key": "78b6eed32f4aabe7be16103e10d4214ab3073144c6d73f8f77bf1665090c2f41ca5f981e3beb3c63d60e12290f857d26769c6224ff530358ce4a25e781e8b396"}, {"line": 11074, "relation": "increases", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Tau protein subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}, "UserdefinedCellLine": {"primary cortical neuron": true}}, "source": 98, "target": 57, "key": "4a510e15b3afccd193970281ea1a10375f0d2a0297b7c94ac583e93399bf495556c32c8437e9b11b2c4cd7769636dbb58fe5fff97c09464d87c777e040ceab3c"}, {"line": 8942, "relation": "positiveCorrelation", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 99, "target": 28, "key": "02cf785506ee43e6f7dc8b288f23dafb9da17ec4f012f735b3edc061d3e04dbb05efe84401986428d7e73445ea2530cd0b60432ca8d426fe851e0de34d347397"}, {"line": 8946, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 99, "target": 101, "key": "dae93830fabadd938a55d835d80c0cb7d433b3fb6507e858d3c72bbf5086c218fa518a29a49a436d1faea5953c471599d1808206a904db57939b7cdbff06f489"}, {"line": 8948, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 99, "target": 103, "key": "6858077889ad70a23d119d39f37ce8c7b38cbc010ca83903e86e3359f1bd407269bd93949dc8958cc1523fe335224a50341a96949526ee3ef1903e139ad746c4"}, {"line": 8950, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 99, "target": 105, "key": "7abe2ce72045de7099322c6253d99f517d05dcbf62c4cfa8fe79b0ce9178a58db14343fb96cc39a0b5ef8996224785218d81b641937feafe6c1d6c09a6d31f15"}, {"line": 8942, "relation": "positiveCorrelation", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 99, "key": "5b23ace5516733ca5ca2155a8830daa2a6624c4259a059922e1f4c590a2a637955461f0b9ac23651ef8201398465a8233202bb81dd9b3068633890a60f0b2d47"}, {"line": 11004, "relation": "decreases", "evidence": "GSK-3 is a serine/threonine kinase, modulated by insulin/IGF-1 signaling. When the IRIIGF-IR pathÂ­ way is activated, GSK-3is phosphorylated by AKT at Scr 9 leading to its inactivation [I 06-109]. However, PP2A dephosphorylates GSK-3(review in [II 0]), which then phosphorylates tau at several sites leading to an equilibrium of phosphorylation and dephosphorylation of tau (Overview : see Fig. 1). Thus, impaired IRIIGF-1 R signaling might lead to hyperphosphory lation of tau protein and an in creased forÂ­ mation of neurofibrillary tangles.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 90, "key": "f89deee7ecee5f9a8427ee4b630f9930d377a0148b3f503d9b136318ed519e9a03b46d565d22de8748c81f8ea88c4e3c4941678e6bac4f4652edf7fb0c914dba"}, {"line": 8947, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 101, "target": 100, "key": "4f1639cf9921268c94c2949d7475e1777ec5b9707a2e65f631667167c6a2cbad02ac2ae7788ce36c6febc9eb84403bbe6ce9d64b76399c52d930726b8d8316db"}, {"line": 8949, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 103, "target": 102, "key": "b7e865c13ddea9c417cc08446011281aa4a1da4ef0835db2cd89ef326ec7f6f5837b3eda2bdca7322892d11163005d33c69e44ee9101ebb9f7a847e35fca475b"}, {"line": 8951, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 105, "target": 104, "key": "84c61ce17ff0f59d3c5bfcac9a9f04a32fabe16e16a23a84ed73e56e27696480f16379acc1cce536389d8e7372fbce44c0e22ed5ed0b86afe99a7626d7723384"}, {"line": 8952, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 100, "target": 43, "key": "94ac55a908ce1a66041910dd878ca32be27ef8054ade2739e74a26f1496499d257eea0ac596048707548b0cf696329672991476a7e43da492d7e587f07244f40"}, {"line": 8960, "relation": "decreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 100, "target": 41, "key": "62645f7b779aea3080d150c680d7205539dbe53c8aaae9680d2e6f0aca36df5ce18c2c4cdbeaef3534f7f147361f81f32a27ac1a9c95a9f5e8fe4d82438a136e"}, {"line": 8967, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 100, "target": 44, "key": "734f7d7a9f232c4609dd20d9bb80db885817b7ad23b86e5a32efb0585d00c7057025597e7aa7eaa35bd2950ef278e60b4c305c8209821d9c0c5e1da9bfed5a14"}, {"line": 8954, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 43, "target": 153, "key": "3e22d1c3040e2552ecfe0ef89232a5e8a32695051ca359812a9da0d1ddbf9fe8e3371a9c9307d74ca1ec24478e4caf1e2b6485d58843deef195797dea45206be"}, {"line": 8969, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 44, "target": 24, "key": "483370ad8c122cd24495f37d4d0d5f607a57e01c6cafb7d7f9625f722c24ef8e035e8cd9057f62755ba3e510cef7d46299d5f60272fcf3c1be07b9170c0bb009"}, {"line": 8970, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 44, "target": 39, "key": "0e06b6fd95c6f7c64fa97e08a0e64f4ea3f7d84d179a7c6dca55ad2cb064bd382c0288479ac6425302ec64c29d8c38b0b65864927f9254e93c6f220291cf38f0"}, {"line": 8945, "relation": "positiveCorrelation", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 29, "target": 97, "key": "633bea668b32004a385ee79cef5b41b02402cf536f7e9ce808da1760b1e0a67e2142ce2a9002b772faa30e6b4a41e2bfbec52a54b725f6a26cc383155a58de55"}, {"line": 11003, "relation": "decreases", "evidence": "GSK-3 is a serine/threonine kinase, modulated by insulin/IGF-1 signaling. When the IRIIGF-IR pathÂ­ way is activated, GSK-3is phosphorylated by AKT at Scr 9 leading to its inactivation [I 06-109]. However, PP2A dephosphorylates GSK-3(review in [II 0]), which then phosphorylates tau at several sites leading to an equilibrium of phosphorylation and dephosphorylation of tau (Overview : see Fig. 1). Thus, impaired IRIIGF-1 R signaling might lead to hyperphosphory lation of tau protein and an in creased forÂ­ mation of neurofibrillary tangles.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 29, "target": 90, "key": "7249b22b0ed60f4c7e3d6427e4cee65c06e0ba46abee1c26cf74f1e47723945a905b79989201b3db755c98c59522499ede121605cc5de9d0c711df8fee6c285d"}, {"line": 8944, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 97, "target": 105, "key": "f9e2ccdd26772edc9a02f2073bd08685093fbbf2066f6789e8ef6524939256c5386592bfb052aa560ecf0b56313564a36bfc4e6b1fe4eac3ca24bb4ad1d3ee0d"}, {"line": 8945, "relation": "positiveCorrelation", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 97, "target": 29, "key": "7fe8df88fc6f9e6dd686c2e3829fb9e6e51dec511c63a3498c97af3e39182d530d67180c578f7269340866cfd179e778f412f439e15519f84b0dd095481e9429"}, {"line": 8943, "relation": "directlyIncreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 96, "target": 97, "key": "81cd7796c7291edfff063af7133e88ab171c301cfeafcd74007a861e5a2f4788e6eff28c0f210b477db92b1db69e326e9eee762439f91339cda0242aa2610f88"}, {"line": 8962, "relation": "decreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 104, "target": 41, "key": "a4de412071f952489fab03fe5d18bbb22199bcaa3449d656b9787776237eb5099e05aeba5a8795bc483f5601bc95ea88ca26d08794755a6a2f942827acf80c15"}, {"line": 8965, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 104, "target": 87, "key": "f9d0237c7d5466256ae57c29a55514d7b7da3efdadaff6c5907e61738db20d3164a904f717ee24ca2ffa977dae72d265d6138f6309f6639a9572d4840d2ea7a4"}, {"line": 8966, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 104, "target": 44, "key": "b86a4065f50008e4dff1307b5c1e526c45d4e3578eb3133c0bf4806661bf69e819803e979ccda5f31e844aeb7cb79dad7da1c9ba241122ac20beb55f948344de"}, {"line": 8953, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 102, "target": 43, "key": "c613ddd533b426746826477088217675168e380ac0145fceb68c621a9428ba3788545bf0eeba6a773fdda221172ab9f37f46a36a676e2cd794bd9375a6f2410a"}, {"line": 8961, "relation": "decreases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 102, "target": 41, "key": "ed2b1193d6435f01a48f92fd2e996afba48921872c1ed8692b4201b36737584783e584e76913468b3248499941e82d95a9c2207bb8740ad18bb2d8ce1d1643fe"}, {"line": 8968, "relation": "increases", "evidence": "By way of review, insulin and IGF-1 mediate their effects by activating complex intracellular signaling pathways starting with ligand binding to cell surface receptors, followed by autophosphorylation and activation of the intrinsic receptor tyrosine kinases.34â€“36 Insulin/IGF-1 receptor tyrosine kinases phosphorylate IRS molecules,34,37â€“39 which transmit signals downstream by activating the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3 kinase/Akt pathways, and inhibit glycogen synthase kinase 3beta (GSK-3beta). Major biological responses to signaling through IRS molecules include increased cell growth; survival, energy metabolism, and cholinergic gene expression; and inhibition of oxidative stress and apoptotic process.39â€“46 ", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Disease": {"type 2 diabetes mellitus": true}, "MeSHAnatomy": {"Adipocytes": true}, "Subgraph": {"Insulin signal transduction": true, "MAPK-ERK subgraph": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 102, "target": 44, "key": "9a6a9f3b63dcfeda459334b433d89cfb4d2ba249faa1aeefe649bce6b6c05cbb945140e1f70d0b29206fe5344c5d14d2b4b2b742b0eaa008688875ca85a8a50f"}, {"line": 9641, "relation": "decreases", "evidence": "Rosiglitazone is a TZD derivative that was recently observed to improve cognition in both APP transgenic mice and AD patients [Watson et al., 2005; Pedersen et al., 2006]. It activates PPARgamma leading to increased glucose disposal rates [Jung et al., 2005] and is also neuroprotective against Abeta neurotoxicity [Inestrosa et al., 2005]. Neuroprotection may result through modulation of Wnt signaling since an increase in beta-catenin and inhibition of GSK-3beta is observed upon exposure to rosiglitazone [Inestrosa et al., 2005], although a different study has shown that activation of PPARgamma by a potent ligand leads to beta-catenin degradation [Liu and Farmer 2004]. Nonetheless, in support of the role for PPARgamma activation in neuroprotection, PPARgamma agonists have potent anti-inflammatory effects [Luna-Medina et al., 2005], inhibit microglial activation [Bernardo et al., 2005; Heneka et al., 2005] and have been shown to improve verbal memory in AD patients with T2DM, possibly in a mechanism dependent on PPARgamma activation . A recent report demonstrates that overexpression of PPARgamma in cultured cells leads to a dramatic decrease in the production of Abeta, by increasing the rate of APP degradation via ubiquitination [D'Abramo et al., 2005]. This study also showed that by decreasing Abeta secretion, PPARgamma protects the cells against H2O2-mediated necrosis [D'Abramo et al., 2005].", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Wnt signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 14, "target": 90, "key": "bdd7fb27377221ccc15e65ee1d58ad666220ac33210092765b25ea637dc4b0d8b827ce348010f81cf1c48deaf093b7dd728b76382ed0e435ed94ed5dbffb7b5a"}, {"line": 24304, "relation": "association", "evidence": "In addition, cdk5/p25 might also interact with other pathways such as glycogen synthetase kinase 3beta (GSK3beta) and c-JUN kinase.", "citation": {"type": "PubMed", "reference": "17160145"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"GSK3 subgraph": true, "Cyclin-CDK subgraph": true}, "Confidence": {"High": true}}, "source": 106, "target": 53, "key": "74f59123bcd14ccb08437bf8cc341bb8fc820740f19ee8a919d0a2e5d3e99b423829187c31164ba33bedb335cc10b9c2f47033e2892ef348587f7012a6707d4e"}, {"line": 15970, "relation": "association", "evidence": "We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "reference": "19429119"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Leptin subgraph": true}, "Confidence": {"High": true}}, "source": 33, "target": 107, "key": "8798c9febd1cdfe8e0f07757308ff97e96ff182386ccb1bc1942fc57d0625ac4e96af8102ad3284f15b5ac08e7662c8a27df9c67effb375eb017c37c029a3f24"}, {"line": 15969, "relation": "decreases", "evidence": "We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "reference": "19429119"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Leptin subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 107, "target": 90, "key": "cd4546879e5875914618ac300d513c3fb429a0208a0dd2b08a1c4a8846d1171391d6539e73d652c00905bc2cc0dae3110fead42e118ba1f410e0866f9bb959d6"}, {"line": 37058, "relation": "decreases", "evidence": "Treatment with leptin reversed the 27-OHC-induced increase in Abeta and phosphorylated tau by decreasing the levels of BACE-1 and GSK-3beta respectively.", "citation": {"type": "PubMed", "name": "Journal of Alzheimer's disease2010", "reference": "20157255"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 107, "target": 90, "key": "aeee7cd0845f6fa1342a558e4fe34a640766ba388f5313cc23e3266afbeebcb7911cb06ff96353cf543c67f8bd83ff959d13a334e53f180b3a8425a7ba58804b"}, {"line": 15970, "relation": "association", "evidence": "We have previously demonstrated that Leptin reduces extracellular amyloid beta (Abeta) protein both in vitro and in vivo, and intracellular tau phosphorylation in vitro. Further, we have shown that these effects are dependent on activation of AMP-activated protein kinase (AMPK) in vitro. Herein, we investigated downstream effectors of AMPK signaling directly linked to tau phosphorylation. One such target, of relevance to Alzheimer's disease (AD), may be GSK-3beta, which has been shown to be inactivated by Leptin. We therefore dissected the role of GSK-3beta in mediating Leptin's ability to reduce tau phosphorylation in neuronal cells. Our data suggest that Leptin regulates tau phosphorylation through a pathway involving both AMPK and GSK-3beta. This was based on the following: Leptin and the cell-permeable AMPK activator, 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR), reduced tau phosphorylation at AD-relevant sites similarly to the GSK-3beta inhibitor, lithium chloride (LiCl). Further, this reduction of tau phosphorylation was mimicked by the downregulation of GSK-3beta, achieved using siRNA technology and antagonized by the ectopic overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "reference": "19429119"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Leptin subgraph": true}, "Confidence": {"High": true}}, "source": 107, "target": 33, "key": "80732c8fa29bed4b28af1f514e8ea7f167a655c0bfef904d95e90090e968809d554dee3c8063f332665e929b1c91d6907693aac30316dd1eab4692bd128e9d1a"}, {"line": 10719, "relation": "increases", "evidence": "CerebraiiR/IGF-1 signaling in APP metabolism. Binding of insulin and IGF-1 to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3 and the tau phosphatase PP2A. InterÂ­ estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK cascade regulate different transcription factors involved in transcriptional regulation of metabolism and clearance of Â­ amyloid. APP is cleaved by a.-, -secretase (BACE-1) and y-secretase (presenilin). - and subsequent y-cleavage of APP leads to generation of -amyloid 1 -4o/ t-42â€¢ IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest that not only BACE-1 is int1uenced by IRIIGF- IR mediated signals but also a.Â­ secretase activity is stimulated by the PI3K pathway.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "GSK3 subgraph": true}, "Confidence": {"Medium": true}}, "source": 135, "target": 58, "key": "794f48f01d354a24ef0a65737553c03565398fb8a02b00a5f56b2223b1a360881a32e3d8af254d13d149effae3d77d8c7dbfed55a4b6f755e18dcfb0b139f6cb"}, {"line": 11085, "relation": "negativeCorrelation", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 135, "target": 132, "key": "da85b4200b1ab42ed4beff40aa082e76dac93fd7b587ea27841c15d743e5be1d4a6b3b2041405d6069eec1a42670a889de80851f379d422ee3a64ae29f133f17"}, {"line": 11087, "relation": "isA", "evidence": "In SHSY5Y cells, a human neuroblastoma cell line, as well as in primary cultu res of rat cortical neurons insulin administration leads to tau hyperphosphorylation (111-113]. In contrast, insulin and IGF- 1 administration in NT2N cells, cultured human neurons, decreases tau phosphorylation [114]. In primary cortical neuron cultures, M esk e et a/ . (115J found that insulin treatment causes a regulatory interaction between PP2A and GSK-3. Inhibition of Pl3-kinase leads to activat ion of GSK-3and PP2A. Enzyme activity of both enzymes al ways changed in the same direction. This balÂ­ anced response seemed to induce a steady state in tau phosÂ­ phorylation at GSK-3/PP2A-dependent sites (115]. Thus, on ly a dysbalance of insulin/IGF-1 regulated tau kinases and phosphatases might lead to tau hyperphosphorylation, partially explaining the different resu lts obtained under different conditions.", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Phosphatidylinositol 3 subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 135, "target": 57, "key": "66b77c0f9d081f2412ac964452b86270333f312e1feb46fb7d17505ff2aa293f759c0fafec0ed542f0f1bd9efffffea4731647c0006fa1cc4a7ec8ac5b778e1a"}, {"line": 10530, "relation": "increases", "evidence": "Activation of the catalytic subunit of the PI3-kinase results in phosphorylation of phosphatidylinositide-diphosphate (PI4,5P) to generate phosphatidylinositide-triphosphate (PI3,4,5P). This leads to activation of several downstream targets, such as phosphoinositide-dependent protein kinase (PDK)-1, protein kinase B (PKB, AKT), p70S6kinase, glycogen synthase kinase(GSK)-3 and BAD a proapoptotic member of the Bcl-2 family. Phosphorylation of GSK-3 and BAD inactivates these proteins and thereby inhibits further signaling leading to apoptosis. Activated AKT phosphorylates the forkhead transcription factor Foxo, which triggers its nuclear exclusion and thereby regulates transcription of genes involved in development, growth, stress resistance, apoptosis, metabolism and aging [29-31]. Several Foxo target genes might play an important role for the pathogenetics of AD (review in [32]): Catalase and MnSOD (manganese superoxid dismutase) are crucial in promoting longevity by possibly acting as antioxidants due to reduced insulin-like signaling in various species such as drosophila [33] and C. elegans [34]. ", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 0, "target": 143, "key": "b97aee4f81296bbd2d0fe5d2c701f61bc3b188937d54227733dd5591d596e54afc1f19dec552d84483f7bfff66a85e0ae665f1ead22e019da578efff54061c11"}, {"line": 10531, "relation": "increases", "evidence": "Activation of the catalytic subunit of the PI3-kinase results in phosphorylation of phosphatidylinositide-diphosphate (PI4,5P) to generate phosphatidylinositide-triphosphate (PI3,4,5P). This leads to activation of several downstream targets, such as phosphoinositide-dependent protein kinase (PDK)-1, protein kinase B (PKB, AKT), p70S6kinase, glycogen synthase kinase(GSK)-3 and BAD a proapoptotic member of the Bcl-2 family. Phosphorylation of GSK-3 and BAD inactivates these proteins and thereby inhibits further signaling leading to apoptosis. Activated AKT phosphorylates the forkhead transcription factor Foxo, which triggers its nuclear exclusion and thereby regulates transcription of genes involved in development, growth, stress resistance, apoptosis, metabolism and aging [29-31]. Several Foxo target genes might play an important role for the pathogenetics of AD (review in [32]): Catalase and MnSOD (manganese superoxid dismutase) are crucial in promoting longevity by possibly acting as antioxidants due to reduced insulin-like signaling in various species such as drosophila [33] and C. elegans [34]. ", "citation": {"type": "PubMed", "reference": "19519303"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 0, "target": 90, "key": "3b16d64d3a6a8611c5d6ae31b51a8f94de7b3463df81574667fc51ecd677f0ee27fd8cbf4082b8b6444909302edd615c66ce905f263c91bf59a83487820f9b2c"}, {"line": 35476, "relation": "association", "evidence": "These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.", "citation": {"type": "PubMed", "name": "FEBS Lett2002", "reference": "12387894"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "MeSHAnatomy": {"Neurofibrillary Tangles": true}, "Confidence": {"High": true}}, "source": 159, "target": 113, "key": "e080c672ca6b90035a74f8a771b25c1eb7ee8022ccc3f29d620fdb6da6ef4bfd96d56339b88ad90b9ab5f196a3009f95b1d571e4f9da1349c81baa8d2b554d2a"}, {"line": 35471, "relation": "increases", "evidence": "These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.", "citation": {"type": "PubMed", "name": "FEBS Lett2002", "reference": "12387894"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 113, "target": 90, "key": "769e33f13a9ffed52bffaae6a43ba48106153d0fa6b1392b6f5db67ae49e08f239826107fdd0153c789325a875c11748ab8fdea753bcf10ed04d8880a20c3f4d"}, {"line": 35476, "relation": "association", "evidence": "These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.", "citation": {"type": "PubMed", "name": "FEBS Lett2002", "reference": "12387894"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}, "MeSHAnatomy": {"Neurofibrillary Tangles": true}, "Confidence": {"High": true}}, "source": 113, "target": 159, "key": "164c67a90548f80f2df95c361fc10a2850ca494938993291d41e1c534a8ba0ae1a1d60241666432fba3d8e9d6fac95015ffcfeaaa6e75871a9c2004e04a08530"}, {"line": 12627, "relation": "increases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 56, "target": 90, "key": "cc7388d8e9b942bbebba3acf5fb972036111f2cc2e52e3130f10898113c3ebe673f7478aad6a2e110f475986534da9b3294d9d9459e3be2cff58c61719073923"}, {"line": 12626, "relation": "directlyIncreases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "source": 56, "target": 114, "key": "c6a96aefec05b554c924ea0e7abe7a401084934e729f705dc36e1a3bb122ac8834cb3dbbf50829bc0fbaf3bcb2f42d8c425d9a9f52577b672d5925b6569cfcce"}, {"line": 12632, "relation": "decreases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "source": 60, "target": 114, "key": "30879c059ec6f723854e4675977b3ce2ec4e10eda541a7e1b14ce799a5fd07807d0608fa7120518226de45f7ae5ca6b07869ca41c5ee933a2285bd71f662b798"}, {"line": 12633, "relation": "directlyDecreases", "evidence": "In this in vitro study, we found that: (a) alpha-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3beta (GSK-3beta), (b) alpha-SN forms a heterotrimeric complex with tau and GSK-3beta, and (c) the nonamyloid beta component (NAC) domain and an acidic region of alpha-SN are responsible for the stimulation of GSK-3beta-mediated tau phosphorylation. Thus, it is concluded that alpha-SN functions as a connecting mediator for tau and GSK-3beta, resulting in GSK-3beta-mediated tau phosphorylation. Because the expression of alpha-SN is promoted by oxidative stress, the accumulation of alpha-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3beta. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the alpha-SN-induced phosphorylation of tau by GSK-3beta through its direct binding to alpha-SN, suggesting that Hsp70 acts as a physiological suppressor of alpha-SN-mediated tau hyperphosphorylation.", "citation": {"type": "PubMed", "name": "FEBS J. 2011 Dec;278(24):4895-904. doi: 10.1111/j.1742-4658.2011.08389.x. Epub 2011 Oct 31.", "reference": "21985244"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Synuclein subgraph": true}}, "source": 60, "target": 145, "key": "3a4e0244cf574ca79943fcbd54005f38e59dfcf71bfbcdbb766e455708978407b1eba9eade76bce04a398944646a31028a9c6a847f5adfc7d2eb5a1f29bf395f"}, {"line": 16242, "relation": "decreases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 150, "key": "4a8bd921676969cacbde919a967cbc5cc597ba29144d451034d7e6269b789356780e7669bde966ed140f9db7f3cb78fcf6c05d6ff38dcb389ab4188a6f5e8523"}, {"line": 16243, "relation": "decreases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 151, "key": "f0d917d7423a332dc8dd45735baa3d37584604be4a16df2b346a96021a49e1364c0dd5f1468e2367cb8aaf3a3cc0f618503fb944469b2fd31fe31b5ebfa275a8"}, {"line": 16246, "relation": "decreases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 149, "key": "05a70834ca1fee15c585aed3b58012f824e0154758a41db4fa384318485454f7f8350b8199a78c9072f725f18016d10b47febaffb774545687e2ae98a9d87a16"}, {"line": 16247, "relation": "decreases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESHCS", "name": "Cell Surface Extensions"}, "toLoc": {"namespace": "MESHCS", "name": "Endosomes"}}}, "source": 18, "target": 148, "key": "d2e317f06c65ac505cad7903e6d7a7a0960a76e39a1ae6eecbe7c04def9972006288a122451f32e72171c90391ec1fb97eaa13d8eaa339a2d744a29d32cd7e31"}, {"line": 16248, "relation": "decreases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 17, "key": "7f4f4669e97a2305fff40f6f3a46820d6def311e210f6bf9f4bb7b659a2af2777428bed42a0e2c57c6495fc979a6f0a099f1a7727607ded3f3915a0b1409609f"}, {"line": 16244, "relation": "increases", "evidence": "Cerebrolysin is a peptide mixture with neurotrophic effects that might reduce the neurodegenerative pathology in Alzheimer's disease (AD). Cerebrolysin might reduce amyloid deposition by regulating amyloid-beta (Abeta) degradation or by modulating APP expression, maturation, or processing. To investigate these possibilities, APP tg mice were treated for 6 months with Cerebrolysin and analyzed in the water maze, followed by RNA, immunoblot, and confocal microscopy analysis of full-length (FL) APP and its fragments, beta-secretase (BACE1), and Abeta-degrading enzymes [neprilysin (Nep) and insulin-degrading enzyme (IDE)]. Consistent with previous studies, Cerebrolysin ameliorated the performance deficits in the spatial learning portion of the water maze and reduced the synaptic pathology and amyloid burden in the brains of APP tg mice. These effects were associated with reduced levels of FL APP and APP C-terminal fragments, but levels of BACE1, Notch1, Nep, and IDE were unchanged. In contrast, levels of active cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3beta [GSK-3beta; but not stress-activated protein kinase-1 (SAPK1)], kinases that phosphorylate APP, were reduced. Furthermore, Cerebrolysin reduced the levels of phosphorylated APP and the accumulation of APP in the neuritic processes. Taken together, these results suggest that Cerebrolysin might reduce AD-like pathology in the APP tg mice by regulating APP maturation and transport to sites where Abeta protein is generated.", "citation": {"type": "PubMed", "reference": "16511867"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true, "Cyclin-CDK subgraph": true, "Nerve growth factor subgraph": true}, "Confidence": {"High": true}}, "source": 150, "target": 149, "key": "9eb7f9ff8ca1acbbf43e223029523b5109ddc433e4a6cd0f3c3b8b1464f9c165b47f25edfa754d4e5c51500f3038417428861136651661d373b0bc37f88de2a9"}, {"line": 16504, "relation": "decreases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 11, "target": 90, "key": "a2e7330219cc01bd98329ab690c9d6eaa454a43b7b669a804d322ed87c68674d67e21cb4c0d818e91edf074fbc94ab6657850229f38105b9369b4473ca1c31e4"}, {"line": 17117, "relation": "increases", "evidence": "Thus, we addressed this paradoxical condition of AD in rat neurons treated with okadaic acid (OA) which inhibits protein phosphatase-2A (PP2A) and induces tau hyperphosphorylation and cell death. Interestingly, OA also induces phosphorylation of GSK3beta at serine-9 and other substrates including tau, beta-catenin and CRMP2 like in AD brains. In this context, we observed that GSK3beta inhibitors such as lithium chloride and 6-bromoindirubin-3'-monoxime (6-BIO) reversed those phosphorylation events and protected neurons. These data suggest that GSK3beta may still have its kinase activity despite increase of its phosphorylation at serine-9 in AD brains at least in PP2A-compromised conditions and that GSK3beta inhibitors could be a valuable drug candidate in AD.", "citation": {"type": "PubMed", "reference": "15314261"}, "annotations": {"Species": {"10116": true}, "MeSHAnatomy": {"Neurons": true}, "Disease": {"Alzheimer's disease": true}, "Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 8, "target": 92, "key": "ffd4d151fd0b563564b8635a79447fa41cecf55a5446892c01279d93d3d171bd5fc359bcb1dba985a3f97afe2aba316c3842ad6a3f8e4ebd35f6bf0d12347d3a"}, {"line": 17217, "relation": "decreases", "evidence": "We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.", "citation": {"type": "PubMed", "reference": "21297267"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 10, "target": 90, "key": "ef91c4c52541f4a97bf11b34f21f34d1363539f143fde3e93a62dcd2c53e162fe0b6ed3495131fcb75eb5643b5e8c46f899d68c5a40916342e3cf5f1a63fd9e4"}, {"line": 17218, "relation": "decreases", "evidence": "We found a significant reduction of calyculin A-induced tau hyperphosphorylation at Ser198/199/202, Ser396, Ser404, Thr205, and Thr231 24 h after treatment with 20 Î¼g/ml berberine. Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively. Furthermore, berberine reversed both the increase of malondialdehyde and the decrease of superoxide dismutase activity induced by calyculin A, indicating its role in anti-oxidative stress.", "citation": {"type": "PubMed", "reference": "21297267"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "source": 10, "target": 12, "key": "0ecada143b847befb9417941fbdc5da3ae24180b1c290ff3874e55baa53e5ff7b3e9150beead9a13f6edad90c94e704fc0ca78b1bcbe0d40c80640a0405d73c3"}, {"line": 26579, "relation": "increases", "evidence": "In cells treated with wortmannin, protein kinase C delta fragments were observed, and the protein kinase C activity increased after 3 hours, whereas treatment of cells with z-DEVD-fmk, an inhibitor of caspase-3, inhibited fragmentation of protein kinase C delta and induced continuous activation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 15, "target": 137, "key": "74a034d57329be886b1f6563e9137052dd8e1a1f20b23818bfe3a32c04b21acdebaab50b468a4856afffd62396bb5be1c1c750d5c7c51aeba983a9a50c0f7ea1"}, {"line": 35559, "relation": "increases", "evidence": "The basal kinase activities of protein kinase-A (PKA), CaM Kinase II and GSK-3 were stimulated more than two-fold by isoproterenol, bradykinin and wortmannin, respectively. ", "citation": {"type": "PubMed", "name": "Neurochem Res2006", "reference": "17120162"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 15, "target": 90, "key": "cc424dabe7bd4a1c7ba98b4d659cd94554068a234f7bd6314baf98b6dc0113ab5e01186161890e2cff945c91d56e35ac894505dc967a5a67e685372d956f0b00"}, {"line": 26580, "relation": "decreases", "evidence": "In cells treated with wortmannin, protein kinase C delta fragments were observed, and the protein kinase C activity increased after 3 hours, whereas treatment of cells with z-DEVD-fmk, an inhibitor of caspase-3, inhibited fragmentation of protein kinase C delta and induced continuous activation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 2, "target": 70, "key": "32401b1c3c003acb6b51b13d042e3bf0e0842ca8b2cf91873d3599fd1dc0952ebc0e683ef9d2bf11ab16b12c679ff307b4830d86130c81989c2a2c6bc952c640"}, {"line": 26581, "relation": "decreases", "evidence": "In cells treated with wortmannin, protein kinase C delta fragments were observed, and the protein kinase C activity increased after 3 hours, whereas treatment of cells with z-DEVD-fmk, an inhibitor of caspase-3, inhibited fragmentation of protein kinase C delta and induced continuous activation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "source": 2, "target": 137, "key": "c9bbfef017751986b2c848bd54e36e276fa6960e5f53fca2aa1ad24c95115bdf069ba94ce3fe18db6ee155889ac7c1041e9f070e2b41d778d1d0bf13cb6680d2"}, {"line": 26582, "relation": "increases", "evidence": "In cells treated with wortmannin, protein kinase C delta fragments were observed, and the protein kinase C activity increased after 3 hours, whereas treatment of cells with z-DEVD-fmk, an inhibitor of caspase-3, inhibited fragmentation of protein kinase C delta and induced continuous activation of GSK-3.", "citation": {"type": "PubMed", "reference": "10850726"}, "annotations": {"Subgraph": {"Phosphatidylinositol 3 subgraph": true, "GSK3 subgraph": true, "Caspase subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 2, "target": 157, "key": "a2884da080b65263fab7695eec2d8012f6213febd8ff69be859cc235675114d7375edfee27994f71725f1794ecd59958b8523bdd3b0611761c53428b74ab6238"}, {"line": 29663, "relation": "increases", "evidence": "Activation of PI3K after CsA treatment appeared to trigger opposite effects. First, CsA induced PI3K-dependent activation of Akt, which mediated cellular responses against cell injury. Akt activation led to transient phosphorylation and inhibition of the pro-apoptotic GSK3beta and Bad, thus preventing GSK3beta-mediated phosphorylation and activation of the pro-apoptotic Bax, and Bad-sequestering of Bcl-2.", "citation": {"type": "PubMed", "name": "Xenobiotica. 2005 Jul;35(7):737-53", "reference": "16316932"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Bcl-2 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 5, "target": 153, "key": "fe3441db3b6dda59531c5dec76d02fc6e4d18e2c024ad1333c9b5e1d9e65db89dcfdb130e82d290bc5cafa9eb0284d7dfae548f1dfa44077016e77dd0c086d9e"}, {"line": 35743, "relation": "decreases", "evidence": "We here report that paullones also act as very potent inhibitors of glycogen synthase kinase-3beta (GSK-3beta) (IC50: 4-80 nM) and the neuronal CDK5/p25 (IC50: 20-200 nM).", "citation": {"type": "PubMed", "name": "Eur J Biochem2000", "reference": "10998059"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 13, "target": 90, "key": "a1e7706a0bc992e3b1ecc1f70e153c700c2de10407c5d8dfa05ef908b83de6cf29c76be492a2aafdb7b9d8066e823180486650a6bfc75b51b1b6df70f22c10e7"}, {"line": 36056, "relation": "decreases", "evidence": "Lithium, the primary therapeutic agent for bipolar mood disorder, is a selective inhibitor of GSK3beta.", "citation": {"type": "PubMed", "name": "Prog Neurobiol2001", "reference": "11527574"}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 7, "target": 90, "key": "3ef96b3ba6b8d9bed2f2e21429c644fd62b412f5094cb70ee565ae4aabb2d5f8a390dfe553b7c4ba955f4792c1ae7badaf27d0af02ac8cf65661b64e182e3fd8"}, {"line": 36687, "relation": "increases", "evidence": "In situ, FRAT-2 significantly increased GSK3 beta-mediated phosphorylation of tau at a primed epitope while not significantly affecting the phosphorylation of unprimed sites.", "citation": {"type": "PubMed", "name": "Journal of Biological Chemistry2005", "reference": "15522877"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true}}, "object": {"modifier": "Activity"}, "source": 85, "target": 90, "key": "228314a22194d3b51c0bb5c2cf372ca091919386265e75189ffd51478d8d0a45e2c48eb42a4f84ff0117f6135814e51c495198eda70f9aec88011b980ae0bbc7"}, {"line": 39961, "relation": "decreases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "source": 1, "target": 125, "key": "50eed6c8a53dddbadf71b04632781345f7d79aea3ddc2af10cc8676eab4e19b0abdb16a2630a9638ed2a1020b937e998284980099e50915778e8b6c02791ad60"}, {"line": 39962, "relation": "decreases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "source": 1, "target": 124, "key": "171bb2f105746ab53e7bb1d4d2a1641285caf6890654357ab1d32ba2e4ba0c7ee1a08ee242516ff86a151c843322bd6bebd61350209e149a9b36d7f572576f64"}, {"line": 39963, "relation": "decreases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "source": 1, "target": 120, "key": "db716893b18b7f11a3dee42886900eb8446dfb50a3e11322c7d48a79e0b2782930997f00f96663aea537c5fbe82125abb28e888618543e95c2044c981eba481e"}, {"line": 39964, "relation": "decreases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "source": 1, "target": 121, "key": "8e7afb160b65986d9aefdba53dc4cb38614716d70717ac3587c06334c6ea66251011354819b9c732cef7297c433c26640b5f44df82833e09b38d220c9f7f303b"}, {"line": 39965, "relation": "decreases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "source": 1, "target": 116, "key": "42d1b3bea90618c054a4d7e9768e44e77f14669becf78bf530f28f765e5aea96622213b02c02a1b8689c6a0113e33f3c1bbe9857b3e07061423ff8ceeb9637df"}, {"line": 39966, "relation": "decreases", "evidence": "We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. ", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Confidence": {"High": true}, "Subgraph": {"GSK3 subgraph": true, "Tau protein subgraph": true, "Estrogen subgraph": true}}, "source": 1, "target": 117, "key": "00cc50f001d3e1a8fb2ebc58c12959063b6e7a8c7be3a661818ad690a25c26e3c2b9eb1e8442074d3c5b5ff68074f3853b485ba0627817f6db6e167b46aefa90"}, {"line": 39974, "relation": "increases", "evidence": "Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta", "citation": {"type": "PubMed", "name": "Journal of Neural Transmission2008", "reference": "18217188"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Estrogen subgraph": true}, "Confidence": {"High": true}}, "source": 1, "target": 92, "key": "a79be495d491f66187ab3aae631c659cb69c55fc354ce81d9c044f313453620a382cc7aee084caf220f634154770ea7eb7a836560d71d915d155ba5c2679056c"}, {"line": 46002, "relation": "association", "evidence": "Another transactivating complex consisting of AICD, Fe65 and Late SV40 Factor (LSF)/leader-binding protein-1 (LBP1)/transcription factor CP2 (TFCP2) has also been reported to induce the expression of GSK3-b (Kim et al. 2003).", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 49, "target": 59, "key": "53a33fca444979f4a3447d8bca507aaa0dd2622a96ea5ec18cfc2901c34f8c632303414e2fdbd12a3b8e6fe70676d06744f55247e7b098f8fed9fb6393ca2a34"}, {"line": 46002, "relation": "association", "evidence": "Another transactivating complex consisting of AICD, Fe65 and Late SV40 Factor (LSF)/leader-binding protein-1 (LBP1)/transcription factor CP2 (TFCP2) has also been reported to induce the expression of GSK3-b (Kim et al. 2003).", "citation": {"type": "PubMed", "name": "J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28.", "reference": "22122372"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Non-amyloidogenic subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 59, "target": 49, "key": "6be89511a7691c4b341d72dacb786a7c4e13be72f07d50a925e32f2f18cc5f5142f55a8fc770c20b4fdb8cf2876ba4ca9e965ba2e17b4054094782f0690b96bc"}, {"line": 45278, "relation": "decreases", "evidence": "The increase in intracellular copper was correlated with a dramatic and rapid decrease in levels of extracellular ABeta¸ including ABeta¸1Ã¢â‚¬â€œ40 and 1Ã¢â‚¬â€œ42. It has been previously reported that CQ/copper complexes trigger the activation of PI3K and its downstream modulator Akt and the inhibition of glycogen synthase kinase 3 that in turn potentiated ERK1/2 phosphorylation.It is not clear if and how environmental factors take part to pathway discussed in this review, in which both ABeta¸PP and PS1 participate in the same signaling pathway leading, through Grb2 binding, to ERK1/2 activation and neurodegeneration. However, we may speculate that ERK1/2 activation by copper may contribute to the signal transduction system activated by ABeta¸PP, and PSs.", "citation": {"type": "PubMed", "name": "J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.", "reference": "22496686 "}, "annotations": {"Subgraph": {"GSK3 subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 4, "target": 90, "key": "b7d25255a5444cb6000628a0d12ae688dc8bf8811f9a392d2e3d13432aef6d6ec49eda3897c75d971d097dcdb8d2bc35c28b80de667225d1af3555f4a63b363e"}]}